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Children with Cystic Fibrosis (CF) are vulnerable to the effects of inhaled 
carbonaceous pollutants, but the underlying mechanism remains unclear. In CF, 
bacterial phagocytosis by alveolar macrophages (AM) is impaired, with increased 
airway prostanoid levels. Since particulate matter (PM) clearance is mainly by AM 
phagocytosis, I hypothesised that in CF, the amount of inhaled carbon 
phagocytosed by AMs is reduced, with increased phagocytosis-inhibitory 
Prostaglandin-E2 (PGE2) production, secondary to increased AM cyclooxygenase-
2 (COX-2) expression. 
Methods 
Children with CF and healthy controls carried portable aethalometers to monitor 
their personal carbon exposure. AMs were obtained by sputum induction. Carbon 
areas of 50 AMs per participant were quantified using image analysis. Purified 
populations of AM were exposed to diesel exhaust particles (DEP) to compare 
phagocytosis in both groups. Addition of PGE2 to the cell-DEP culture assessed its 
phagocytosis effects. AM COX-2 expression was determined by flow cytometry. 
Urinary prostanoid metabolites, as prostanoids production markers, were measured 
by mass spectrometry. Data were analysed by Mann-Whitney/Wilcoxon and paired 
t- tests.
Results 
Despite no significant difference in median personal carbon exposure (CF 1394 
ng/m3, n=25 vs control 1587 ng/m3, n=21; p=0.83); in vivo AM carbon was lower in 
CF (median 0.12 µm2 vs 0.30 µm2, p<0.001). AMs from both groups demonstrated 
considerable DEP uptake in vitro (CF median fold change 72 vs control 40); addition 
of PGE2 attenuated DEP uptake (mean difference -3.88 µm2, p<0.001). AM COX-2 
expression was increased in CF (MFI median 10217 vs 8142; p<0.05), who also 
had higher urinary concentrations of PGE2 metabolites (median 35965 pg/mg creat 
vs 15873 pg/mg creat, p<0.001). 
Conclusion 
AM phagocytosis of carbon is impaired in CF in vivo, but comparable with controls 
in vitro, suggesting inhibitory constituents are present in CF airways. Since COX-2 
expression and PGE2 production are increased in CF, I conclude that PGE2 is 
inhibitory on CF AM function.  
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Figure 2.10. Flow cytometry gating strategy. 
Figure 2.11. Standard curve using manufacturers’ suggested concentrations. 
Figure 2.12. Standard curve using the modified standard concentrations. 
Figure 3.1. Flow diagram of CF patients’ recruitment. 
Figure 3.2. Flow diagram of healthy children’s recruitment. 
Figure 3.3. Age distribution of CF and control participants. 
Figure 3.4. Modelled exposure to NO2 of CF and control groups, 12 months before 
their participation in the study, based on their home addresses.  
Figure 3.5. Modelled exposure to PM10 of CF and control groups, 12 months before 
their participation in the study, based on their home addresses. 
Figure 3.6. Modelled exposure to PM2.5 of CF and control groups, 12 months before 
their participation in the study, based on their home addresses. 
Figure 3.7a. Aethalometer reading of a participant’s typical school day. 
Figure 3.7b. Aethalometer reading of another participant over 2 typical school days, 
showing peaks of black carbon levels during outdoor activities including walking to 
and from school, and walking between school buildings during lunch and between 
periods. 
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Figure 3.8. Aethalometer readings matched with GoPro camera footage to 
demonstrate real life environment responsible for black carbon spikes. 
Figure 3.9. Personal black carbon exposure: each data point represents the mean 
per minute across 2 typical school days. 
Figure 3.10. Indoor NO2 levels: each data point represents the mean across 2 
weeks for each participant. 
Figure 3.11. Indoor NO2 levels for gas vs electric cook stoves, combining data from 
CF and control groups. 
Figure 3.12. Personal NO2 levels: each data point represents the mean across 2 
weeks for each participant. 
Figure 3.13. Spearman correlation between mean black carbon per minute over 2 
days and mean personal nitrogen dioxide over 2 weeks. 
Figure 3.14a. 50 AMs with phagocytosed black carbon (arrows) from a CF 
participant. 
Figure 3.14b. 50 AMs with phagocytosed black carbon (arrows) from a healthy 
participant. 
Figure 3.15. Alveolar macrophage black carbon (AMBC): each data point 
represents the mean of 50 randomly selected AMs from each participant. 
Figure 3.16. Bland-Altman: difference vs average. Bias and agreement of AMBC of 
11 participants (CF and controls) by two independent observers. 
Figure 3.17. Spearman correlation between alveolar macrophage black carbon and 
mean black carbon per minute over 2 days for CF (a) and control (b) groups.   
Figure 3.18. Number of alveolar macrophages available following cell enrichment 
and overnight adhesion for both CF and control groups.  
Figure 3.19. Alveolar macrophages from children with CF (a) and healthy controls 
(b), following exposure to diesel exhaust particles. 
Figure 3.20. Alveolar macrophage black carbon (AMBC) of alveolar macrophages 
extracted from CF (a) and control (b) participants, unexposed to diesel exhaust 
particles (DEP -) vs exposed (DEP+); presented in log scale and compared by 
Wilcoxon test. Data transformed into fold change in (c) and (d); compared by Mann-
Whitney test, bars represent median. (e) Comparison of AMBC of unexposed (DEP 
-) alveolar macrophages from CF group, exposed (DEP +) alveolar macrophages 
from CF group, and exposed (DEP +) alveolar macrophages from control group; 
using one-way ANOVA Tukey’s multiple comparisons test, bars represent SE.  
Figure 3.21. Alveolar macrophages from children with CF showing clusters of 
intracellular bacteria.  
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Figure 4.1. Median fluorescence intensities (MFI) for COX-2 expression in alveolar 
macrophages isolated from CF and controls. 
 
Figure 4.2. Bland-Altman: difference vs average. Bias and agreement of median 
MFI for COX-2 expression in AMs from 8 participants (CF and controls) by the same 
observer, blinded vs unblinded to the participants’ health status. 
 
Figure 4.3. Urinary metabolite of prostaglandin E2: 13,14-dihydro-15-keto-E2 for 
CF and control groups. 
 
Figure 4.4. Urinary metabolite of prostaglandin E2: 13,14-dihydro-15-keto-tetranor-
E2 for CF and control groups. 
 
Figure 4.5. Urinary metabolite of prostaglandin E2: tetranor-PGE-M for CF and 
control groups. 
 
Figure 4.6. Spearman correlation: relationship between urinary tetranor PGEM and 
age of children with CF, r=0.16, p=0.50. 
 
Figure 4.7. Spearman correlation: relationship between urinary tetranor-PGE-M 
and FEV1 predicted (%) in children with CF, r=0.26, p=0.42. 
 
Figure 4.8. Spearman correlation: relationship between urinary tetranor-PGE-M 
and FVC predicted (%) in children with CF, r=0.35, p=0.21. 
 
Figure 4.9. Urinary metabolite of prostaglandin D2: 13,14-dihydro-15-keto-D2 for 
CF and control groups. 
 
Figure 4.10. Urinary metabolite of prostaglandin D2: 13,14-dihydro-15-keto-
tetranor-PGD2 for CF and control groups. 
 
Figure 4.11. Urinary metabolite of prostaglandin D2: tetranor-PGD-M for CF and 
control groups. 
 
Figure 4.12. Urinary metabolite of prostaglandin D2: 9a,11b-PGF2 for CF and 
control groups. 
 
Figure 4.13. Urinary metabolites of prostaglandin J2: 15-doexy-delta12,14-PGJ2, 
for CF and control groups. 
 
Figure 4.14. Urinary leukotriene E4 (LTE4) for CF and control groups. 
 
Figure 4.15. Sputum supernatant PGE2 levels of CF and control groups. 
 
Figure 4.16. Using AMs from CF participants: comparison of alveolar 
macrophage black carbon in cultures: control (no DEP or PGE2) vs DEP vs 





Figure 4.17. Using responder AMs from healthy controls: comparison of 
alveolar macrophage black carbon in cultures: control (no DEP or PGE2) vs 
DEP vs DEP and PGE2.  
Figure 4.18. Alveolar macrophage black carbon of cell-DEP cultures with and 
without EP2 antagonist, using responder alveolar macrophages from healthy 
controls.  
Figure 4.19. Using responder alveolar macrophages from healthy controls: alveolar 
macrophage black carbon of cell-DEP cultures treated with or without PGE2 and/or 
EP2 antagonist.  
Figure 4.20. Comparison of alveolar macrophage black carbon in cell-DEP cultures 
untreated and treated with CF supernatant, using responder alveolar macrophages 
from healthy controls. 
Figure 4.21. Using responder alveolar macrophages from healthy controls: 
alveolar macrophage black carbon in cell-DEP cultures treated with or 
without CF supernatant and/or EP2 antagonist.  
Figure 4.22. Urinary 13,14-dihydro-15-keto-PGE2 of children with cystic fibrosis, 
before and after a 3-day course of standard dose Ibuprofen, presented in log scale. 
Figure 4.23. Urinary 13,14-dihydro-15-keto-tetranor PGE2 of children with cystic 
fibrosis, before and after a 3-day course of standard dose Ibuprofen, presented in 
log scale. 
Figure 4.24. Urinary tetranor PGE-M of children with cystic fibrosis, before and after 
a 3-day course of standard dose Ibuprofen, presented in log scale. 
Figure 4.25. Urinary 13,14-dihydro-15-keto-E2 of children with CF after a 3-day 
course of Ibuprofen and healthy controls.  
Figure 4.26. Urinary 13,14-dihydro-15-keto-tetranor E2 of children with CF after a 
3-day course of Ibuprofen and healthy controls.
Figure 4.27. Urinary tetranor PGEM of children with CF after a 3-day course of 
Ibuprofen and healthy controls. 
Figure 5.1. Epithelial-macrophage in vitro model: A549 cells adhered to the well 
overnight, followed by addition of primary responder alveolar macrophages and 
DEP. 
Figure 5.2. Light microscopy of A549 epithelial cells following exposure to diesel 
exhaust particles, showing particle invasion into the cells.  
Figure 5.3. (a) Area of black carbon in A549 epithelial cells with and without alveolar 
macrophages. (b) A549 epithelial cell (E) and a neighbouring alveolar macrophage 
(AM) which has phagocytosed black carbon. 
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Figure 5.4. Area of black carbon in A549 epithelial cells in the presence of alveolar 
macrophages, with and without PGE2. 
 
Figure 5.5. Standard curve created using a curve-fitting software, with the 
background absorbance subtracted. 
 
Figure 5.6. (a) Interleukin 8 (IL-8) levels: cultures of A549 epithelial cells with and 
without 10 µg/ml DEP. Comparison by Wilcoxon test. (b) Fold change in IL-8 release 
in epithelial cell cultures exposed to DEP, compared to those unexposed. 
Comparison by Mann-Whitney test. Bar represents median.  
 
Figure 6.1. Modelled annual mean PM10 and PM2.5 levels 12 months prior to 
delivery date, based on participants’ home addresses. 
 
Figure 6.2. Selected light microscopy images of placental macrophages showing 
black inclusions compatible with the appearances of phagocytosed black carbon. 
 
Figure 6.3. Spearman correlation between modelled PM (PM10 and PM2.5) and 
placental macrophage black carbon (PMacBC). 
 
Figure 6.4. Electron microscopy images of placental macrophages showing black 
inclusions in vacuoles compatible with diesel exhaust particles appearances. 
 
Figure 6.5. Electron microscopy images of placental macrophages exposed to 
diesel exhaust particles in vitro. 
 
Figure 6.6. Light microscopy images of placental macrophages after exposure to 
diesel exhaust particles, demonstrating in vitro phagocytic ability. 
 
Figure 6.7. Placental macrophage black carbon in PMac cells unexposed (DEP-) 
and exposed (DEP+) to diesel exhaust particles, presented in log scale. 
 
















Table 1.1. WHO guidelines, EU limits and main sources of ambient (outdoor) air 
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Table 2.1. Panel of urinary prostanoid metabolites analysed, with their prostanoid 
precursors. 
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24 
Glossary and Abbreviations 
ABC ATP-binding cassette 
AM Alveolar (airway) macrophage 
AMBC Airway macrophage black carbon 
ASL Airway surface liquid 
ATS American Thoracic Society 
BAL Broncho-alveolar lavage 
BC Black carbon 
CF Cystic fibrosis 
CFTR Cystic fibrosis transmembrane conductance regulator 
CO Carbon monoxide 
COX-2 Cyclooxygenase-II 
DC Dendritic cell 
DEP Diesel exhaust particle 
DMEM Dulbecco's Modified Eagle Medium 
DPBS Dulbecco’s phosphate buffered saline 
ERS European Respiratory Society 
EU European Union 
FBS Foetal bovine serum 
FEV1 Forced expiratory volume in 1 second 
FVC Forced vital capacity 
HAP Household air pollution 
IL Interleukin  
IQR Inter-quartile range 
LAQT London Air Quality Toolkit 
LPS Lipopolysaccharides 
MDP Macrophage-dendritic progenitor 
MHC Major histocompatibility complex 
NICE National Institute for Health and Care Excellence 
NO Nitric oxide 
NO2 Nitrogen dioxide 
NOx Nitrogen oxide 
NSAID Non-steroidal anti-inflammatory drug 
O3 Ozone 





PM Particulate matter 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute buffer 
SO2 Sulphur dioxide 
TLR Toll-like receptor 
TNF tumour necrosis factor 
TRAP Traffic related air pollution 
UK United Kingdom 
UV Ultra-violet 
VOCs Volatile Organic Compounds 
WHO World Health Organisation 
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1. Introduction
1.1. Air pollution 
Air pollution is a global public health burden, with half of the world’s population 
residing in cities, megacities or peri-urban areas. According to World Health 
Organisation (WHO), 1.8 billion children and young people under the age of 15 
across the world are breathing polluted air. WHO estimates that air pollution 
accounts for 600,000 paediatric deaths a year secondary to associated acute 
pneumonia. In Europe, more than 80% of city inhabitants are exposed to pollution 
levels exceeding the limits set by the WHO air quality guidelines 1. In the United 
Kingdom (UK), numerous cities regularly breach the European Union (EU) legal 
limits and WHO guidelines for air pollutants (Table 1.1) 2.  
Pollutants WHO guidelines 
(averaging period) 






50 µg/m3  (24 hours) 
20 µg/m3  (1 year) 
50 µg/m3  (24 hours) 
40 µg/m3  (1 year) 
Transport (exhaust, 







25 µg/m3  (24 hours) 
10 µg/m3  (1 year) 




200 µg/m3 (1 hour) 
40 µg/m3 (1 year) 
200 µg/m3 (1 hour) 
40 µg/m3 (1 year) 
Transport, combustion 
Ozone (O3) 100 µg/m3 (8 hours) 120 µg/m3  (8 hours) Reaction of 
hydrocarbons, nitrogen 
oxides and volatile 





500 µg/m3  (10 min) 
20 µg/m3  (24 hours) 
350 µg/m3  (1 hour) 
125 µg/m3 (24 hours) 
Coal combustion and 
road transport 
Table 1.1. WHO guidelines, EU limits and main sources of ambient (outdoor) air 
pollutants. Adapted from World Health Organization (WHO) ambient (outdoor) air 
quality and health fact sheet (updated Sept 2016), European Commission Air 
Quality Standards (updated Sept 2017), and Lethal & Illegal, Solving London’s Air 
Pollution Crisis by Institute for Public Policy Research, November 2016.  
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It is worth noting that national and international guidelines employ different risk 
assessment tools, resulting in different pollutant limits; risk assessment is based on 
the target population’s social standards, background air pollution severity, and the 
extent and feasibility of risk adversity. 
In the UK, 40,000 excess deaths per year are attributable to air pollution – these 
comprise new disease incidence secondary to chronic air pollution exposure, and 
exacerbations of established diseases; costing the nation over £20 billion in health 
and social services each year 3. There is robust epidemiological evidence that air 
pollution impacts on every stage of life, and is linked to adverse effects on the 
respiratory, cardiovascular, and neurological systems 3-5. Children and young 
people are more vulnerable because air pollutants can impede the normal 
development of their organs, particularly the lung – rendering children with 
respiratory diseases more susceptible. Moreover, children’s immature immune and 
metabolic systems are also less capable of tackling inhaled pollutants.  
1.1.1. Major air pollutants 
1.1.1.1. Particulate matter 
Particulate matter (PM) is made of solid and liquid organic and inorganic particles 
suspended in air. PM is categorised into PM10 and PM2.5 based on its aerodynamic 
diameter – less than 10 or 2.5 micrometres (µm) respectively. For reference 
purpose, the diameter of human hair ranges from 17 to 181 µm. Coarse particles 
settle mainly in the upper airway, whereas finer particles are regarded as more 
harmful because they can reach the lower smaller airways and alveoli, and have 
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the potential to penetrate the systemic circulation and translocate to distant organs. 
The composition and size of PM are determined by its source. A key constituent of 
PM is black carbon (BC), which forms the core of these particles, and is responsible 
for the black appearance of “soot”. Transition metals and aromatic hydrocarbons 
are amongst other components of PM 6. 
 
“Primary” PM is defined as fine particles that are emitted directly to the atmosphere, 
including anthropogenic sources such as traffic-related air pollution (TRAP), coal 
and oil combustion in power stations and factories, biomass burning, construction 
work and agriculture. “Secondary” PM is formed by photochemical reactions of 
pollutants, such as nitrogen oxides (NOX), in the atmosphere. 
 
1.1.1.2. Nitrogen oxides  
Nitrogen oxides (NOX, including nitric oxide, NO and nitrogen dioxide, NO2) 
formation can occur in natural or anthropogenic ways, such as when nitrogen reacts 
with oxygen during lightning, microbial processes, and fossil fuel combustion; the 
last being the biggest contributor to urban NOX, responsible for 40% of Europe’s 
total emission 7. 
 
1.1.1.3. Ozone 
Ozone (O3) is generated from photochemical reactions between NOX, volatile 
organic compounds, and oxygen under strong ultraviolent (UV) light. Its levels 
therefore peak on hot, sunny, windless days. O3 is able to travel far and accumulate 
in the atmosphere distant from its source.  
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1.1.1.4. Sulphur dioxide 
Sulphur dioxide (SO2) is a colourless acidic gas formed during volcanic activity, and 
also as a by-product when sulphur-containing fuels, such as coal and heavy oils, 
are burned. The largest contributor of SO2 in the developed world is power 
generation.  
1.1.2. Outdoor (ambient) air pollution 
The major sources of ambient pollutants are gasoline- and diesel-powered engines 
(producing PM, NOX), vehicle tyre and brake wear (producing PM), power stations 
and factories where coal combustion and biomass burning (producing PM, NOX, 
SO2) occur 8-10. 
Globally, 93% of children are exposed to PM2.5 levels higher than WHO air quality 
guidelines 11.  Road traffic has been increasing in urban areas over the last few 
decades, with active forms of transport such as walking and cycling being on a 
decline 3. In the UK, 50% of NO2 emissions are generated on the roads 12, with 
about half the cars and the majority of heavy vehicles and trains being powered by 
diesel engines 13, which generate the most PM and NOX amongst all engine types. 
Diesel soot is categorised as carcinogenic by WHO 14. Children are inevitably 
exposed to outdoor pollution during their commute to and from school and outdoor 
activities. Many nurseries and schools in the UK are located close to highly polluted 
roads where NOX concentrations regularly breach the legal limits (40 µg/m3 annual 
mean or 200 µg/m3 1-hour mean) 12,15.  
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1.1.3. Indoor air pollution 
Indoor air pollution is mainly caused by inefficient fuel or biomass combustion during 
cooking and heating, generating NO2 and carbonaceous PM; it can also come from 
ingress of outdoor pollutants. Other common indoor air pollutants include carbon 
monoxide (CO), SO2 and volatile organic compounds (VOCs). These are found in 
cigarettes, building materials, furnishing chemicals, insecticides, cleaning products, 
dust, and mould. Across the globe, WHO reports that household air pollution (HAP) 
increases the risk for paediatric pneumonia twofold, and is liable for 45% of 
pneumonia deaths in children aged less than 5 years. In high income countries, the 
urban population tend to dwell indoors for the majority of time, making indoor air 
pollution, even at low levels, a significant factor in health effects.  
Summary: Indoor and outdoor air pollution 
 Air pollution is a growing global public health problem, mainly caused by
incomplete fossil fuel or biomass combustion.
 Traffic-related air pollution (TRAP) is one of the biggest sources of
pollutants such as particulate matter, nitrogen oxides, ozone and sulphur
dioxide. For example, in the UK, TRAP is responsible for 50% of nitrogen
dioxide emissions.
 There are national and international guidelines on air pollutant limits –
urban cities such as London are regularly non-compliant with such limits.
 There is strong epidemiological evidence linking air pollution exposure to
negative health effects, affecting every stage of the life course. In the
UK, 40,000 excess deaths are attributable to air pollution each year.
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1.2.  The body’s defence mechanism against air pollution 
1.2.1. Barrier mechanisms: airway epithelium and surface liquid layer 
In a healthy lung, the luminal respiratory tract is lined by epithelial cells, which form 
the body’s first line of defence – this airway epithelium acts as a physical and 
chemical barrier. Its surface is lined with the airway surface liquid (ASL) which is 
important for airway homeostasis. ASL is responsible for regulating ciliary function, 
mucociliary clearance, and anti-pathogenic activities. The ASL is made of two layers 
– the mucus layer is dominated by gel-forming mucins, which trap inhaled particles
for mucociliary clearance; the periciliary liquid layer maintains an optimal distance 
between the mucus and the underlying epithelia – this layer contains mucins bound 
to the cilia, forming a tight mesh which prevents the invasion of inhaled particles 
16,17. The two major types of epithelial cells are goblet (mucin producing) and 
columnar (ciliated). Goblet cells produce the mucin that lines the epithelium, while 
ciliated cells propel the particle-containing mucus and secretions upwards towards 
the pharynx (figure 1.1). 
Figure 1.1. Airway epithelium and airway surface liquid layer – a physical and 
chemical first line of defence of the respiratory tract. 
Ciliated cell  Goblet cell
Mucus layer  Airway surface 
liquid (ASL) 
Periciliary layer  
Airway lumen  
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1.2.1.1. Inflammatory mechanisms 
Other than a physical and chemical barrier, the epithelium also contributes to host 
defence by releasing arachidonic acid derivatives 18 and producing inflammatory 
mediators – leading to differentiation, activation and chemotaxis of inflammatory 
cells. Epithelial cells can produce various cytokines (interleukin 1β (IL-1β), 
interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 11 (IL-11), and tumour necrosis 
factor α (TNF-α)) when exposed to stimulants such as diesel exhaust particles 
(DEP) and NO2 19 20. Not only can air pollutants cause cytokines release and pro-
inflammatory cell signalling, they can also damage epithelial cells. DEP and NO2 
can reduce ciliary beat frequency 21 20 and damage the cell membrane, thereby 
increasing cell permeability 19. Traditionally, it was thought that the fine physical 
diameter of DEP (PM) was the main reason for their negative health effects. 
However, these effects are seen in filtered liquid forms of DEP as well, suggesting 
that their chemical composition is just as significant 19. Furthermore, exposure to 
engine exhausts can lead to increased peripheral leucocytes, neutrophils and 
airway eosinophils 22, all contributing to the inflammatory cascade. 
1.2.2. Cellular removal mechanisms 
1.2.2.1. Dendritic cells 
Dendritic cells (DC) are antigen-presenting cells. A tight network of DCs is present 
within the airway epithelium, most of these reside in an immature state 23. By 
extending their dendrites between epithelial cells, they sense and trap invading PM, 
followed by transporting them to the lymphatic system and stimulating T-cells to 
secrete cytokines, acting as a bridge between the innate and adaptive immune 
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systems. Indeed, it has been shown that DEP can increase the production and 
maturation of DCs, and recruitment of neutrophils and monocytes 23.  
 
1.2.2.2. Alveolar space 
Particulate matter which escapes the aforementioned mechanisms will be 
confronted by the phagocyte system. It is long recognised that monocytes, 
macrophages and dendritic cells are closely related. In mice, DC and monocytes 
arise from a common precursor – the macrophage-dendritic progenitor (MDP) 24. In 
humans, the differentiation is less well understood. The role of monocytes is to 
sense the environment, and to govern and maintain the populations of 
macrophages and DCs. They can alter their phenotype according to the 
environmental need – for example, upon infection, monocytes can differentiate into 
macrophages and DCs. Different subsets of monocytes are distinguished by their 
surface markers, and they play different roles. Circulating anti-inflammatory 
monocytes maintain a stable composition of monocytes – during steady state, they 
become tissue resident macrophages; but they can differentiate into anti-
inflammatory macrophages for tissue damage repair upon inflammation 25. On the 
other hand, inflammatory monocytes recognise pathogens and apoptotic debris, 
phagocytose, and produce cytokines to initiate inflammation; they can also 
differentiate into inflammatory macrophages to further help remove pathogens and 
debris 25. Classical monocytes seem to be the main source of monocyte-derived 





1.2.2.2.1. Alveolar macrophages 
Macrophages are the major effector cells in immune responses. Lung macrophages 
are categorised into alveolar macrophages (found on alveolar epithelial surface), 
and interstitial macrophages (found within alveolar walls and lung parenchyma) 27,28. 
A subgroup of lung macrophages are found on the airway epithelium – airway 
macrophages – these have similar phenotypical and functional characteristics to 
alveolar macrophages, most likely because they are in fact alveolar macrophages 
migrating up the bronchial tree 27. 
Alveolar macrophages (AM) are the resident phagocytes in the lower airways. AMs 
can adapt and coordinate inflammatory responses depending on the host 
requirements – initiating either an inflammatory response when invaded by 
pathogens and particles, or an anti-inflammatory response when clearing and 
degrading apoptotic debris 29. These opposing pro- and anti-inflammatory 
responses suggest that macrophage function is regulated sophisticatedly, dictated 
by the environment. AMs are divided into classic- (M1) or alternatively- (M2) 
activated phenotypes 30. M1-activated macrophages are pro-inflammatory, they are 
polarised following lipopolysaccharides (LPS) stimulation; whereas M2-activated 
macrophages are inflammation-resolving, and are polarised after cytokine 
stimulation 31 (figure 1.2).  
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Figure 1.2. Activation of macrophages into M1 (pro-inflammatory) and M2 
(inflammation-resolving) phenotypes depending on the environmental stimuli.  
Despite the traditional view of AMs being monocyte-derived terminally differentiated 
cells which are replaced by circulating monocytes following acute lung insult 32, 
newer studies have suggested that they can self-renew and proliferate locally 33. 
Not only can conditions such as pulmonary fibrosis and allergic inflammation 
promote monocyte-derived macrophage infiltration, they can also enhance 
mitogenic signalling and macrophage proliferation, leading to an increased number 
of macrophages 33. Self-renewed macrophages have been shown to be protective 
against inflammation, while monocyte-derived macrophages can aggravate it 33.  
Cytokines 
M1 macrophage: pro -inflammatory 
• Microbial and pathogen killing
• Antigen presenting
• Tissue damage
M2 macrophage: inflammation -resolving 
• Debris clearance
• Immune regulation




AMs recognise insults such as damaged cells, apoptotic cells, pollution particles 
and microbes. They sample their environment through opsonic (FcR, CR3) and non-
opsonic receptors (lectin, scavenger, and toll-like receptors) 34 (figure 1.3).  
Figure 1.3. Macrophage receptors: non-opsonic receptors (in blue) recognise 
targets directly; opsonic receptors (in red) require opsonin to coat the target, 
allowing for recognition indirectly. 
Opsonic recognition is indirect, requiring opsonin to coat the substance, thereby 
allowing for its recognition by receptors; non-opsonic recognition is when receptors 
directly recognise the substance. For example, toll-like receptors (TLRs) recognise 
gram-positive and -negative bacteria and particulate matter, whereas scavenger 
receptors (e.g. macrophage receptor with collagenous structure, MARCO) 
recognise lipoproteins and particulate matter, and lectin receptors recognise 
components of fungi 34. AMs internalise material through receptor-mediated 
endocytosis and extension of pseudopodia. The pseudopodia surround the 
material, forming a phagosome which fuses with lysosomes to become a 








Figure 1.4. An alveolar macrophage encountering inhaled particulate matter (or any 
other foreign insults) via surface scavenger receptors, followed by the formation of 
a phagosome, fused with lysosomes to form a phagolysosome before elimination of 
the invading substance. 
Autophagy is one of the mechanisms through which degradation of engulfed 
cytoplasmic contents occur: double-membraned vesicles enclose intracellular 
components for lysosomal degradation. Autophagy is also associated with antigenic 
fragment delivery to major histocompatibility complex (MHC) class II molecules, 
which are expressed on the macrophage surface, for presentation to T-cells 36,37. It 
has been reported that increased autophagy following exposure to PM may protect 
against PM-induced cytotoxicity 38,39.  
Additionally, AMs can induce inflammation and recruit neutrophils, which when 
activated, will initiate monocyte recruitment and contribute to insult elimination 34. 
Alternatively, macrophages can eradicate phagocytosed material through 











AMs patrol the surface of the lower airways, neutralising and phagocytosing 
unwanted substances such as inhaled carbonaceous particulate matter, thus 
preventing their accumulation within the lungs (figure 1.5). Inhaled PM is 
phagocytosed in a dose-dependent manner 41,42. As mentioned in section 1.1.1.1., 
coarser PM tends to deposit in the larger proximal airway, while ultrafine PM can 
penetrate further into smaller distal airways and alveolar space. Therefore, normal 
AM function is crucial in preventing PM accumulation within the lungs, limiting PM 
exposure to other airway cells and reducing its negative effects on lung health.  
Figure 1.5. Alveolar macrophages patrolling the airway, phagocytosing unwanted 
substances along the way. 
AM phagocytosis of inhaled PM is further discussed in section 1.5.3. 
39 
Summary: The body’s defence mechanism against air pollution 
 The respiratory tract is the first point of contact of inhaled particulate
matter.
 The epithelium and airway surface liquid form the first line of defence,
acting as a physical-chemical barrier which traps particulate matter.
 Particulate matter that overcome the physical-chemical barrier will be
confronted by cellular removal in the lower airways.
o Alveolar macrophages are the main phagocytes for inhaled
particle removal, facilitated by cell surface receptor recognition of
particle, followed by phagolysosomal formation and particle
destruction.
 The epithelium and alveolar macrophages both contribute to the
inflammatory processes (e.g. cytokine release, neutrophils recruitment)
associated with exposure to inhaled particulate matter.
What is still unknown? 
 The consequences of residual particulate matter in the distal airways,
not phagocytosed due to impaired AM function or saturation of AM
functional capacity, remain unclear.
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1.3. Health effects of air pollution across the life course 
There is robust epidemiological evidence showing that the adverse effects of air 
pollution transpire across the human life course 3. While some effects may be 
reversible, others have long-term impacts. However, to determine the health effects 
of each component of air pollution is challenging because many pollutants share 
common origins – with the most common source being fossil fuel combustion and 
vehicle engines. 
 
1.3.1. Antenatal effects and mechanisms 
Fetal cells are fast replicating and sensitive to external insults such as air pollution. 
Organogenesis of the lung begins at 4 weeks of gestation, with alveolar 
development starting at around 36 weeks, continuing into early adulthood. Although 
it is challenging to separate the effects of maternal air pollution exposure from those 
of post-natal exposure, independent associations of antenatal air pollution exposure 
and impaired lung development and function have been reported 43. Intrauterine 
exposure to NO2, particularly during the second trimester, is associated with 
reduced forced expiratory volume in 1 second (FEV1) later in childhood – Morales 
et al. 44 reported that an interquartile range (IQR) increase in NO2 exposure would 
result in -28.0 mL of FEV1, with a relative risk of having low lung function, defined 
as < 80% of predicted FEV1, of 1.30. Other studies have described a link between 
maternal exposure to traffic-related air pollutants and adverse birth outcomes such 
as increased infant mortality, premature birth, restricted fetal growth and low birth 
weight at term 45,46. Worryingly, the increased risk of low birth weight could occur at 
PM2.5 levels below the EU limit recommendation of 25 µg/m3 per year 46,47.  
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There are several potential mechanisms through which fetal development is 
affected. It is generally recognised that adverse fetal outcomes are related to 
underlying placental insufficiency. Fetal health is closely related to maternal health 
– oxidative stress and inflammation within maternal airways could result in
haemodynamic and vascular changes, leading to reduced placental circulation and 
fetal nutritional delivery 45. Indeed, there is evidence that PM exposure has a dose-
dependent effect on the development of pre-eclampsia, a condition in which the 
placenta plays an important role 48.  Another probable mechanism is particle 
translocation from the maternal lung, via the circulation, to the placenta and fetus, 
where particle toxicity is exerted directly 45. It is known that PM is cytotoxic to human 
placental cells, affecting their gene expression profile and cell signaling 49; placental 
epigenetic modification and fetal re-programming can result in predisposition to 
diseases in adulthood 50. For example, it has been shown that antenatal exposure 
to PM2.5 is associated with increased risk of asthma later in life 51. Further discussion 
on particle translocation outside the respiratory system can be found in section 
1.4.4. 
1.3.2. Postnatal effects 
Air pollution can alter children’s developmental trajectory as the human body 
continues to grow until the end of adolescence or early adulthood. The first 6 years 
of life represent a crucial time for lung development – during which formation of over 
80% of alveoli occurs. The negative associations between TRAP and children’s lung 
growth, lung function, and respiratory health are well recognised.  
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Antenatal exposure to air pollution is associated with increased respiratory need 
and airway inflammation in newborn infants 52, leaving them more susceptible to 
wheeze and bronchiolitis, which are worsened by postnatal outdoor pollutant 
exposure 53-55. The combination of an infant’s physical proximity to traffic exhaust 
fumes during outdoor travel (due to the lower level of their prams) and their higher 
relative minute ventilation compared to adults, render them more vulnerable to 
pollution’s adverse effects. 
 
1.3.2.1. Lung development and function 
 
Residing in areas with high concentrations of PM and NO2 can lead to suppression 
of lung function growth in school children 56,57. Those with existing chronic 
conditions, or living in close proximity to road traffic are most susceptible 54,58. A 
study in southern California showed that children and young people residing within 
500 m of a motorway had significant growth deficit in FEV1 (-81 mL over 8 years), 
compared to those living more than 1500 m away 59 (figure 1.6).  
Figure 1.6. Percent-predicted lung function at 18 years of age, comparing different 
distances between home and a motorway – data from The Children's Health Study 
in southern California, showing significant Forced Expiratory Volume in 1 second 
(FEV1) deficit in those living within 500 m of motorway; with insignificant effects on 
forced vital capacity (FVC) at all distances, and maximal mid-expiratory flow 
(MMEF) at all distances except for <500 m. Reproduced with permission from 
Gauderman et al 59, the Lancet. 
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Urman et al. 60 reported that increasing NOX by 17.9 ppb led to -1.56% in forced 
vital capacity (FVC) and -1.1% in FEV1 in children’s lung function. Encouragingly, 
improvement in air quality can reverse or halt this reduction in lung growth and 
function. The Children’s Health Study in southern California 61 demonstrated that 
the mean growth of FEV1 over a 4-year period improved by 91.4 mL per 14.1 ppb 
reduction in NO2, 65.5 mL per 8.7 µg/m3 reduction in PM10, and 65.5 mL per 12.6 
µg/m3 reduction in PM2.5; with comparable changes seen in FVC (figure 1.7).  
Figure 1.7. Mean FEV1 and FVC growth in children over 4 years, plotted against 
levels of nitrogen dioxide and PM10 for different communities in southern California. 
Data from the Children’s Health Study, showing improvement of both FEV1 and FVC 
growth with reduction of nitrogen dioxide and PM10. Adapted from and reproduced 
with permission from Gauderman et al 61, Copyright Massachusetts Medical 
Society.  
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1.3.2.2. Respiratory symptoms in previously healthy children 
Evidence linking air pollution to asthma is robust – not only is air pollution strongly 
associated with exacerbations of pre-existing asthma, it can also result in new-onset 
asthma 6. At high concentrations, NO2 and PM2.5 can cause airway inflammation 
and hyper-responsiveness 62, and may lead to oxidative stress, inflammation and 
remodelling in the airways, thereby predisposing children to sensitisation 6, 
bronchitis and wheeze 56. A meta-analysis concluded that NO2 exposure is linked 
to new onset asthma, while PM2.5 exposure is connected to new onset wheeze 58, 
with its short-term variations closely associated with asthma exacerbations 63. In 
addition to asthma, short term exposure to TRAP can aggravate respiratory 
infections and result in more frequent emergency department attendances in young 
children 64. Reassuringly, as with lung function improvement, ambient NO2 and PM 
reduction can decrease incidence of asthma, bronchitis, respiratory infections and 
hospital admissions 65,66. 
1.3.2.3. Effects of air pollution on other body systems 
There is evidence to support a link between air pollution and neurological 
development and function in children, resulting in reduced neurocognitive ability 67-
69, due to disruption of brain maturation by high levels of TRAP 70. These cognitive 
effects can linger into adulthood, with dementia and Parkinson’s disease also 
associated with air pollution 71,72.  
As mentioned above, air pollution can affect fetal wellbeing and result in low birth 
weight, which has an inverse association with cardiovascular morbidity and mortality 
in adulthood 73; with evidence of increased pulmonary arterial pressure and diastolic 
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blood pressure following chronic air pollution exposure 74,75. PM is also associated 
with DNA damage and genomic alterations, thus contributing to the development of 
lung carcinoma in non-smokers 22. 
 
With regards to the endocrine system, animal studies show strong associations 
between air pollution exposure and type 2 diabetes, with epidemiological studies 
supporting this link in humans 76. Indeed, Thiering et al. 77 demonstrated that NO2 






Summary: Health effects of air pollution across the life course 
 Antenatal exposure to air pollution can affect the unborn fetus, resulting 
in premature delivery, low birth weight at term, and infant mortality. 
 Postnatal exposure to air pollution is associated with reduced lung 
growth, lower lung function, increased risk or respiratory infections, pre-
school wheeze, new onset asthma, and asthma exacerbations. 
 There is evolving evidence suggesting air pollution also impacts on 
children’s neurocognitive development. 
 Exposure to air pollution is associated with cardiovascular and endocrine 
co-morbidities all through to adulthood. 
What is still unknown? 
 The specific impact of air pollution exposure on children with respiratory 
conditions (e.g. cystic fibrosis) remains unclear. 
 Whether the reported remote effects of air pollution on extra-pulmonary 




1.4. Mechanisms underlying air pollution’s negative health 
effects 
1.4.1. Oxidative stress 
Air pollutants such as PM2.5 and NOX are potent oxidants and can generate reactive 
oxygen species (ROS). ROS are usually formed as by-products of normal oxygen 
metabolism, their levels are controlled by the body’s production of antioxidants and 
detoxification enzymes which counteract ROS production. Pollutants and ROS 
interact and undergo radical and redox reaction cycles in the epithelial lining fluid 
(ELF) 78. When there is high concentration of ROS, the protective antioxidant 
response becomes inadequate – the imbalance between ROS generation and 
antioxidants is known as oxidative stress. High level of ROS can cause biological 
processes (e.g. inflammation) with various cytotoxic effects, leading to cell damage 
and cell death 79. Not only can oxidative stress occur in individuals inhaling 
pollutants, maternal oxidative stress during pregnancy can also result in 
haemodynamic changes, affecting placental circulation 45, thus influencing fetal 
wellbeing (as discussed in section 1.3.1.). Evidence of oxidative stress related to air 
pollution can also be seen in extra-pulmonary organs such as the heart 80, and one 
mechanism by which inhaled air pollutants can affect distant organs. 
1.4.2. Inflammatory responses 
Further to section 1.2.1.1., air pollutants, particularly those from TRAP, are known 
to promote inflammatory cytokines production 81,82. In particular, interleukin 1-beta 
(IL-1β), interleukin 6 (IL-6), and tumour-necrosis-factor alpha (TNF-α) productions 
are intensified by PM exposure 83. The inflammatory response, and any subsequent 
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respiratory symptoms, vary according to the chemical composition and source of 
PM 84, with the mix of diesel exhaust particles (DEP) from TRAP being amongst the 
most toxic 85. Indeed, DEP has been shown to stimulate IL-6 and IL-8 expression in 
nasal cells, thereby causing and/or aggravating conditions such as allergic rhinitis 
and rhinosinusitis 86. 
1.4.3. Structural effects on epithelial cells 
By exposing epithelial cells (A549 adenocarcinomic human alveolar basal epithelial 
cell line) to ultrafine titanium dioxide (TiO2) particles, Stearns et al. 87 demonstrated 
that the particles were able to adhere to the cells despite multiple in vitro washing; 
the epithelial cells could also internalise TiO2 particles by means of endocytosis, 
where they aggregated mostly in membrane-bound vacuoles. Other research also 
supports that endocytosis is a crucial process in the uptake of nanoparticles by 
human alveolar epithelial cells 88. Not only can nanoparticles induce lung oxidative 
stress and inflammation, they can also cause biomechanical changes in human 
alveolar epithelial cells – leading to reduced actin stress fibres, reduced cell stiffness 
and traction forces; resulting in altered cell permeability 89. 
1.4.4. Translocation of pollution particles across the air/tissue 
interface 
As postulated in section 1.3.1., despite inhaled air pollutants largely ending up in 
the respiratory tract where they are phagocytosed and removed, they can also 
deposit in the airway, and may migrate elsewhere in the body. Non-phagocytosed 
PM may leach into the systemic circulation, causing oxidative stress and 
inflammation at distant organs (figure 1.8).  
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Figure 1.8. Inhaled particles encountering alveolar macrophages in the distal 
airways. Non-phagocytosed particulate matter will either stay within the airway and 
invade other airway cells, or leech into the systemic circulation, resulting in oxidative 
stress and inflammation at a distant site.  
Using animal models, Nemmar et al. 90 showed that ultrafine particles were able to 
penetrate tissue compartments, travel through the circulation, and be taken up by 
mouse erythrocytes; Oberdorster et al. 91 showed that particles could deposit along 
the respiratory tract lining in rats, followed by translocation to extra-pulmonary 
organs within 24 hours of inhalation exposure; Campagnolo et al. 92 reported 
increased production of placental inflammatory cytokines following translocation of 
inhaled nanoparticles to placenta in mice. For human studies, in vitro work has 
demonstrated invasion and accumulation of nanoparticles in placental tissue 93, with 
the smaller particles (3-4 nm) being able to penetrate deeper 94; while a human ex 
vivo study showed that nanoparticles with a diameter up to 240 nm were able to 
cross the placental barrier and be taken up by placental tissues 95. Particle 
translocation is another possible explanation for pollutants’ adverse effects on the 
developing fetus.  
Circulation 
Other airway cells 
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Besides translocating via the circulation, ultrafine particles instilled intra-nasally can 
travel along the olfactory nerve into the central nervous system, by-passing the 
blood-brain barrier 96. Indeed, a recent study showed that magnetite pollutant 
particles with diameter <200 nm, arose from inorganic high temperature 
combustion, could enter the brain via the olfactory bulb 97.  
To this date, however, the transport of particles beyond the human respiratory 
system remains unclear.  
Summary: How does air pollution affect health? 
 Inhaled air pollutants such as particulate matter and nitrogen oxides are
potent oxidants and can cause oxidative stress, resulting in cell damage
and/or death.
 Air pollutants promote airway inflammation by enhancing the production
of inflammatory mediators.
 Inhaled particles that are not phagocytosed by alveolar macrophages
can cause local inflammation and damage in other airway cells, but may
also translocate via the circulation and exert their toxic effects directly at
a distant site – as demonstrated by animal models.
What is still unknown? 
 The direct and local consequences of non-phagocytosed inhaled
particles within the human airway remain unclear.
 There is a lack of data on the feasibility, mechanism, and consequences
of particle translocation in humans.
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1.5. Measuring air pollution exposure in children 
As discussed so far, air pollution poses short-term and long-term health effects 
across the life course, with children, particularly those with respiratory conditions, 
being most vulnerable. In order to further understand the impact of air pollution on 
the population, it is important to measure their pollution exposure.  
Measurement and quantification of an individual’s exposure to air pollution can be 
challenging. Long-term exposure depends on numerous variables such as weather, 
individual’s daily routine and behaviour (e.g. nature of work, mode of transport, 
outdoor activities), home and work environment (urban vs rural).  
Pollution exposure can be estimated by models generated from static 
measurements, or measured by pollution monitors. 
1.5.1. Air pollution monitoring networks 
Air pollution monitoring networks are established in most urban areas worldwide – 
London has one of the world’s biggest networks (the London Air Quality Network 
(LAQN)), with nearly 100 monitors scattered across the city 98 (figure 1.9). Pollutant 
concentrations are measured continuously, providing data on temporal and 
seasonal variabilities of air pollution. These data are sometimes used to model the 
population’s external exposure to air pollution – using the mean concentration over 
a defined time period, with the assumption that exposure remains the same for all 
inhabitants in the area over the course of the day 99. 
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Since busy roads contribute to most of London’s pollution hotspots, roadside 
monitors are usually mounted on lampposts or road signs within 1-5 m of busy 
roads, aimed to not only give an estimate of the public’s exposure to air pollutants, 
but to also identify traffic hotspots 98. 
Figure 1.9. London Air Quality Network monitoring sites, showing locations of road 
side, suburban and urban pollution monitors, measuring carbon monoxide, nitrogen 
dioxide, ozone, particulate matter (PM2.5 and PM10), and sulphur dioxide.  
Adapted from the London Air website 
(https://www.londonair.org.uk/london/asp/publicdetails.asp?region=0).  
The LAQN website provides real time and annual information on air pollution in 
London and south east England. The data are readily available for the general 
public. Figure 1.10 is an example of real time air pollution map using postcodes. 
Figure 1.11 is a map showing modelled annual mean NO2 level in London in 2016. 
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Figure 1.10. Real time air pollution map, showing indices of nitrogen dioxide (NO2), 
ozone (O3), particulate matter (PM10 and PM2.5), modelled using postcode. Adapted 




Figure 1.11. Modelled annual mean nitrogen dioxide (NO2) level in London, 
using measurements from 2016. Adapted from the London Air website 
(https://www.londonair.org.uk/london/asp/annualmaps.asp). 
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The advantage of using modelled data on air pollution exposure is that it is easy 
and ready-made. The disadvantages being it is difficult to separate background 
from local levels of pollutants; modelling assumes uniform exposure to the 
population so unless the individual resides closely to a monitor, it may not be an 
accurate representation of exposure. 
1.5.2. Portable monitors 
Portable monitors are designed to measure short-term personal exposure to air 
pollutants more accurately than roadside monitors, without the need to assume 
equal temporal, spatial and personal factors across the population. 
1.5.2.1. Aethalometer 
An aethalometer (figure 1.12) is an instrument which measures the concentration of 
optically absorbing suspended black carbon in a gas stream, as seen in polluted 
ambient air. Ambient air is forced through the instrument by suction, depositing any 
black carbon on the filter. A light beam projected through the filter is attenuated by 
the deposited particles, which are absorbing “black”, since black colour is the most 
optically absorbent. Measurements are made at successive regular time intervals. 
The advantages of aethalometers include their pocket-size so they can be worn on 
person and provide black carbon concentrations in real time, allowing for exposure 
monitoring in different micro-environments (e.g. commute, outdoor activities, indoor 
at home or at school). Their use, however, is limited by high cost and battery life – 
each full battery charge will last approximately 24 hours. This will be discussed in 
more detail in chapter 2. 
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Figure 1.12. A portable aethalometer with a black sampling suction tube, measuring 
the concentration of black carbon in ambient air in real time.  
1.5.2.2. Gas diffusion samplers 
Gaseous pollutants, such as NO2 and SO2, can be collected onto a sampler (figure 
1.13) using molecular diffusion technique, measuring their concentrations over time. 
The advantages include the lower price and ease to use – they are not electrical 
and can be clipped onto an individual’s clothing during the sampling period. The 
disadvantages are that they are unable to give real time results; the results are 
derived using multifaceted calculations based on estimated temperature and 
atmospheric air flow; more details will be discussed in chapter 2. Besides, the 
samplers are clipped onto clothing or schoolbags, and are easily damaged or 
misplaced. 
Figure 1.13. Nitrogen dioxide diffusive sampler, manufactured by IVL Swedish 
Environmental Research Institute. The sampler can be clipped onto clothing. NO2 
molecules are quantitatively collected onto a filter behind the silver mesh, which 
prevents turbulent diffusion, giving a concentration value of NO2 integrated over 
time. 
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1.5.3. Alveolar macrophage black carbon 
As mentioned in section 1.2.2., inhaled carbonaceous particles reaching the distal 
airways are phagocytosed by alveolar macrophages, found along the epithelial 
surface 100. The surface area of black carbon visible in AM – alveolar macrophage 
black carbon (AMBC) – can be measured using light microscopy image analysis. 
AMBC has been shown to have a dose-dependent relationship with lung function 
and asthma severity in children 101,102, and is universally accepted as an internal 
marker which reflects an individual’s cumulative exposure to combustion-derived 
PM 103. The average clearance half-life of AMBC is reported to be 53 to 116 days, 
subject to the carbon load 104.  
AMs can be sampled by sputum induction or bronchoalveolar lavage (BAL). While 
BAL is likely to sample macrophages from the alveoli and distal airway, sputum 
induction may amass macrophages from both lower and upper airway. As 
mentioned in section 1.2.2.2.1, airway macrophages are thought to be AMs which 
have travelled upwards along the bronchial tree, therefore they have similar 
phenotype and functional capacity – sputum induction is therefore accepted as a 
method of AM sampling. Tillery et al.105 have shown that AMs obtained by sputum 
induction are larger than those obtained by BAL, containing a higher carbon load. 
However, once the macrophage size is normalised, AMs obtained by both methods 
have similar BC phagocytic ability, suggesting both forms of collection are 
comparable when assessing AMBC. However, BAL is more invasive and requires 
general anaesthesia in children, while sputum induction carries low risks and can 
be performed outside of clinical settings. The use of sputum induction to sample 
AMs will be further discussed in sections 2.6. and 3.5.  
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1.5.4. Urinary black carbon 
A different internal marker for black carbon has been used in recent years – 
systemic carbon cleared from the circulation can be detected in urine, using white-
light generation under laser illumination. Urinary black carbon has been shown to 
reflect medium to long term exposure to PM 106, and is a non-invasive monitoring 
method. However, there is risk of contamination from ambient air black carbon 
during urine collection. Besides, urinary carbon does not exclusively reflected 
inhaled dose of black carbon which can enter the body through other routes (e.g. 
gastro-intestinal tract). 
Summary: Monitoring individual’s air pollution exposure 
 Air pollution exposure can be measured either on a population level,
using stationary monitors within a national network; or on an individual
level using portable monitors.
 Internal biological markers of air pollution exposure are available –
alveolar macrophage black carbon loading reflects an individual’s long
term exposure to particulate matter, albeit relying on the functional
capacity of alveolar macrophages.
What is still unknown? 
 There is limited data on individual’s exposure within different micro-
environments (e.g. indoor at school/work, indoor at home, commute
to/from school/work, outdoor activities).
 Data on individual’s long term personal exposure to pollutants is lacking.
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1.6. Protection against air pollution 
Since the main sources of air pollution are from fossil fuel combustion and road 
traffic, policy makers for national and international regulations hold the main 
responsibility to reduce overall air pollution for the benefit of the general public. 
However, raising individuals’ awareness, and taking various measures to reduce 
one’s exposure to pollution will still be beneficial, particularly for children with chronic 
respiratory conditions. 
1.6.1. Health advice 
Information on air pollution is readily available on the internet. WHO publishes 
guidelines and reports on air pollution regularly; the UK Department of Environment, 
Food and Rural Affairs website has an air quality forecast; the London Air Quality 
website provides real time air pollution data across the capital. The British Lung 
Foundation provides recommendations on various actions to take at different 
pollution levels (table 1.2).  However, these measures cannot provide complete 
protection, and there is limited information on whether these are attainable over long 
periods of time in order to achieve health benefits. 
Table 1.2. Recommendations on measures to take according to air pollution levels. 
Adapted from the British Lung Foundation website (https://www.blf.org.uk/support-
for-you/air-pollution/tips). 
Pollution level Measures 
Low  Avoid spending long periods of time along busy roads
Moderate  Reduce or avoid strenuous outdoor activities
High  Reduce or avoid strenuous outdoor activities
 Avoid pollution hotspots
 Avoid rush hours, travel before pollution levels build up
 Use less polluted routes when cycling, walking or running
 Use of reliever inhaler if pollution is a trigger to asthma
 ± Seek medical attention
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1.6.2. Measures to reduce air pollution exposure 
Based on information from the abovementioned organisations, the public are 
advised to avoid busy roads and pollution hotspots. On an individual level, active 
forms of transport such as walking, cycling, and scooting are encouraged. 
Carpooling or use of public transport are more fuel-efficient, and can reduce 
individuals’ contribution to air pollution emissions.  
Adequate ventilation during cooking can lower indoor air pollution exposure, 
especially in houses using gas cook stoves. Air purification is a contemporary 
solution to indoor air pollution, however even high efficiency air purifiers have 
limitations. Pollutants may settle before reaching the filter; gaseous pollutant filters 
have short lifespans and require regular replacement; and ambient air humidity can 
affect purifiers’ performances. Besides, air purifiers rely on electricity, which may 
not come from sustainable sources. 
There are numerous facemasks which claim to reduce inhaled dose of air pollutants, 
their effectiveness is tested in a laboratory rather than real-life setting. To date, there 
are limited studies on the biological effectiveness of these masks; their actual health 
benefits remain unclear.  
On a national level, tree and hedge plantations around playgrounds and schools 
may reduce children’s exposure to PM – these act as a physical barricade to 
intercept airborne particles, but will not remove the presence of such particles.  
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Tougher governmental regulations on vehicle emissions and scrappage schemes 
are effective ways to improve ambient air quality. For example, the Institute for 
Public Policy Research (IPPR) predicted that phasing out diesel engines in London 
would lead to enough NO2 reduction to fulfil EU standards 107. They estimated that 
1.4 million life-years could be gained, and up to £800 million financial benefits could 
be achieved with a 56% reduction in NO2 and a 45% reduction in NOX 107.  
Summary: Health advice on air pollution exposure reduction 
 On an individual level, the public are advised to avoid pollution hotspots,
and to engage in activities (e.g. walking, cycling) that contribute less to
air pollution generation.
 Online resources are available to advise the public, especially patients
with chronic diseases, on measures to take to reduce air pollution
exposure.
 On a national level, stricter policies on vehicle emissions and fuel
choices are urgently required.
What is still unknown? 
 There is limited evidence base for whether the air pollution exposure
reduction measures, especially those on an individual level, are
achievable over the long periods of time, or sufficient to significantly
improve health.
 The biological effectiveness of facemasks remains unclear.
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1.7. Cystic fibrosis 
In section 1.3., the negative health impact of air pollution was discussed. Children, 
particularly those with existing respiratory conditions such as cystic fibrosis, are 
especially vulnerable.  
Cystic fibrosis (CF) was first formally described as a disease in 1930s, but 
references to CF date back to the medieval times when Northern European folklore 
cautioned “woe is the child who tastes salty from a kiss on the brow, for he is cursed, 
and soon must die”. 
Cystic fibrosis is the most common hereditary life limiting respiratory condition in the 
Caucasian population, affecting around 1 in 2500 live births 108. It is inherited in an 
autosomal recessive fashion, caused by mutation in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene, located on the long arm of 
chromosome 7. CFTR is a 1480-amino-acid-long transmembrane glycoprotein, an 
ATP-binding cassette (ABC) transporter-class anion (chloride and bicarbonate) 
channel protein, which is found in the apical membrane of epithelial cells and 
submucosal glands 109-111. The airways have one of the highest expressions of 
CFTR 112, which also regulate epithelial sodium channel 111. Over 2000 CFTR 
mutations have been identified but not all result in CF 113, with some extremely rare 
variants of unknown functional significances.  
Mutations lead to absent (class I), misfolded (class II), defective gating (class III), 
defective conduction (class IV), insufficient (class V), or unstable (class VI) CFTR 
(figure 1.14), resulting in defective ion transport, enhanced sodium absorption, 
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1.7.1. Host defence in cystic fibrosis 
Since ion transport is coupled with water flow, dysfunctional chloride channels will 
lead to reduction and dehydration of the ASL 115, and subsequent mucociliary 
functional impairment, allowing harmful inhaled particles and pathogens to persist 
within the airways 116. Accumulation of thickened mucus in the lung results in chronic 
cough, wheeze, recurrent respiratory infections and airway inflammation; the 
combination of which instigate lung function decline and irreversible lung damage 
117.  
Normally, the ASL layer is able to initiate rapid bacterial killing. However, a porcine 
model has shown that a lack of functional CFTR can result in reduced ASL 
eradication of bacteria, even with relatively little infection or inflammation 118. This 
can potentially be explained by the lower pH in CF ASL, which can attenuate anti-
microbial peptides such as lysozyme 111. The low pH is caused by defective 
bicarbonate transport, which is partly responsible for the production of viscous 
mucus 111. Moreover, it has been shown that mice with ASL depletion could develop 
spontaneous airway inflammation 119, suggesting mucus plugging alone might be 
significant – potentially due to airborne irritants, such as air pollutants, being trapped 
in the airways, causing pro-inflammatory cytokines release.  
The thick mucus and dehydrated environment of the CF airway can affect the 
phenotype of macrophages, altering their ability to phagocytose and regulate 
inflammation 120. Indeed, studies have suggested that other than epithelial cells, 
CFTR is also expressed in immune cells such as neutrophils and macrophages – 
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CFTR in AMs help maintain phagosomal pH, its mutations can therefore lead to 
defective bacterial killing 121.  
1.7.1.1. Alveolar macrophage function in CF 
As discussed in section 1.2.2, AMs are important cells for inhaled PM removal. AMs 
obtained from BAL samples of children with CF showed reduced phagocytic ability 
secondary to reduced MHC Class II and mCD14 (a monocyte/macrophage 
differentiation antigen which plays a role in macrophage TLRs activation by 
lipopolysaccharide) expression during disease exacerbations 122. Reduced 
scavenger receptor expression was seen on AMs obtained from induced sputum of 
patients with CF, resulting in impaired florescent particle uptake compared to their 
healthy counterparts 123. This was supported by findings in a bronchiectasis cohort, 
where AMs from children with bronchiectasis also had reduced expression of 
scavenger receptors and dysfunctional phagocytosis in vitro 124. The size of AMs 
can also influence their function – compared to healthy controls, smaller AMs are 
often found in patients with CF; these AMs have weaker phagocytic ability when 
confronted by un-opsonised particles 123. Interestingly, despite their smaller size, 
absolute number of AMs found in CF airways is higher during late fetal stage and 
childhood, even in the absence of active infection 120, suggesting the condition is 
intrinsically pro-inflammatory – this will be explored further in section 1.7.2. 
To better understand AM phagocytic function in CF, a literature search on PubMed 
was performed. Using the key terms “alveolar macrophage”, “cystic fibrosis”, and 
“phagocytosis”, searching articles published in English from years 1980-2019, 60 
articles were identified, 9 of which were summarised in appendix 1 – excluding 
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review articles, studies focusing on how bacteria invade or interfere with AM function 
(rather than looking at CF AM function as a primary objective), and studies not 
related to cystic fibrosis. From the studies reviewed, CFTR knock-out mice showed 
reduced phagocytosis of bacteria (e.g. Pseudomonas aeruginosa and 
Staphylococcus aureus); human studies using AMs obtained from sputum induction 
or bronchoalveolar lavage, and human monocyte-derived macrophages, not only 
showed similar phagocytic impairment, but further demonstrated the suppressive 
effects of CF secretions. These in vitro findings suggest that AM phagocytosis of 
bacteria, fungi, apoptotic cells and un-opsonised fluorescent particles is impaired in 
CF, potentially related to the altered airway environment that the cells are exposed 
to. 
1.7.1.2. Other host defence impairment in cystic fibrosis 
The altered CF immune system is undoubtedly multifactorial. Aside from the 
aforementioned mechanisms, other immune pathways are also affected. For 
example, not only is CFTR involved in neutrophil development, its mutation can also 
disturb neutrophil conductance of halides across the phagosomal membrane, 
thereby reducing their bacterial-killing capacity 125. CFTR is also responsible for 
maintaining expression of many genes which are implicated in important immune 
processes, such as phagocytosis, complement activation, T-cell and B-cell 
activation, and apoptosis; suggesting CFTR has alternative roles to chloride 
transportation 126.  
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1.7.1.3. Opportunistic infections in cystic fibrosis 
With an altered immune system, children with CF are susceptible to opportunistic 
infections; pathogen colonisation is encouraged by viscous mucus and impaired 
mucociliary clearance. An example is Pseudomonas aeruginosa, which is isolated 
in 80% of patients’ airways 127, contributing substantially to morbidity and mortality. 
P. aeruginosa is able to form biofilms, express virulence factors in order to resist
the innate immune system, and adapt and mutate during chronic infections 128. 
Despite the hypoxic environment of CF airways due to increased oxygen 
consumption by the epithelium 129, the growth of P. aeruginosa can occur through 
anaerobic means using nitrate and nitrite, both are found within CF respiratory 
secretions 130. Other pathogens commonly isolated in CF airways include 
Staphylococcus aureus, Haemophilus influenzae, Stenotrophomonas maltophilia, 
Achromobacter xylosoxidans, non-tuberculous mycobacteria and Burkholderia 
cepacia, all contributing to recurrent chest exacerbations and lung function 
deterioration. 
1.7.1.4. Mechanisms of bacterial survival within the host 
Comparing macrophages with normal vs defective CFTR showed that the 
autophagy genes were downregulated in CFTR defected cells, resulting in an 
increased amount of bacteria present intracellularly 131. Indeed, there is evidence 
that some organisms are able to invade and survive intracellularly in patients with 
CF via two ways: 1) cytosolic bacteria can avoid endocytosis, and replicate within 
the host cytosol; 2) intravacuolar bacteria can reside and replicate within the host 
vesicular endomembrane system, inside a modified membrane-bound 
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compartment 132.  Remarkably, despite being key immune cells, macrophages seem 
to be targeted by these intracellular bacteria as a place of residence.  
 
An example of such bacteria is Burkholderia cepacia. With resistance to multiple 
antibiotics, it renders the host ineligible for lung transplantation and presents a major 
challenge in CF management. It has been shown that Burkholderia species are able 
to enter, survive, invade and replicate intracellularly within macrophages 133, where 
they grow as single or clusters of cells 134.  
 
Other than CF, bacteria-laden macrophages can also be found in other chronic 
inflammatory diseases such as inflammatory bowel disease. These macrophages 
express higher levels of cytokines compared to un-laden macrophages, thereby 
contributing to and worsening the chronic inflammation cascade 135. Indeed, high 
amounts of cytokines are present in the CF airway – this will be further discussed 
in the next section. 
 
1.7.2. Airway Inflammation in cystic fibrosis 
CF lung disease is predominantly secondary to recurrent bacterial infections and 
chronic airway inflammation, inevitably resulting in respiratory decline 116. As 
mentioned in section 1.7.1.1., while recurrent infections were traditionally accepted 
as promoters for inflammatory cascades, studies have demonstrated that an 
intrinsic pro-inflammatory state exists in the CF airway even without evidence of 
infection during the fetal stage 136.  The overwhelming presence of inflammatory 
cytokines and prostaglandins within the CF airway contributes to inflammation 137 
and lung damage. This pro-inflammatory environment can also promote 
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macrophage polarisation to M1 macrophages 120; while dysfunctional CFTR can 
affect polarisation to M2 macrophages – this imbalance of M1 and M2 macrophages 
plays a part in the excessive inflammatory response in CF 31. There is also evidence 
that peripheral macrophages from CF patients have an amplified inflammatory 
response to mediators, suggesting that CF macrophages are intrinsically pro-
inflammatory 120.  
Upon infections, airway cells release inflammatory mediators which stimulate 
neutrophil influx. While neutrophils are recruited to fight pathogenic organisms, they 
also pose detrimental effects. Neutrophil influx leads to the release of oxygen 
radicals and proteases such as elastase. This, coupled with overwhelmed anti-
elastase defence, result in structural lung damage 116,138,139. Indeed, airway 
neutrophil elastase activity detected in early life of children with CF was shown to 
be related to the development of bronchiectasis in childhood 112.  
1.7.2.1. Prostaglandins and cyclooxygenase in cystic fibrosis 
It has been suggested that defective CFTR is associated with altered regulation of 
inflammation. For example, prostanoid metabolism in the lower airways in CF is 
abnormal, causing an overproduction of prostaglandins (PGs) 140. This can 
theoretically explain the presence of inflammation despite a lack of infection in early 
neonatal life.  
PGs, leukotrienes (LT) and lipoxins are all eicosanoids. PGs are lipid compounds 
that regulate inflammatory responses such as vasoconstriction or dilatation, 
inflammatory cell chemotaxis, platelet aggregation and pain sensitisation; they play 
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an important part in lung diseases such as asthma and CF. PGs are produced by 
most nucleated cells, and are released in the airways from epithelial cells, DCs, 
fibroblasts and AMs. Types of PGs include prostaglandin D2 (PGD2), prostaglandin 
E2 (PGE2), prostaglandin F2α (PGF2α), and prostaglandin I2 (PGI2) – these 
subtypes have different roles and bind to different E-prostanoid receptors (EP1-
EP4). For example, PGD2 is known to play a role in the development of atopy; while 
PGE2 acts mostly on the smooth muscles of the respiratory and gastrointestinal 
tracts, mediating inflammation through ligation of G protein-coupled receptors 141. 
Arachidonic acid (AA), a fatty acid derived from diet, is metabolised by 
cyclooxygenase (COX) to form PGs (figure 1.15).  
Figure 1.15. Prostaglandin synthesis pathway. 
COX are classified into COX-1 and COX-2. COX-1 enzymes are found in most 
tissues and are involved in PG production under physiological conditions. 













































Conversely, COX-2 enzymes are rarely found in tissues, they act to produce PGs 
only when induced by inflammatory stimulants 142. COX-2 is therefore regarded as 
an anti-inflammatory target. Indeed, in a human CF bronchial epithelial cell line, 
Chen et al. 137 demonstrated that COX-2 expression was increased with over-
production of PGE2; they also showed similar findings in CFTR knockout mice 
(figure 1.16). Roca-Ferrer et al. 140 showed that COX-2 was up-regulated in nasal 
polyps in patients with CF, leading to increased production of PGs (figure 1.17). 
CFTR is therefore proposed to play a role in AA metabolism – as a protective 
regulator of the inflammatory response mediated by PGE2 143. Certainly, increased 
levels of PGE2 are seen in BAL, sputum, exhaled air, saliva and urine of patients 








Figure 1.16. Real‐time quantitative reverse transcription polymerase chain 
reaction (RT‐PCR) results showing higher levels of cyclooxygenase-2 (COX‐2) 
mRNA in the lungs of CFTR −/− (KO) mice compared to CFTR +/+ (WT) mice 





Figure 1.17. Reverse transcription polymerase chain reaction (RT-PCR, 106 cDNA 
molecules/μg total RNA) of cyclooxygenase-2 (COX-2) in CF nasal polyps, non-CF 
nasal polyps, and nasal mucosa. Reproduced with permission from Roca-Ferrer et 
al. 140, Thorax. 
Of all PG types, PGE2 is reported to have an inhibitory effect on AM functions. In 
the airway, production of PGE2 takes place in epithelial cells, endothelial cells and 
leukocytes including AMs, neutrophils, T cells and dendritic cells – with AMs being 
a dominant source during infections 149.  Using rat AMs, PGE2 has been shown to 
inhibit microbicidal activities and phagocytosis of apoptotic cells 141 (figure 1.18). It 
can also inhibit phagocytosis of urban particulate matter 102 (figure 1.19) 
Figure 1.18. Inhibition of rat alveolar macrophage phagocytosis of IgG-opsonised 
sheep red blood cells (sRBC), immune serum (IS)-opsonised live K. pneumoniae, 
and FITC-labelled IgG-opsonised E.coli; when exposed to different concentrations 
of PGE2. Data showing the inhibitory effects of PGE2 on phagocytic ability. 
Reproduced with permission from Aronoff et al. 141, The Journal of Immunology. 
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Figure 1.19. Effect of PGE2 on phagocytosis of urban PM10 by rat airway 
macrophages. Data demonstrating the inhibitory effect of PGE2 on AM phagocytosis 
(*p<0.05). Reproduced with permission from Brugha et al, Thorax. 
Acting via inhibition of TNF-α and IL-12 production, and reduction of MHC II 
expression, PGE2 can suppress proliferation, differentiation, migration, and 
activation of macrophages at a concentration as low as 10-10 M 150.  This suppressive 
effect is associated with increased intracellular cyclic adenosine monophosphate 
(cAMP) production on ligation of receptors EP2 and 4 141,151. EP2 receptor activation 
prohibits FcR-mediated phagocytosis 149; and is most frequently expressed on 
maturing macrophages. It is therefore considered the major mediator in the 
inhibitory effect of PGE2 150. Unsurprisingly, the inhibitory effect of PGE2 can be 
reversed by EP2 antagonists 141 (figures 1.20 and 1.21). 
Figure 1.20. Left: PGE2 acting on a macrophage via EP2 receptors. Right: EP2 







Figure 1.21. Effects of PGE2 on AM phagocytosis in wide type (WT) and EP2 knock-
out (KO) mice, when exposed to opsonised E.Coli. Data showing EP2 KO mice are 
protected from the inhibitory effect of PGE2 on phagocytosis. Reproduced with 
permission from Aronoff et al. 141, The Journal of Immunology. 
 
Since PGs are chemically unstable, urinary metabolites of PGs are generally 
accepted as an index of PG biosynthesis. Notably, concentrations of PGE2 
metabolites are shown to be associated with genotype severity in CF 143.  
 
In order to better understand the interactions between PGE2 and AM function, a 
literature search on PubMed was performed, using the key terms “PGE2”, “alveolar 
macrophage” and “phagocytosis”. Searching articles published in English from 
years 1980-2019, 52 articles were identified, 9 of which were reviewed, excluding 
review articles and studies unrelated to PGE2 or AM function. A summary of these 
studies can be found in appendix 2. All reviewed studies suggest that PGE2 can 
inhibit macrophage function, including bacterial, viral or fungal clearance and killing. 
Of note, increased production of PGE2 is seen in post bone marrow transplant 
murine models, resulting in impaired host defence against bacteria. One animal 
model showed that pre-treatment with COX inhibitor could reverse AM phagocytosis 
suppression. Despite strong associations between PGE2 and impaired AM 
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phagocytosis, studies using primary human AMs to assess the effects of PGE2 are 
lacking.  
Despite previous work showing both PGE2 and PGD2 supressing human monocyte-
derived macrophage phagocytosis (figure 1.22), albeit PGD2 to a lesser extent than 
PGE2 152, other studies have shown that PGD2 enhances and activates macrophage 
effector function 153,154. Therefore, PGE2 remains a major focus as a suppressor of 
AM function.  
Figure 1.22. Left: Human monocyte-derived macrophages pretreated with 
PGE2 (10 μM) and PGD2 (10 μM) for 15 min, assessed for in vitro phagocytosis of 
cultured neutrophils. The percentage of macrophages ingesting apoptotic 
neutrophils is expressed as the mean ± SEM. *p < 0.05 compared with control. 
Right: Concentration-response effects of PGE2 and PGD2 on macrophage 
recognition of apoptotic cells. Human monocyte-derived macrophages pretreated 
with varying concentrations of PGE2 and PGD2 for 15 min, assessed for in vitro 
phagocytosis of cultured neutrophils. The percentage of macrophages ingesting 
apoptotic neutrophils is expressed as the mean ± SEM. Reproduced with 
permission from Rossi et al.152, the Journal of Immunology. 
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1.7.2.2. Cytokines in cystic fibrosis 
The CF airway is overwhelmed with inflammatory cytokines. These are secreted by 
epithelial cells, macrophages and neutrophils; secondary to COX-2 expression 155 
and CFTR dysfunction 117. As mentioned above, structural and disease progression 
in CF may be independent of bacterial infections 156, signifying that intrinsic 
inflammatory processes occur intuitively even without external insults or triggers.  
Upon pathogenic invasion, phagocytes, including macrophages, eliminate and 
maintain inflammation by producing tumour necrosis factor (TNF), and interleukin 
(IL-1, IL-6, IL-8, IL-12) 37,157, all known to be elevated in CF lungs 120. With 
macrophages being the first responders to invasion, they are likely to be the first to 
release cytokines such as IL-8, which subsequently recruit neutrophils 37. Indeed, 
IL-8 is found to be increased in respiratory secretions of CF patients even during 
stable clinical states 158.  
1.7.3. Treatments and therapies in cystic fibrosis 
Life expectancy of CF has improved dramatically over the last few decades. In 2011, 
the median survival was 41.4 years, but patients born after 2000 are estimated to 
survive beyond 50 years 159.  
Traditional treatments of CF include airway clearance with nebulised mucolytics 
(e.g. hypertonic saline, dornase alfa), inhaled bronchodilators (e.g. salbutamol), 
topical nasal steroids for polyps, and chest physiotherapy. Chest exacerbations are 
managed with antibiotics which are usually empirical but can also be tailored 
according to sputum or cough swab microbiology growths. Special dietary 
75 
requirements in CF include pancreatic enzymes (e.g. Creon) with meals, vitamins 
and mineral supplements, and in some cases, high calorie supplements. In severe 
cases of CF, lung transplantation will be considered. This is a complex process 
requiring meticulous planning, and candidate selection can be challenging. The 
timing of listing patients for transplant is crucial, usually guided by lung function and 
respiratory complications such as exacerbations, pneumothorax and haemoptysis. 
Contraindications such as infections with resistant organisms such as B. cepacia, 
also need to be considered. 
A more recent development in CF treatment is CFTR modulators which restore or 
improve mutant CFTR function. To date, three CFTR modulators have been 
approved for use in CF – ivacaftor (a “potentiator” for gating mutations – e.g. G551D 
– by opening the defective chloride channels), lumacaftor/ivacaftor (a combination
treatment with a “corrector” which enables correct CFTR formation and trafficking 
to cell surface, and a “potentiator”) and tezacaftor/ivacaftor (another combination of 
“corrector” and “potentiator”). Presently, triple drug combination therapies are 
undergoing clinical trials with the potential to enhance overall clinical effectiveness. 
Although promising as the CFTR modulators appear to be in clinical trials, many 
patients are not able to receive these treatments. Lumacaftor/ivacaftor was 
previously not recommended by the National Institute for Health and Care 
Excellence (NICE) guidelines due to funding; while the NICE review on 
tezacaftor/ivacaftor was suspended. It was only recently that these drugs became 
available on the National Health Service in the UK. Beside the availability of these 
drugs, there are also patients with mutations that are not targeted by the modulators. 
Therefore, while new treatments should be explored and developed, management 
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of disease complications (e.g. viscous mucus, recurrent infections, inflammation 
and chest exacerbations) should remain a priority in order to improve patients’ 
quality of life.  
In relation to the discussion in section 1.7.2.1., COX inhibitors such as non-steroidal 
anti-inflammatory drugs (NSAID, e.g. Ibuprofen), when used in high dose (defined 
as peak serum concentration of 50 to 100 µg/ml, daily dose adjusted accordingly 
for each individual), were shown to slow lung disease progression in patients (adult 
and paediatric) with CF with overall good tolerance 160,161 (figure 1.23). This was 
supported by a recent paediatric cohort study which showed that high dose 
Ibuprofen was associated with slower lung function deterioration and improved 
survival in children with CF 162. 
Figure 1.23. Annual rate of change in lung function between ibuprofen and placebo 
groups: forced vital capacity (FVC) % predicted of −1.62% ± 0.52% for placebo vs 
−0.07% ± 0.51% for ibuprofen. No significant difference in mean annual rate of 
decline in forced expiratory volume in 1 second (FEV1) % predicted. Reproduced 
with permission from Lands et al. 157, the Journal of Pediatrics. 
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Summary: Host defence in cystic fibrosis 
 CFTR mutations result in thickened airway secretions, rendering the
hosts susceptible to recurrent bacterial infections, lung function decline
and structural damage.
 Alveolar macrophages in CF are smaller in size, with reduced expression
of cell surface receptors, and therefore reduced phagocytic capacity.
 CF patients are susceptible to opportunistic infections, not only is the CF
airway encouraging to bacterial growth due to increased mucus viscosity,
bacteria (e.g. Burkholderia species) can survive and replicate within
phagocytes.
 There is an imbalance of M1 and M2 macrophage polarisation in CF,
which further aggravates the underlying airway inflammation caused by
recurrent respiratory infections.
 Prostaglandin mediated inflammatory responses are regulated by CFTR;
and there is an increased production of prostaglandins in CF.
 PGE2 is shown to impair AM phagocytosis in animal models.
What is still unknown? 
 There are no current studies looking at AM phagocytosis of air pollutants.
 There is a lack of human studies looking at the role of PGE2 in AM
functional impairment in CF, and the consequences of such dysfunction.
 It is unclear whether PGE2 is permanently elevated in CF airways.
 The roles of other prostaglandins remain unclear.
 The potential modulation of PGE2 production, and the benefits of using
low dose COX inhibitor in CF remain uncertain.
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1.8. Air pollution and cystic fibrosis 
With a compromised immune system, children with CF are more vulnerable to the 
adverse effects of ambient air pollution, which predisposes them to chest 
exacerbations 163  and subsequent lung function deterioration.  
1.8.1. Respiratory infections and pulmonary exacerbations 
It has been shown that PM, NO2 and ozone levels around CF patients’ home 
addresses correlate positively with episodes of chest exacerbations 163 (figure 1.24). 
Figure 1.24. Antibiotic (AB) treatment per 10 µg/m3 increase in PM10, ozone and 
NO2. Data showing: (A) Assessment of all events (at the start of either oral or IV 
treatment): at lag 0, there is an overall significance. At lag 1, only NO2 showed 
significance. (B) Assessment of start of IV treatment: at lag 0, there is an overall 
significance. (C) Assessment of start of oral treatment: at lag 0, there is an overall 
significance, except for ozone.  
lag 0 = the day of the start of antibiotic treatment; lag 1 = the day before the start of 
antibiotic treatment; lag 2 = 2 days before the start of antibiotic treatment. Adapted 
and reproduced with permission from Geominne et al163, Chest. 
79 
A retrospective study of children aged <5 years by Psoter et al. 164 showed that a 
10 µg/m3 increase in PM2.5 exposure was associated with earlier Pseudomonas 
aeruginosa acquisition (i.e. 24% increased risk of Pseudomonas acquisition). They 
later demonstrated in another retrospective study of children <6 years of age, that 
the same increase in PM2.5 exposure led to a 68% increased risk of methicillin 
resistant Staphylococcus aureus (MRSA) acquisition during follow up 165, 
suggesting PM2.5 as a risk factor for initial Pseudomonas and MRSA acquisition in 
children with CF. 
1.8.2. Lung function decline 
Further to section 1.3.2.1., air pollution can impact on children’s lung function and 
growth. These effects will affect children with CF more, because FEV1 is an 
important predictor of their morbidity and mortality. Indeed, Goss et al. 166 showed 
that an increase of PM2.5 by 10 µg/m3 could reduce the FEV1 by 155 ml in patients 
with CF.   
1.8.3. Dysfunctional alveolar macrophage in cystic fibrosis 
Functional AMs phagocytose inhaled PM, thereby protecting other airway cells from 
the inflammatory processes induced by non-phagocytosed PM – this is likely to be 
attenuated in CF, where phagocyte function is deficient. As reported by Wright et 
al. 123, sputum macrophages from patients with CF are smaller and have reduced 
MARCO and CD206 (mannose receptor) expression (figures 1.25 and 1.26). 
Impaired autophagy with altered phagosome maturation, phagolysosome 
formation, lysosomal function and lysozyme production are seen in CF 120. This is 
supported by an animal study which demonstrated impaired nanoparticles uptake 
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by macrophages in CFTR mutant mice, resulting in increased particle uptake by 
epithelial cells, and a normal inflammation resolution 167. 
Figure 1.25. Percentage of small macrophages in adult classical CF patients (age 
21.5 ± 4 years), non-classical CF patients (age 42.5 ± 10 years), and controls (age 
35.2 ± 12 years). The average value for the controls was 16 ± 8%; classical CF was 
73 ± 18%, and non-classical CF was 31 ± 20%. * p < 0.0001, unpaired t–test. Bars 
represent means. Reproduced with permission from Wright et al. 123, Journal of 
Leukocyte Biology. 
Figure 1.26. Presence of CD206 and MARCO receptors mRNA isolated from 
control (n = 3) and CF (n = 3) macrophages. * p < 0.01. Reproduced with permission 
from Wright et al. 123, Journal of Leukocyte Biology. 
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Further to section 1.7.2.1., increased levels of prostaglandin can inhibit AM function. 
Since CFTR increases PG production, it is reasonable to consider PG as a one of 
the causes of dysfunctional AM in CF.  
 
In order to obtain a more comprehensive view on the effect of air pollution on cystic 
fibrosis, a literature review on PubMed for articles published in English from years 
1980-2019 was performed, using the key search terms “air pollution” and “cystic 
fibrosis” identified 89 articles, 12 of these were summarised in appendix 3, excluding 
review articles, or articles not related to the effects of air pollution on patients with 
cystic fibrosis. The studies suggest patients with CF are more susceptible to air 
pollution – exposure to air pollutants can reduce the CF host’s immune capacity to 
respond to insult, leading to increased oxidative stress, necrosis and cell death. It 
is also associated with an increased risk of initial bacterial acquisition, antibiotic 
usage, and pulmonary exacerbation. 
 
1.8.4. The potential speculated mechanisms of adverse effects of air 
pollutants on patients with CF 
1) This chapter has demonstrated that AM phagocytosis is impaired in CF – this 
could potentially lead to residual carbonaceous PM remaining in the airway. The 
non-phagocytosed particles may invade other airway cells, such as epithelial 
cells, propagating the inflammatory cascade, thereby worsening the pre-existing 





The shift of inhaled PM away from AMs to other cells can affect the release of 
cytokines such as IL-8 from epithelial cells – a study using human bronchial 
epithelial cells demonstrated that PM exposure encouraged pro-inflammatory 
cytokine production168. On the contrary, another study using a bronchial 
epithelial cell-line (BEAS-2B) showed that IL-6 and IL-8 secretions were 
reduced following exposure to realistic doses of gasoline exhaust, suggesting 
impairment of the epithelial defence mechanisms 169. Indeed, exposure of CF 
human bronchial epithelial cells to nanoparticles could enhance necrosis 
compared to healthy controls, with a dose-dependent rise in cytokines 170, thus 
potentiating the inflammatory process. 
2) PM can promote bronchial epithelial cell apoptosis in CF, via the activation of
caspase-9 protein 22. As a result, particle clearance can be hindered.
3) O3 can down regulate CFTR transcription in epithelial cells, reducing CFTR-
mediated chloride transport 171 – this phenomenon is understandably
exaggerated in CF.
4) Air pollution can increase CF patients’ susceptibility to respiratory infections,
another driver for their respiratory decline. Studies have demonstrated that PM
exposure could impede clearance of P. aeruginosa, increase Streptococcus
pneumoniae adhesion to epithelial cells, and alter the biofilm structure of












Summary: Air pollution and cystic fibrosis 
 Air pollution exposure can impact on the lung function of patients with 
CF. 
 The immune system is impaired in CF – with altered AM function and 
abnormal phagocytosis. 
 Impaired AM phagocytosis of nanoparticles can lead to increased 
particle uptake by epithelial cells, as demonstrated by animal models. 
  In vitro studies suggested air pollutants could cause inflammation and 
impair epithelial defence mechanism.  
 Air pollution exposure can hinder bacterial clearance in CF. 
What is still unknown? 
 There is a lack of human studies on the mechanisms underlying the 
vulnerability of patients with CF to air pollution. 
 The specific impacts of chronic exposure to air pollution on patients with 
CF remain unclear.  
 There is limited data on the role of prostaglandin in the susceptibility of 
patients with CF to air pollution. 
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1.9. Summary 
Air pollution is an ongoing and evolving problem in the UK. In high income countries, 
the main culprit of ambient air pollution is road traffic, with diesel engines being 
responsible for the majority of air pollutants, such as PM and NO2 in big cities. Air 
pollution can affect everyone at every stage of the life course, but children are most 
vulnerable because of their immature immune system and ongoing organ growth, 
with lung growth and function being most affected. Children with chronic respiratory 
conditions are even more susceptible.  
In CF, the disease pathogenesis dictates that the immune system is compromised 
and therefore patients are more affected by air pollution. Thickened airway mucus 
and impaired mucociliary clearance impede removal of inhaled particles; recurrent 
respiratory infections and ongoing airway inflammation are further exacerbated by 
pro-inflammatory insults such as air pollutants; defective AM phagocytosis renders 
epithelial cells vulnerable to the pro-inflammatory effects of non-phagocytosed PM 
lingering along the airways. Indeed, air pollution can worsen the outcome in CF – it 
increases the risks of bacterial infections and pulmonary exacerbations, and 
subsequent lung function decline. Furthermore, ultrafine non-phagocytosed PM 
could leach into the systemic circulation and affect distant organs, leading to new 
onset or exacerbations of other systemic conditions.  
Despite clear evidence that patients with CF are vulnerable to the adverse effects 
of air pollution, to date, human studies underpinning the underlying mechanism of 
impaired phagocytosis are lacking. However, it is known that AM phagocytosis of 
bacteria is impaired in CF compared to healthy controls; and that phagocytosis is 
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attenuated by prostanoids – which are present in higher quantities in CF than the 
healthy counterparts. It is therefore reasonable to consider prostanoids as a putative 
explanation for the phagocytosis impairment in CF. 
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1.10. Research hypothesis and aims 
I hypothesised that phagocytosis of black carbon by alveolar macrophages was 
impaired in CF, contributing to the vulnerability of children with CF to air pollution; 
and that this was mediated by increased production of phagocytosis-inhibitory 
prostanoids in the airways. 
Since the amount of BC in AMs is used as an internal marker for long-term exposure 
to air pollution, AMBC can also be used to determine the intrinsic phagocytic ability 
of AMs, provided that the dose of inhaled PM are relatively constant. I therefore 
hypothesised that, under the exposure to comparable levels of ambient air pollution, 
the amount of inhaled BC phagocytosed by AMs in vivo would be reduced in CF 
compared to healthy controls; and that this was secondary to increased production 
of prostaglandins in patients with CF. 
As a result of impaired uptake of PM by AMs in CF, residual PM would affect other 
airway cells, worsening pre-existing airway inflammation, with the potential for 
ultrafine particles to leach into the systemic circulation and travel to distant organs. 
There is robust evidence to support the link between air pollution and adverse fetal 
and neonatal outcome, but the underlying mechanisms remain unclear. The 
placenta can be used as a proxy for distant organs – i.e. ultrafine particles not 
phagocytosed by maternal lung can penetrate the tissue barriers and infiltrate the 
systemic circulation, translocating to the placental tissues. 
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1.10.1. Specific hypotheses 
In children with cystic fibrosis, alveolar macrophage function is impaired due to 
upregulation of cyclooxygenase and increased production of prostaglandin 
(particularly prostaglandin E2) – which can be reversed by cyclooxygenase inhibitor. 
Impaired macrophage phagocytosis will result in residual inhaled carbonaceous 
particles in the airway, affecting epithelial cells and aggravating airway 
inflammation; while residual ultrafine particles may cross tissue barrier and 
translocate to distant organs via the circulation.  
1.10.2. Aims 
o To compare personal exposure to air pollution of children with CF and healthy
controls.
o To compare in vivo alveolar macrophage black carbon between children with
CF and healthy controls.
o To assess in vitro phagocytic function of alveolar macrophages isolated from
children with CF and healthy controls.
o To compare COX-2 expression in alveolar macrophages isolated from
children with CF and healthy controls.
o To compare the production of prostaglandins by measuring prostanoids and
metabolites in sputum and urine between the two groups.
o To establish the effects of PGE2 on phagocytosis by alveolar macrophages.
o To assess the possibility of reducing in vivo prostanoids production with
cyclooxygenase inhibitors.
o To investigate the possibility of epithelial cell invasion by particulate matter
in the presence vs absence of functional alveolar macrophages.
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o To model whether exposure to black carbon increases release of cytokines
(e.g. IL-8) from airway epithelial cells in vitro.
o To identity any carbonaceous material in placental tissues from healthy full
term pregnancies – as a proxy organ for particle translocation.
o To improve participants’ knowledge on air pollution and provide advice on
how to reduce personal pollution exposure.
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2.1. Ethical approval 
The project protocol were reviewed and approved by the Joint Research 
Management Office for Barts Health NHS Trust and Queen Mary University of 
London. 
 
For the Cystic Fibrosis project, ethical approval to recruit children was granted by 
the NHS Research Ethics Committees (REC, REC references 17/EM/0023, IRAS 
project ID 215879) in January 2017, following a full ethical review. Health Research 
Authority (HRA) approval was obtained in February 2017. See Appendix 4 for the 
latest version of the study protocol. 
 
Five subsequent amendments were approved for the following reasons: 
I. To expand the healthy recruit population and allow for sputum induction to 
be performed outside of the hospital. 
II. To change sponsor details; and expand participant groups with the addition 
of non-CF bronchiectasis patients. 
III. To include microbiology experiments on macrophages from children with CF. 
IV. To update the European Union General Data Protection Regulation (GDPR); 
and add in the use of systemic over-the-counter dose of Ibuprofen in order 
to investigate the possibility of reducing in vivo prostanoids production. 
V. To expand healthy recruits population to pan-London. 
See appendix 7 for all correspondences with the ethics committee.  
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2.2. Participants 
Children with cystic fibrosis were recruited from the Royal London Children’s 
Hospital, one of the largest tertiary CF centres in the UK. Age-matched healthy 
controls were recruited from siblings of paediatric patients at the Royal London 
Hospital, and also through the research team’s media and public engagement work 
across London. Since the Royal London Hospital is a specialist referral centre for 
north/ northeast London and Essex, the home addresses of the CF cohort scattered 
across central and greater London. In order to map the healthy cohort accordingly, 
siblings of patients were targeted as healthy recruits. However, in view of air 
pollution variations in and outside of London, all recruits were limited to those 
residing within the M25. 
2.2.1. Inclusion criteria 
I. Children with cystic fibrosis aged 1-17, residing within the M25 in London.
II. Age and gender-matched healthy controls residing within the M25 in London.
2.2.2. Exclusion criteria 
I. Current active smoker.
II. Receiving immunosuppressive drug therapy.
III. For children with CF who were not on regular nebulised hypertonic saline:
drop in FEV1 of >15% post-bronchodilator (exclusion criterion for sputum
induction).
IV. For healthy controls: post-bronchodilator FEV1 <80% (standard exclusion
criterion for sputum induction in healthy individuals).
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V. For participants involved in other research study, they were excluded if the
other research study had any potential impact on sampling or results of this
study.
2.3. Recruitment process 
Potential participants were referred by a member of their clinical care team, the 
research team then reviewed and ensured they met the eligibility criteria. Potential 
participants were approached individually. Age appropriate information sheets were 
available for participants and their parents, these were divided into age groups 1-6 
years, 7-11 years, 12-15 years, and 16 years and above (examples of these 
information sheets can be found in appendix 5). Informed consent and assent were 
obtained at least 24 hours after dissemination of information sheets (examples of 
consent and assent forms can be found in appendix 6). Participants and parents 
who took part in activities which were added to the study at a later stage were asked 
to sign the modified consent and assent forms. Children with CF were approached 
and recruited first, followed by recruitment of healthy controls – this allowed for age, 
gender, and home address matching of the control group to the CF group. 
2.4. Air pollution questionnaire 
Participants and their parents were asked to fill in a one-page questionnaire 
following informed consent. The questionnaire contained questions on the home 
environment – cigarette smoking exposure, type of cook stove, ventilation method 
during cooking, use of candles; travel information – mode and duration of daily 
transport; and outdoor activities.  
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2.5. Exposure to air pollution 
2.5.1. Modelled exposure at home address 
The London Air Quality Toolkit (LAQT) is an established emissions dispersion 
model developed by the Environmental Research Group at King’s College London. 
The LAQT includes all London Atmospheric Emissions Inventory (LAEI) sources 
such as road transport, industrial processes, railways, shipping, aviation, and 
agriculture. It incorporates meteorology and urban topology, producing detailed 
spatially accurate air quality maps – allowing for fore- and back-casting of air quality 
across the capital. It can model annual means of NOX, NO2, PM10, PM2.5 and O3 in 
Greater London, at a resolution of 20 m x 20 m.  
Colleagues at King’s College London estimated the mean PM and NO2 
concentrations based on participants’ home postcodes, 12 months prior to the date 
when participants underwent first sputum induction.  
2.5.2. Black carbon monitoring 
Participants’ real-time black carbon (BC) exposure was measured by a pocket-sized 
microAeth AE51 aethalometer (firmware 709, Aethlab, California, USA). An 
aethalometer contains a built-in pump, with flow control and data storage capacity. 
The sampled air is collected on a Teflon coated glass fibre filter situated within the 
device. The aethalometer measures the rate of change in transmitted light 
absorption during continuous BC deposition on the filter, based on the fact that black 
material absorbs light the strongest. It can provide measurement resolution of 0.001 
µg/m3 with precision of ± 0.1 µg/m3.  The device battery is able to run for up to 24 
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hours on a single charge. Aethalometer technology has been used worldwide to 
measure BC exposure for over 30 years. The AE51 was chosen for this study 
because of its reliability from previous pollution studies across the world, and its 
portability and ease of operation. 
Participants were asked to carry an aethalometer for 2 typical school days, using 
an activity diary (appendix 12) to record their mode and time of commute, and time 
spent in- and out-door (figure 2.1). The aethalometer was programmed to provide a 
reading (ng/m3) every 60 seconds, at a flow rate of 100 mL/min. Mean per minute 
BC exposure (ng/m3) across the two days was determined. 
Figure 2.1. A participant carrying a portable aethalometer in a small backpack. The 
tip of the sampling tube (red arrow) was clipped to his jacket collar, sampling the air 
he was breathing in. Photo used with patient and parental permission. 
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2.5.3. Nitrogen dioxide monitoring 
Nitrogen dioxide (NO2) analysis using diffusive samplers (IVL Swedish 
Environmental Research Institute Ltd, Gothenburg, Sweden) is based on molecular 
diffusion of the gas. The gas molecules diffuse and are quantitatively collected onto 
a filter, giving a concentration value integrated over time, after adjusting for 
temperature and estimated air flow. Turbulent diffusion is prevented by a mesh 
overlying the filter. Results were analysed at the IVL Swedish Environmental 
Research Institute, expressed as average concentrations during the sampling time 
periods. 
2.5.3.1. Indoor NO2 monitoring 
Participants were given a NO2 diffusion sampler to be placed at home for two weeks 
– they were instructed to place this in a room, other than the bedroom, that the
participant stayed in most. 
2.5.3.2. Personal NO2 monitoring 
Participants carried a NO2 diffusion sampler on their person (e.g. on school jacket 
or school bag) for two weeks.  
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2.6. Alveolar macrophage in vivo function 
2.6.1. Spirometry 
Spirometry was performed using MicroMedical MicroLab Spirometer (Care Fusion, 
UK) with a data management system compliant with American Thoracic Society 
(ATS)/ European Respiratory Society (ERS) 2005 guidelines 172. Flow volume loops 
were displayed for immediate quality control. Both unadjusted lung function and 
percentage predicted values adjusted for age, ethnicity, gender and height were 
measured.  
Spirometry was only performed in children over the age of 7 years for practical 
reasons – their ability to understand instructions and coordinate with good technique 
was crucial to generating meaningful readings. A baseline lung function test was 
performed, followed by inhalation of 400 µg (4 puffs) salbutamol, a short-acting β2 
agonist, by metered dose inhaler (MDI) via a Volumetic spacer (Allen and Hanbury, 
UK). "Post-bronchodilator" lung function was performed 15 min after. Forced 
expiratory volume in 1 sec (FEV1) and forced vital capacity (FVC) were measured 
to ensure participants fulfil the inclusion criteria set out above. A final lung function 
test was repeated following sputum induction to ensure no side effect such as 
bronchospasm had occurred. 
2.6.2. Sputum induction 
Sputum induction was performed according to the ERS guidelines 173, on all 
recruited children over the age of 7 years for practical reasons stated above. 
Sputum, containing alveolar macrophages, was induced using approximately 4 mL 
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of 3.5-7% saline via a portable Multisonic Profi 80180 nebuliser (Schill, Germany), 
nebulised at approximately 0.6 mL/min. Hypertonic saline was used to thin 
secretions in the lower respiratory tract, especially in mucous consolidation seen in 
CF. It therefore aided the upward movement and clearance of respiratory secretions 
mediated by ciliated cells. 
400 µg Salbutamol, given prior to nebulised hypertonic saline administration, was 
used to limit the potential side effect of bronchospasm, hence the need for lung 
function monitoring.  
Multiple induced sputum samples (limited to 1 sample per day) were obtained per 
participant, at separate house visits, due to the limited number of alveolar 
macrophages expectorated from each induction session. Each sample often 
contained enough alveolar macrophages for only one of the experiments described 
below.  
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2.6.2.1. Children with cystic fibrosis 
For children with CF, hypertonic saline forms part of their daily routine chest 
physiotherapy treatment (figure 2.2). Their usual concentration (7%) of saline was 
used. Sputum induction was performed at a time and place most convenient to the 
participant, such as after school at home, during their routine clinic appointment, or 
during the beginning of their elective hospital admissions – these were limited to 
admissions with no signs of pulmonary exacerbations, such as lung function decline 
or respiratory symptoms. The timing of sputum induction was synchronised with the 
children’s routine chest physiotherapy session to limit inconvenience. Sputum 
samples were collected into sterile pots and transported at 4oC to the laboratory 
within 4 hr.  
Figure 2.2. A participant receiving nebulised hypertonic saline for sputum induction 
during a home visit. Photo used with patient and parental permission. 
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2.6.2.2. Healthy children 
For healthy controls, sputum induction was done either at the Royal London 
Children’s Hospital, or, more commonly, at an appropriate and safe place which was 
convenient for the participants and their family, such as home visits after school. 
The same sputum induction protocol applied but the hypertonic saline concentration 
used was 3.5%. Healthy individuals produce less viscous respiratory secretions 
compared to the CF group, therefore a lower concentration of hypertonic saline 
would usually suffice and could limit the potential of bronchospasm.   
2.6.3. Sputum processing 
Traditional sputum processing protocols 174 recommend sample processing within 
4 hr of collection, in order to ensure cell viability. However, owing to the fact that the 
majority of samples were collected in the evening after school hours, followed by 6 
or more hours of experiments, the protocol was adapted accordingly. Sputum 
samples were kept in 20 mL of Dulbecco’s phosphate-buffered saline with 2% 
Foetal Bovine Serum (FBS) (DPBS/FBS, STEMCELL, Canada) at 4oC overnight, 
until processing the next morning – all samples were fully processed within 24 hr of 
collection. Despite overnight storage, alveolar macrophage viability was maintained 
with preserved phagocytic ability seen in vitro.   
Whole sputum was diluted 1:1 in Dulbecco’s phosphate buffered saline (Corning, 
USA) and agitated, followed by centrifugation at 3500 rpm (2401 x g) for 10 
min. The pellet was resuspended in 1 mL 0.1% Dithiothreitol (DTT) (Fisher 
Scientific, USA), agitated by vortex and gently rocked at room temperature for 15 
min. The suspension was then passed through a 36 μm gauze (NITEX 03-
100 
36/28, Sefar, Switzerland) and centrifuged at 10000 rpm (7840 x g) for 10 min. 
The pellet was resuspended in 1 mL DPBS/FBS (2%). An aliquot of 35 μL was 
transferred and secured in a Shandon™ single Cytofunnel™ (ThermoFisher 
Scientific, UK) and spun at 1500 rpm (277 x g) for 3 min, followed by staining with 
Hemacolor®  (Merck, Darmstadt, Germany). The glass slide was air dried and 
mounted with a glass coverslip using Vectamount glue. The cytospin slides were 
used to analyse alveolar macrophage black carbon loading. The remaining 
samples underwent macrophage enrichment as described below (figure 2.3). 
Figure 2.3. Flow diagram showing sequence of sputum processing for various 
experiments – further details of each experiment are discussed later in this chapter. 
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2.6.3.1. Protocol adaptation for cystic fibrosis 
Traditionally, sputum was processed by selecting cell-rich plugs of airway mucus 
before processing. However, this was modified due to the presence of viscous 
mucus in CF, rendering plugs picking challenging, with abundant cell loss. Whole 
sputum samples were therefore used and diluted with 20-40 mL of DPBS depending 
on sputum consistency, followed by centrifugation and pellet resuspension as 
described above. 
 
2.6.4. Alveolar macrophage black carbon analysis 
Alveolar macrophage black carbon (AMBC) was analysed as previously 
described 101. Briefly, light microscopy was used to visualise AMs. Digital colour 
images of 50 randomly selected AMs from each participant were captured using a 
stereo-histology microscope (Mazurek Optical Services, UK) at x100 objective 
under immersion oil using PictureFrame 2.2 computer software. The images were 
imported into ImageJ 1.50i (National Institute of Health, USA). 
 
Each AM was outlined manually using a freehand tool (figure 2.4a). The software 
measured the number of pixels within the outlined area, and converted that into a 
dimension (µm2) – i.e. size of the AM. The software was set to correspond 1473 
pixels to 100 µm2 when imaging at x100 objective.   
 
Areas of inorganic carbon (stained black) deposited within each AM were 
distinguished from other darkly stained substances such as the nucleus and 
adherent or phagocytosed bacteria (stained dark purple). The black (carbonaceous 
particulates) areas were selected with the freehand tool (shown in yellow, figure 
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2.4b), the image was then converted to a 32-bit greyscale image (figure 2.4c), 
followed by adjustment of the image threshold in order to identify the most darkly 
coloured areas (shown in red, figure 2.4d). The software measured the red area 
within the pre-selected yellow boundary – this was the AMBC load. The mean 
AMBC (µm2) of 50 AMs from each participant was determined.  
Figure 2.4.  Measuring alveolar macrophage black carbon: (a) Area of an alveolar 
macrophage outlined (in yellow) by a freehand tool and the area (µm2) is measured. 
(b) Areas of black carbon outlined by freehand tool. (c) Image converted to 32-bit
greyscale. (d) Image threshold adjusted to highlight the darkest areas (shown in
red).
A second observer blinded to the participants’ health status (CF v control) repeated 
the image analysis for 11 randomly selected samples; agreement between both 
observers was determined using the Bland-Altman method.  




2.7. Alveolar macrophage in vitro function 
2.7.1. Sputum purification and alveolar macrophage Isolation 
Following the cytospin slide production, the remaining suspension for each sputum 
sample was enriched to isolate alveolar macrophages. 40 μL of cell depleted 
erythrocytes and 60 μL of human monocyte enrichment cocktail (RosettSep, 
STEMCELL, Canada) were added to the suspension, followed by 20 min rocking at 
room temperature. Concentrations were modified from the manufacturer’s protocol 
(30 μL of cell depleted erythrocytes and 50 μL of human monocyte enrichment 
cocktail); the modified concentrations provided a better purification yield with >98% 
of enriched cells being macrophages. 
Cell depleted erythrocytes were obtained from fresh human capillary blood, drawn 
on the day of sputum processing. 1 mL of fresh human blood was diluted with 0.6 
ml incomplete (supplemented with 4% FBS) Roswell Park Memorial Institute (RPMI-
1640) medium (Gibco, Thermo Fisher Scientific, USA) before suspension on an 
equal volume of density gradient medium, Ficoll-Paque Plus (GE Healthcare, 
Sweden), and centrifugation at 1821 rpm (650 x g) for 22 min. RPMI dilution was 
conducted to reduce blood viscosity and improve the separation process. Cell 
depleted erythrocytes were collected as a pellet. Other sources of erythrocytes 
including refrigerated horse blood, refrigerated human blood and frozen human 
erythrocytes, were trialled but had suboptimal yield of AM enrichment – refrigerated 
horse and human blood did not separate properly in density gradient medium for 
erythrocytes isolation; frozen human erythrocytes resulted in poor separation in the 
monocyte enrichment step.  
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The cell suspension with erythrocytes and enrichment cocktail was diluted 1:1 in 
PBS/FBS (2%), suspended on density gradient medium (1:1), and centrifuged at 
2020 rpm (800 x g) for 30 min. The resulting monolayer of enriched AMs was 
aspirated using a 3 ml Pasteur pipette (Sarstedt, Germany) from the density 
medium: plasma interface. The enriched cells were washed in 500 µL of PBS/FBS 
(2%) to remove residual Ficoll-Paque. The final cell pellet was resuspended in 
appropriate cell culture medium for investigations. 
Enrichment of AMs enabled functional assessment of AMs alone, without the 
presence of mucus, inflammatory cells, epithelial cells, and bacteria, thus allowing 
clear visualisation of AMs and their contents. This was particularly useful in CF 
where the sputum samples were often heavily laden by these materials (figure 2.5). 
Figure 2.5. (a) Cytospin slides from children with CF, heavily laden with mucus and 
bacteria, making visualisation of cells and image analysis very difficult; alveolar 
macrophages identified with red arrows. (b) Enriched alveolar macrophages from 
children with CF, with the majority of mucus, bacteria, and other cells (e.g. epithelial 
cells, neutrophils, etc) removed.  
a1 a2 a3 
b1 b3 b2 10µm
2
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2.7.2. Alveolar macrophage uptake of diesel exhaust particles 
Nunc™Lab-Tek™ cell culture chambers (ThermoFisher Scientific, UK) were pre-
coated in 1:5 collagen (calf skin, Sigma-Aldrich, Missouri, USA) for at least 30 min 
at 37 °C. 1:10 collagen concentration was tested, but due to limited number of AMs 
available from each sample, cell adhesion was encouraged to avoid cell loss, hence 
the increase in concentration.  
Enriched AMs were suspended in chamber wells and allowed to adhere overnight 
at 37°C, 5% CO2 in complete RPMI supplemented 10% FBS and Penicillin-
Streptomycin (Sigma-Aldrich, Missouri, USA). 
Cells were washed the following day with incomplete RPMI. Experimental chamber 
wells were exposed to 10 µg/mL of diesel exhaust particles (DEP) (SRM 2975, 
NIST, USA) for 2 h at 37°C, 5% CO2; control wells were unexposed. Cells were 
subsequently washed with incomplete RPMI, chambers were removed and slides 
washed before staining (Hemacolor®, Merck, Darmstadt, Germany) and imaging by 
light microscopy using a stereo-histology microscope (Mazurek Optical Services, 
UK).  
AM phagocytosis of DEP was assessed by image analysis as described above. As 
the number of AMs extracted varied between individuals, image analysis was kept 
consistent by using the same number of cells, ranging from 10 to 50 cells per 
participant, pre- and post- DEP exposure.  
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2.7.2.1. Choice of media and antibiotics 
RPMI is a widely used basal medium for mammalian cell culture. Standard complete 
RPMI is supplemented with FBS and penicillin-streptomycin. However, sputum 
samples from CF participants were often laden with bacteria due to their disease 
process and organism colonisations. As a result, some CF samples had substantial 
bacterial growth during the overnight incubation period for cell adhesion – bacterial 
growth affected subsequent AM phagocytosis of DEP and impeded visualisation of 
AMs under light microscopy (figure 2.6). It was therefore decided that complete 
RPMI should also be supplemented with Primocin™ (Invivogen, Tolouse, France). 
Penicillin-streptomycin is effective against gram positive and gram negative 
bacteria; while primocin is effective against not only gram positive and negative 
bacteria, but also mycoplasma and fungi, and is non-toxic to primary cells. However, 
it was noted that some cells did not withstand primocin well, resulting in poor cell 
survival and adhesion overnight. Thus, for each sputum sample, standard complete 
RPMI (with FBS and penicillin-streptomycin) was used in half the chamber wells, 
and RPMI with primocin was used in the other half. 
 
 
Figure 2.6. Enriched alveolar macrophage (red arrow) from a participant with CF. 
Extensive bacterial growth overnight, impeding visualisation of AM.  
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2.7.2.2. Concentration of diesel exhaust particles 
The DEP concentration of 10 µg/mL was informed by earlier research 102. Higher 
concentrations (20 and 40 µg/mL of DEP) were tested and a dose-dependent 
response was seen (figure 2.7). Concentrations above 10 µg/mL was proved to 
render visualisation of AM intracellular content difficult (figure 2.8), therefore 10 
µg/ml was used despite it not being a maximum concentration.   
Figure 2.7. Dose-dependent response in alveolar macrophage phagocytosis (mean 
AMBC of 50 randomly selected AMs) after 2 h exposure to 0, 10, 20 and 40 µg/mL 
of diesel exhaust particles. Alveolar macrophages isolated from a healthy individual. 
Figure 2.8. Alveolar macrophages isolated from a healthy individual, showing dose-
dependent responses to diesel exhaust particles (DEP) exposure: 0, 10, 20, and 40 
µg/mL of DEP in (a), (b), (c) and (d) respectively. 10 µg/mL (b) was the final chosen 
concentration as intracellular contents were difficult to analyse accurately with 
higher concentrations of DEP (c and d). 




















One limitation of image analysis using light microscopy is the difficulty in 
distinguishing black carbon phagocytosed from those adhering to the cell surface, 
however, the distribution of black carbon suggests that the carbon load has been 
phagocytosed.  
2.7.3. Effects of prostaglandin on alveolar macrophages function 
Using enriched AMs isolated from both CF and control groups, the effect of 
prostaglandin-E2 (PGE2) on AM phagocytosis was assessed by adding synthetic 
PGE2 (P0409, Sigma-Aldrich, USA) to the cell-DEP culture, followed by image 
analysis. Briefly, following AMs enrichment, cells were allowed to adhere in 
chamber wells overnight as previously described, the chamber wells washed and 
resuspended in incomplete RPMI, and divided into two groups: i) 10 µg/mL of DEP; 
and ii) 10 µg/mL of DEP and 10−6 M of PGE2. PGE2 was added to the group (ii) 
chamber wells 15 min before all wells were exposed to 10 µg/mL of DEP for 2 h. 
The concentration of PGE2 was informed by the literature 102,141. As before, the 
entire population of AMs extracted from each sample was equally divided between 
the two cultures. Image analysis was kept consistent by using the same number of 
cells, ranging from 10 to 50 AMs per participant, between cultures with and without 
PGE2. Using light microscopy, mean AMBC of 10 to 50 cells with and without the 
presence of PGE2 were compared.  
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2.7.4. Effects of EP2-receptor antagonist on alveolar macrophages 
function 
To further confirm the relationship between PGE2 and phagocytosis, the effect of 
PGE2 was reversed by the addition of an EP2-receptor antagonist (AH6089, Sigma-
Aldrich, USA) to the cell-DEP culture.  
Responder AMs from healthy participants were used for this analysis. Enriched AMs 
were allowed to adhere in chamber wells overnight. These were divided into three 
groups; i) 10 µg/mL of DEP; ii) 10 µg/mL of DEP and 10−6 M of PGE2; and iii) 10 
µg/mL of DEP, 10−6 M of PGE2 and 75µM of EP2-receptor antagonist 175. The EP2-
receptor antagonist was added to group (iii) wells and left for 1 h at 37oC, followed 
by addition of PGE2 to groups (ii) and (iii) for another 15 min, before all wells were 
exposed to DEP for 2 h. Image analysis was performed as previously described, 
using the entire population of extracted AMs from each participant, while keeping 
the number of AMs in each culture consistent. 
2.7.5. Expression of cyclooxygenase 2 in alveolar macrophages 
Enriched AMs from both groups of participants were washed and resuspended in 
PBS/FBS (2%) before being fixed, permeabilised and labelled with antibodies for 
flow cytometry.  
2.7.5.1. Fixation and permeabilisation 
Using a cell fixation and cell permeabilisation kit (FIX & PERM, Thermo Fisher 
Scientific, USA), enriched AMs were fixed and permeabilised. The kit allowed for 
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preservation of the morphological scatter characteristics of the cells, enabling 
intracellular detection of enzymes (e.g. cyclooxygenase 2). Fixing reagent was 
added to the cells for 15 min and washed in PBS/FBS (2%), centrifuged at 1200 
rpm (218 x g) for 3 min, the supernatant discarded, followed by pellet resuspension 
in permeabilisation reagent and left for 20 min at room temperature. 
2.7.5.2. Antibody labelling and macrophage marking 
At the same time as exposure to the permeabilisation reagent, cells were labelled 
with anti-CD11b macrophage markers (1:100, Abcam, ICRF44), and COX-2 
primary antibodies (1:200, Abcam, UK, EP1978Y), followed by washing as above, 
and labelling with secondary antibodies (1:2000, Abcam, UK) in the dark for 20 min 
at room temperature (figure 2.10). The secondary antibodies for COX-2 conjugated 
to Alexa Fluor 488 (Goat anti-Rabbit IgG H&L, A42731), and the macrophage 
marker secondary antibodies conjugated to Alexa Fluor 647 (Goat anti-mouse IgG 
H&L, A32728). Cells were washed again before resuspension in DPBS for flow 
cytometry. An isotype control was used to adjust for non-specific immunostaining.  
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Figure 2.10. Cell fixation and permeabilisation, allowing antibodies to penetrate 
following membrane permeabilisation. COX was labelled with primary antibodies, 
which were then labelled with secondary antibodies conjugated to fluorophore. The 
cell (macrophage) was also labelled with macrophage markers which were labelled 
with secondary antibodies conjugated to fluorophore as well.  
2.7.5.3. Flow cytometry 
Data was acquired using the BD FACS Canto II flow cytometer and 
BD FACSDiva software version 6.1.13 (BD Biosciences, UK) to determine the 
median fluorescence intensities (MFI) for COX-2 expression in AMs from both CF 
and control groups.  
2.7.5.4. Flow cytometry analysis 
CD11b is traditionally used as a marker for myeloid cell types. It has been shown 
that CD11b is expressed on all human alveolar macrophages, although the extent 
is variable between individuals 176. The cell populations used for flow cytometry had 
COX COX 
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been enriched by monocyte enrichment cocktail to isolate AMs, the addition of 
macrophage markers during antibodies staining further enhanced the AM isolation. 
2.7.5.5. Gating strategy 
Using forward and side scatter, the larger and more granular population was 
selected (figure 2.11a, population P1). The APC fluorophore channel allowed for 
identification of CD11bhigh cells (figure 2.11b,c, population P6). Using the FITC 
fluorophore channel and eliminating non-specific isotype staining, the final cell 
population was identified (figure 2.11d, e), and MFI determined. 
Due to the small number of cells available per participant, slight variation in gating 
strategy between different observers could result in drastic changes in MFI values. 
Therefore, the same observer repeated the analysis on a randomly selected set of 
data, while blinded to the participants’ health status (CF vs control). The agreement 
between blinded and unblinded analyses was determined using the Bland-Altman 
method.  
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Figure 2.11. Flow cytometry gating strategy. (a) Large and granular population 
selected (P1). (b) and (c) APC-A channel to help gate CD11bhigh cell population 
(P6). (d) Gating of final cell population (P7) while eliminating non-specific isotype 
staining (e). 
a b c 
e d 
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2.8. Prostanoid profiles in cystic fibrosis vs healthy 
controls 
2.8.1. Urinary analysis for prostanoids 
Due to the chemical instability of prostaglandins (PGs), it is often difficult to directly 
measure them in bodily fluids. It is therefore generally accepted to measure urinary 
metabolites of prostanoids as a reflection of endogenous PG synthesis 177.  
Urine samples were collected from both CF and control groups immediately after 
first sputum induction – for the CF group, samples were collected during clinically 
stable state. Samples were transported to the laboratory on ice, followed by storage 
at -80oC within 1 h, until analysis by high performance liquid chromatography–
tandem mass spectrometry (HPLC-MS). This was performed at the Jagiellonian 
University Medical College, Krakow, Poland by Professor Marek Sanak’s team, who 
provided the following methodology.  
Creatinine concentration in urine was measured using a small volume of 0.15 mL 
per sample on COBAS Integra 400 plus analyser with a clinically validated assay. 
0.5 mL of urine sample was added to deuterated internal standard mixture (2ng 
13,14-dehydro-15-keto-PGE2-d4, 13,14-dehydro-15-keto-PGD2-d4, 8-iso-PGF2-
d4, 9,11β-PGF2-d4, 10ng tetranor-PGE-M-d6, tetranor-PGD-M-d6 and 2ng LTE4-
d3). After acidification with acetic acid, samples were extracted to the organic phase 
using a mixture of 80% tert-buthyl-ether and 20% methanol. The solvent was next 
evaporated and the residue was reconstituted in 40 µl methanol.  
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Quantitation of eicosanoids was performed using HP-LC with autosampler for 
analysis (Prominance UHLC, Shimadzu Corporation, Kyoto, Japan), on Kinetex 
Biphenyl column 100 mm x 2.1 mm 2.5 µm (Phenomenex), in negative ionization. 
Details on analytes measured, which included additionally prostaglandins systemic 
metabolites are presented below.  
Quantitation of urinary prostaglandins: 8-iso-PGF2, 9,11β-PGF2 and 
thromboxanes: TXB2 and 11-dehydro-TXB2 was performed using gas 
chromatography (GC) by evaporation and derivatization. These were sequential 
chemical reactions to render the analytes necessary volatility by modifications of 
carboxyl group (15 µl 10 % pentafluorobenzyl bromide (PFBBr) in acetonitrile with 
10% N-ethyldiisopropylamine (DIPE) in acetonitrile). After formation of 
pentafluorobenzyl ester, samples was evaporated and reconstituted in 30 µl 
methanol and next cleaned up using thin-layer chromatography (TLC) using a 
mobile phase of ethyl :n-heptane (90:10). After collection of silica gel with the 










Tetranor-PGE-M-d0 327>143 -30 327>309 -20 11.88 
Tetranor-PGE-M-d6 333>149 -32 333>315 -20 11.83 
Tetranor-PGD-M-d0 337>143 -30 327>309 -20 12.12 
Tetranor-PGD-M-d6 333>149 -32 333>315 -20 12.07 
13,14-dehydro-15-
keto-PGE2-d0 
351>333 -16 351>175 -24 16.12 
13,14-dehydro-15-
keto-PGE2-d0 
355>337 -16 355>179 -26 16.09 
13,14-dehydro-15-
keto-PGD2-d0 
351>175 -24 351>333 -16 16.51 
13,14-dehydro-15-
keto-PGD2-d0 
355>179 -26 355>337 -16 16.47 
LTE4-d0 438>333 -27 440>289 -30 17.92 
LTE4-d3 441>336 -27 443>291 -30 17.89 
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mm for 11dehydro TXB2 with 1 mL of ethyl acetate and evaporation, hydroxyl groups 
were blocked with BSTFA (Bis(trimethylsilyl)trifluoroacetamide) in pyridine. Next, 
evaporated sample was dissolved in toluene (50 µl). GC-MS/MS analysis was done 
using on Shimadzu GC-2010 plus (Kyoto, Japan) instrument in a single ion 
monitoring (SIM) mode and capillary column Zebron 5MS (30 m x 0.25 mm x 0.25 
µm, Phenomenex). 
Described methods were validated for linearity using calibration curves. All analytes 
reported were above the lowest limit of detection. Concentration of each eicosanoid 
was calculated from the area under the peak on MRM or SIM trace, using internal 
deuterated standard peak as a reference (denominator). This method compensates 
for recovery errors during preparation and is referenced as a stable isotope dilution 
quantification. Results were reported in picograms per milligram of creatinine. 
All the solvents were of HPLC grade and purchased from Mallincrodt Baker, Inc. 
(Phillipsburg, NJ, USA), while other chemicals were from Sigma–Aldrich Co. (St. 
Louis, MO, USA).  
Eicosanoid metabolites measured are listed in Table 2.2, along with their eicosanoid 
precursors.   
Urinary eicosanoids metabolites Eicosanoid precursors 
13,14-dihydro-15-keto-E2 15-oxo-prostaglandin E2
13,14-dihydro-15-keto-D2 Prostaglandin D2 
13,14-dihydro-15-keto-tetranor-E2 Prostaglandin E2 
13,14-dihydro-15-keto-tetranor-D2 Prostaglandin D2 
Tetranor PGEM * Prostaglandin E2 
Tetranor PGDM * Prostaglandin D2 
15-doexy-delta12,14-PGJ2 Prostaglandin J2 
9a,11b-PGF2 Prostaglandin D2 
Table 2.1. Panel of urinary prostanoid metabolites analysed, with their prostanoid 
precursors. * Major urinary metabolites of the specified PG. 
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2.8.2. Sputum supernatant analysis for prostanoids 
For measurement of PGs and their metabolites in sputum supernatant, a different 
approach to sputum processing 178 was employed in order to maintain equal dilution 
factor for both CF and control groups. The previously described method involved 
diluting the sputum samples with various amount of DPBS, depending on the 
sputum viscosity. Variable dilutions, volumes and weights made adjusting PG 
metabolites levels challenging. 
Briefly, whole sputum sample was weighed before adding DTT (1:1), followed by 
shaking on a rocker for 15 min at 37oC. The mixture was then filtered through a 36 
µm gauze, followed by weighing and centrifugation of the filtrate at 10000 rpm (7840 
x g) for 10 min. Cell-free supernatant of sputum samples after gauze filtration was 
stored at -80oC until analysis by HPLC-MS.   
Protein concentration was measured in 0.15 mL of each sample on COBAS Integra 
400 plus analyzer using a clinically validated assay. Total sputum supernatant 
sample (volume from 1.2 to 28 mL) was thawed on ice and next spiked in with a 
mixture of 2 ng each of deuterated, chemically identical standards (5-HETE-d8, 12-
HETE-d8, 15-HETE-d8, PGE2-d4, 8-iso-PGE2-d4, PGD2-d4, PGA2-d4, 13,14-
dehydro-15-keto-PGE2-d4, 13,14-dehydro-15-keto-PGD2-d4, 8-iso-PGF-d4, 
9,11β-PGF2-d4, TXB2-d4, 11-dehydro-TXB2-d4, tetranor-PGE-M-d6, tetranor-
PGD-M-d6 and 4ng LTE4-d3, LTD4-d5, LTB4-d4, 5-oxo-ETE-d7). The samples were 
adjusted to pH 4.5 with acetic acid and were centrifuged at 2500 x g for 10 min at 
4ºC to remove precipitates. A solid phase extraction (SPE) was done using JT Baker 
SPE-12 g Extraction System (JT Baker Chemical Company Netherlands). Each 
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sample was passed through an individual cartridge (Waters C-18) preconditioned 
with methanol (5 mL) and distilled water (5 mL). Following binding of eicosanoids, 
two washes of the cartridge were done with distilled water (5 mL) and n-heptane (5 
mL) to remove impurities. Eicosanoids were eluted form the cartridge with methanol 
(5 mL). Next, methanol solution was evaporated under nitrogen and the residue was 
reconstituted in 50 µl methanol. HPLC column injection was 5 µl of the sputum 
supernatant extract, HPLC with autosampler was used for analysis (Prominance 
UHLC, Shimadzu Corporation, Kyoto, Japan). Conditions for chromatographic 
separation were as follows: 
 HPLC Column Zorbax Eclipse XDB-C18 50 mm x 1mm 3.5 µm  (Agilent)
 Column Kinetex Biphenyl 100 mm x 2.1 mm 2.5 µm (Phenomenex) – two
different gradients of elution were used (see below).
Eicosanoids were quantified using multiple reaction monitoring mode (MRM) 
tandem mass spectrometry (Qtrap 4000, Applied Biosystems, Foster City, CA, 
USA) equipped with electrospray ion source, in four separate runs including positive 
and negative athmospheric pressure ionization. Details of individual compound 
analysis were: 
Positive mode (Zorbax Eclipse) 
Compound MRM [m/z] CE [eV] Confirmatory  
MRM [m/z] 
CE [eV] Rt [min] 
LTE4-d0 440>189 25 440>301 15 7.30 
LTE4-d3 443>192 22 443>304 15 7.27 
LTD4-d0 497>189 25 497>301 18 7.38 
LTD4-d5 502>194 25 502>306 18 7.35 
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Negative mode (Zorbax Eclipse) 
Compound MRM [m/z] CE [eV] Confirmatory 
MRM [m/z] 
CE [eV] Rt [min] 
LTB4-d0 335>151 -35 335>129 -38 8.16 
LTB4-d4 339>153 -35 339>130 -38 8.13 
5-HETE-d0 319>115 -20 319>257 -18 9.93 
5-HETE-d8 327>116 -22 327>265 -18 9.89 
12-HETE-d0 319>179 -21 319>257 -18 9.74 
12-HETE-d8 327>184 -21 327>265 -18 9.70 
15-HETE-d0 319>219 -19 319>257 -18 9.51 
15-HETE-d8 327>226 -19 327>265 -18 9.49 
5-oxo-ETE-
d0 
317>203 -30 317>163 -25 10.10 
5-oxo-ETE-
d7 
324>210 -25 324>167 -25 10.06 
11-dehydro-
TXB2-d0 
367>161 -24 367>305 -16 6.16 
11-dehydro-
TXB2-d4 
371>165 -26 371>309 -16 6.12 
Mobile phase: A 80% H2O+20% ACN + 0.01% CH3COOH 
                        B 55% ACN+45% IPA + 0.01% CH3COOH 
Flow rate: 0.11 µl/min, column temperature 40ºC. 
Gradient was used as follows: 0-1 min 8%B, 1-8 min 95% B, 8-10 min 95%, 10-12 












Negative mode (Kinetex Biphenyl) 
Compounds MRM 
[m/z] 
CE [eV] Confirmatory 
MRM [m/z] 
CE [eV] Rt [min] 
8-iso-PGE2-
d0
351>271 -24 351>189 -38 36.90 
8-iso-PGE2-
d4
351>275 -26 339>193 -34 36.83 
PGE2-d0 351>271 -24 351>189 -38 37.82 
PGE2-d4 351>275 -26 339>193 -34 37.75 
PGD2-d0 351>271 -24 351>189 -38 38.49 
PGD2-d4 351>275 -26 339>193 -34 38.39 
PGA2-d4 333>271 -24 333>189 -30 44.42 
















355>179 -26 355>337 -16 43.87 
Mobile phase: A 100% H2O + 0.01% CH3COOH 
  B 55% ACN+45% IPA + 0.01% CH3COOH 
Flow: 0.1 µl/min, column temperature 40ºC 
Gradient  0-1 min 12%B, 1-50 min 45% B, 50-60 min 100%, 60-68 min 100% B, 68-
78 min 12%  B  – equilibrate 6min. 
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Negative mode (Kinetex Biphenyl) 
Compound MRM 
[m/z] 
CE [eV] Confirmatory 
MRM [m/z] 
CE [eV] Rt [min] 
Tetranor-PGE-
M-d0 
327>143 -30 327>309 -20 11.88 
Tetranor-PGE-
M-d6 
333>149 -32 333>315 -20 11.83 
Tetranor-PGD-
M-d0 
337>143 -30 327>309 -20 12.12 
Tetranor-PGD-
M-d6 
333>149 -32 333>315 -20 12.07 
Mobile phase: A 100% H2O + 0.01% CH3COOH 
    B 100% ACN + 0.01% CH3COOH 
Flow: 0.11 µl/min, column temperature 40ºC 
  Gradient  0-1 min 0%B, 1-20 min 95% B, 20-22 min 100%, 22-25 min 100% B, 25-
30 min 0%  B  – equilibrate 6min. 
After HPLC analysis, methanol extract of eicosanoids was prepared for gas 
chromatography (GC) by evaporation and derivatization. These were sequential 
chemical reactions to render the analytes necessary volatility by modifications of 
carboxyl group (15 µl 10 % pentafluorobenzyl bromide (PFBBr) in acetonitrile with 
10% N-ethyldiisopropylamine (DIPE) in acetonitrile). After formation of 
pentafluorobenzyl ester, samples was evaporated and reconstituted in 30 µl 
methanol and next cleaned up using thin-layer chromatography (TLC) using a 
mobile phase of ethyl :n-heptane (90:10). After collection of silica gel with the 
analyte at 7-19 mm for 8-iso-PGF2, 9,11β-PGF2, 38-50 mm for TXB2 and 61-69 
mm for 11dehydro TXB2 with 1mL of ethyl acetate and evaporation, hydroxyl groups 
were blocked with BSTFA (Bis(trimethylsilyl)trifluoroacetamide) in pyridine. Next, 
evaporated sample was dissolved in toluene (50 µl). GC-MS/MS analysis was done 
using on Shimadzu GC-2010 plus (Kyoto, Japan) instrument in a single ion 
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monitoring (SIM) mode and capillary column Zebron 5MS (30 m x 0.25 mm x 0.25 
µm, Phenomenex). 
Compound SIM [m/z] Rt [min] 
8-iso-PGF2-d0 569 12.52 
8-iso-PGF2-d4 573 12.49 
9,11β-PGF2-d0 569 12.78 
9,11β-PGF2-d4 573 12.75 
TXB2-d0 585 13.49 
TXB2-d4 589 13.45 
11-dehydro-TXB2-d0 511 16.08 
11-dehydro-TXB2-d4 515 16.04 
Results were reported in picograms per milligram of protein. 
2.8.3. Effects of CF supernatant on responder alveolar macrophage 
To test the hypothesis that phagocytosis-inhibitory factors (e.g. PGE2) are found 
within the CF airways, supernatant from CF sputum was added to enriched 
responder AMs isolated from healthy participants. All sputum samples from the CF 
group were processed as described above, following dilution with DPBS and 
centrifugation – prior to addition of DTT – supernatant was collected and stored at 
-80oC until experiment. Responder AMs were isolated and allowed to adhere in
chamber wells overnight as above. After washing and resuspending chamber wells 
with incomplete RPMI to a final volume of 300 µL, wells were divided into two 
groups: i) 10 µg/mL of DEP; ii) 10 µg/mL of DEP and 150 µL of CF supernatant. The 
CF supernatant was added simultaneously with incomplete RPMI, cells were 
exposed to DEP for 2 h. CF supernatant from different patients were used for 
experimental replicates with responder AMs from different healthy participants. CF 
supernatant was selected at random each time. The number of AMs used for 
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subsequent image analysis was kept consistent (ranged from 10 to 50 cells) 
between cultures. 
2.8.4. Effects of EP2-receptor antagonist on responder alveolar 
macrophages cultured in CF supernatant 
Since PGE2 was the suspected inhibitory factor present in CF airways, an EP2 
antagonist was used antagonise its effects in CF supernatant. CF supernatant and 
responder AMs were prepared as described before. Adhered AMs were washed 
and chamber wells resuspended with incomplete RPMI to a final volume of 300 µL, 
these were divided into three groups: i) 10 µg/mL of DEP; ii) 10 µg/mL of DEP and 
150 µL of CF supernatant; and iii) 10 µg/mL of DEP, 150 µL of CF supernatant and 
75µM of EP2-receptor antagonist. EP2-receptor antagonist was added to group (iii) 
for 1 h, followed by the addition of CF supernatant to groups (ii) and (iii), before 
exposing all wells to DEP for 2 h. Consistent number of AMs (ranged from 10 to 50 
cells) between cultures were used for image analysis. 
2.8.5. Effects of cyclooxygenase 2 inhibitors on prostaglandin 
production 
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) which works by inhibiting 
the activities of COX (both COX-1 and COX-2), was used to reduce the production 
of prostaglandin in children with CF. Urine samples were collected from the children 
before and after a 3-day course of Ibuprofen (dosage according to the British 
National Formulary, three times a day). Urinary metabolites of prostaglandin were 
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measured by high performance liquid chromatography–tandem mass spectrometry 
as described before. 
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2.9. Modelling the effects of impaired alveolar macrophages 
phagocytosis in vitro 
2.9.1. The in vitro epithelium-macrophage model 
To investigate the potential consequences of non-phagocytosed inhaled 
carbonaceous particles in the airways, an in vitro epithelium-macrophage model 
was used. The A549 adenocarcinoma human alveolar epithelial cells (Sigma 
Aldrich, Poole, UK) was used to model type II alveolar epithelium, whereas 
macrophages were primary human responder AMs isolated from healthy children 
by sputum induction.  
2.9.1.1. Epithelial cell line 
A549 adenocarcinoma human alveolar epithelial cells were grown in T75 cell 
culture flasks under standard growth conditions (i.e. 20 mL of complete Dulbecco's 
Modified Eagle Medium (DMEM) (F-12, Gibco, Thermo Fisher Scientific, USA) 
kept at 37°C, 5% CO2 in humidified air in an incubator). Cells were passaged a 
maximum of 20 times. The A549 cell line was chosen because of its robust nature, 
enabling the cells to withstand a high dose of DEP, and is also a standard cell line 
used widely in respiratory research. 
2.9.1.2. Choice of media and antibiotics 
DMEM/F-12 is a basal medium widely used to support mammalian cell growth. 
DMEM/F-12 does not contain proteins, lipids, or growth factors, and therefore 
requires supplementation with FBS. The Ham’s F-12 component of DMEM/F-12 is 
known to support epithelial cell growth. Complete DMEM was supplemented with 
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10% FBS and penicillin-streptomycin (Sigma-Aldrich, Missouri, USA), which was 
added to prevent bacterial (gram positive and negative) contamination.  
Using the chamber wells as before, 1X103 A549 cells per well were allowed to 
adhere overnight at 37°C, 5% CO2, in complete DMEM. The cells were washed and 
chambers wells were resuspended with 150 µL of incomplete DMEM 
(supplemented with 4% FBS) and 150 µL of incomplete RPMI the following day. 
Chamber wells were divided into two groups: i) 10 µg/mL of DEP; and ii) 10 µg/mL 
of DEP and the entire population of enriched responder AMs previously extracted. 
Cells were exposed to DEP for 2 h before washing and staining. Light microscopy 
was used to determine the amount of black carbon associated with 50 randomly 
selected A549 epithelial cells from each culture – with and without primary AMs. 
2.9.2. Effects of prostaglandin on the epithelium-macrophage model 
To assess the effect of prostaglandin overproduction in the CF airways, PGE2 was 
added to the epithelium-macrophage model. As before, 1X103 A549 cells adhered 
to chamber wells overnight, before wells were washed and resuspended with 150 
µL of incomplete DMEM and 150 µL of incomplete RPMI. Chamber wells were 
divided into three groups: i) 10 µg/mL of DEP; ii) 10 µg/mL of DEP and the entire 
population of enriched responder AMs extracted; and iii) 10 µg/mL of DEP, the 
entire population of enriched responder AMs previously extracted, and 10−6 M of 
PGE2. PGE2 was added to group (iii) 15 min before the 2 h exposure of DEP to all 
wells. Chambers wells were washed and stained for image analysis as above – 50 
randomly selected A549 epithelial cells were analysed for black carbon content from 
each culture. 
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2.9.3. Cytokine release from epithelial cells following diesel exhaust 
particles exposure 
IL-8 release from epithelial cells and AM was measured using an Enzyme-Linked 
Immunosorbent Assay (ELISA) assay.  
For the trial run, the Duoset IL-8 ELISA kit (R&D systems, Minnesota, USA) was 
used. In accordance with the manufacturer’s instructions, clear flat-bottom 92-well 
plate was pre-coated with capture antibody (100 µL/well at 4 µg/mL) overnight at 
4oC.  
Standard wells were prepared by serial dilutions of the recombinant standard 
(“Top”) well (1000 pg/mL) using the reagent diluent, generating 1:2 – 1:1024 
dilutions.  
Samples were tested in triplicate, in addition to negative and internal controls. Wells 
were washed with wash buffer (WA126, R&D systems) three times, flicking off the 
contents to ensure complete removal of capture antibody to safeguard good 
performance. Wells were then blocked (block buffer DY995, R&D systems) for 2 h 
at room temperature before the contents were flicked off and tapped dry. Samples 
and standards were added to wells and left for 2 h before washing, followed by 
addition of detection antibody for 2 h and washing. Working dilution of Streptavidin-
HRP was added to each well in the dark for 20 min at room temperature before 
washing. Substrate Solution (1:1 Color Reagent A (H2O2) and Color Reagent B 
(Tetramethylbenzidine), DY999, R&D systems) were added to the wells in the dark 
for 20 min before stop solution (DY 994, R&D systems) was added to terminate the 
reaction. Optical density of each well is determined immediately after, using a 
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microplate reader set to 450 nm, with wavelength correction set to 540 nm. (i.e. 
subtract readings at 540 nm from readings at 450 nm).  
The standard concentrations were adjusted according to the trial run standard curve 
(figure 2.12) – the highest 3 concentrations were omitted, subsequent standard 
concentrations started 1:8 of the original concentration (i.e. 125 pg/mL) (figure 
2.13). 
Figure 2.12. Standard curve using manufacturers’ suggested concentrations. R2 = 
0.991. 
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Figure 2.13. Standard curve using the modified standard concentrations. R2 = 
0.998. 
 
However, the Duoset IL-8 kit was replaced by the Human IL-8 ELISA Kit (Invitrogen, 
California, USA) later in the project because it was less time consuming. Since 
experiments were performed in batches, it was deemed cost effective to use the 
pre-coated kit, where the microplate was pre-coated with target specific antibody. 
The kit was used according to the manufacturer’s instructions. 7 serial dilution 
standards were used: 1000, 500, 250, 125, 62.5, 32.2, and 15.6 pg/mL, as well as 
blank wells containing only dilution buffer. Standards, blank controls and samples 
were added to the pre-coated wells and allowed for capture (immobilised) antibody 
binding, followed by the addition of detector antibody. A substrate solution was used 
to react with the enzyme-antibody-target complex, producing a signal which was 
proportional to the target concentration present. Absorbance reading was carried 
out at 450 nm. A standard curve was created using a curve-fitting software, 
subtracting the background absorbance. Values were adjusted by appropriate factor 
to correct for sample dilution (50 µL of each original sample was used). Duplicates 
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were used for each sample, mean values for each set of duplicates were 
determined. 
2.9.3.1. Epithelial model 
The A549 epithelial cell line was used to model the epithelium, 2x105 A549 cells per 
well were allowed to adhere in a 24-well cell culture plate (Corning® Costar® , 
Corning, USA) overnight at 37°C, 5% CO2 in complete DMEM.  
To compare the effects of DEP on the epithelial model, the wells were divided into 
two groups: i) unexposed controls; and ii) 10 µg/mL of DEP. The cells were washed 
the next morning, each well was resuspended with 1 mL of incomplete DMEM. DEP 
was added to group (ii) wells for 2 h. The plate was centrifuged at 1237 rpm (300 x 
g) for 5 min, the top 900 µL of supernatant was aspirated and stored at -80 oC until
ELISA experiment, which was performed in batches. 
Note: Methods of translocation of air pollution particles (research aim 1.10.1.2) can 
be found in chapter 6. 
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2.10. Statistical analysis 
The initial aim of the project was to compare the personal exposure to air pollution 
and alveolar macrophage black carbon contents of 50 children with CF, with 50 age-
matched healthy children. This would provide power of 90% at the 5% significance 
level to detect a difference between two means of 0.7 standard deviations, when 
comparing the CF and healthy control groups. However, expansion of the project 
(increased number of sputum inductions and experiments) resulted in fewer children 
recruited within the time frame, but statistically significant results were seen before 
reaching the original target. 
Data were tested for normal distribution using the D’Agostino and Pearson omnibus 
normality test. Normally distributed parametric data are presented as mean  
standard error of the mean (SEM); non-parametric data are presented as median 
with inter-quartile range (IQR). Parametric data between 2 groups were compared 
using Student’s unpaired or paired t-tests. Non-parametric data between 2 groups 
were compared by either Mann Whitney test (unpaired) or Wilcoxon matched-pairs 
signed rank test (paired). Comparisons between two observers or two analyses 
were done using Bland-Altman plots.  
Multiple comparisons were performed using one-way ANOVA test, comparing 
means of difference  standard error (SE). 
Analyses were performed using Prism 8.00 for Windows (GraphPad Software, CA, 
USA). Results are considered significant at p <0.05. 
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Chapter 3:  
In vivo and in vitro 
alveolar macrophage 
function in cystic fibrosis 
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3. In vivo and in vitro alveolar macrophage function in
cystic fibrosis
3.1. Background 
Air pollution has substantial harmful effects to various human body systems, with 
the lungs being most affected as the first point of contact after inhalation. Particulate 
matter (PM2.5 and PM10) and nitrogen oxide (NOX) can cause oxidative stress and 
inflammation in the airways. Under normal circumstances, inhaled carbonaceous 
PM are phagocytosed by alveolar macrophages (AM) patrolling the lower airways. 
Phagocytosed particles are destroyed and removed from the airway, thereby 
reducing their accumulation and protecting other airway cells such as epithelial cells 
from their harmful effects. As discussed in section 1.7.1, the immune system in 
cystic fibrosis (CF) is altered, secondary to CFTR mutations. Not only does the 
presence of viscous airway mucus render mucociliary action challenging, the 
phagocytic ability of AMs is also impaired, leaving patients with CF susceptible to 
pathogens and inhaled pollutants. Impaired AM function will lead to less black 
carbon (BC) being phagocytosed, and accumulation of residual black carbon in the 
airways. Furthermore, organisms such as Burkholderia cepacia are able to invade, 
survive and replicate within macrophages, rendering their hosts susceptible. 
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3.2. Aims 
In this chapter, the hypotheses tested are: 
o Children with CF have reduced alveolar macrophage black carbon in vivo
compared to healthy controls, despite being exposed to similar amount of air
pollution.
o Alveolar macrophages from children with CF have reduced capacity to
phagocytose particulate matter in vitro.
Personal exposure to air pollutants, particularly black carbon and nitrogen dioxide, 
in children with CF and healthy controls are compared. Using AMs obtained and 
enriched from induced sputum, the in vivo and in vitro AM function from both groups 
are assessed and compared.  
 135 
3.3. Overall project: participants’ demographics 
3.3.1. Children with cystic fibrosis 
36 children were approached at the Royal London Hospital, 2 did not wish to take 
part. 34 children with CF were recruited, 2 of whom withdrew after informed consent 
(1 participant found sputum induction challenging, 1 participant decided the study 
was too time consuming). Of the 32 enrolled children, 12 (38%) were male and 20 
(62%) were female, age ranged from 2 to 16 years. Figure 3.1 gives an overview of 
patients’ recruitment and participation in various parts of the study. Table 3.1 
summarises the participants’ CFTR mutations, most recent sputum or cough swab 
microbiology results at the time of recruitment, and lung function (FEV1 predicted at 
the time of recruitment). The age and gender of participants are not shown in order 
to maintain pseudo-anonymity.  
 
Figure 3.1. Flow diagram of CF patients’ recruitment. 
 136 
Patient CFTR Mutations Microbiology results at the time of recruitment FEV1 predicted 
(%) 
1 Delta F508: Delta exon 11 compound Escherichia coli; Pseudomonas aeruginosa N/A 
2 Delta F508: N1303K Staphylococcus aureus 76.8 
3 Delta F508 homozygous Staphylococcus aureus* 66.4 
4 Delta F508 homozygous Achromobacter xylosoxidans 73.8 
5 Delta F508: R1158X Throat flora 58 
6 p.Gln685fs homozygous No growth N/A 
7 Delta F508 homozygous Aspergillus fumigatus 103.1 
8 Delta F508 homozygous Achromobacter xylosoxidans; Serratia 74.7 
9 Delta F508 homozygous No growth N/A 
10 p.CYS491Phe:CSER1118Phe No growth N/A 
11 Delta F508: p.Arg352Gln Throat flora N/A 
12 Delta F508 homozygous Throat flora N/A 
13 Delta F508 homozygous Yeast; Pseudomonas aeruginosa * 101.5 
14 Delta F508: G551D Haemophilus influenza; Burkholderia vietnamiensis N/A 
15 F549N homozygous Throat flora 52.2 
16 161Del C homozygous Staphylococcus aureus* 73.9 
17 Delta F508 homozygous Pseudomonas aeruginosa* N/A 
18 Delta F508: c280s_2810del No growth 81.6 
19 Delta F508: R1158x No growth 101.6 
20 Delta F508 homozygous Yeast; Throat flora 100.7 
21 TRX4-10 del homozygous Throat flora 90.5 
22 Delta F508: parg158 Haemophilus influenza; Staphylococcus aureus N/A 
23 Delta F508 homozygous Throat flora 97.1 
24 Delta F508 homozygous Stenotrophomonas maltophilia 102 
25 Delta F508 homozygous Throat flora 112.8 
26 Delta F508 homozygous Pseudomonas aeruginosa 70.1 
27 Delta F508: 365insT No growth 75.1 
28 Delta F508 homozygous Pseudomonas aeruginosa* 93.7 
29 Delta F508: p.GLU60X Throat flora 86.4 
30 Delta F508 homozygous Staphylococcus aureus; Aspergillus fumigatus 74.1 
31 Delta F508 homozygous Staphylococcus aureus; Scedosporium 70.2 
32 Delta F508 homozygous Stenotrophomonas maltophilia; Achromobacter xylosoxidans 92 
 
Table 3.1. Summary of CF participants’ CFTR mutation, most recent sputum or cough swab microbiology results at the time of 
recruitment, and lung function (FEV1 predicted at the time of recruitment). 
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3.3.2. Healthy children 
30 children were approached, and 4 did not wish to take part. 26 healthy children were 
therefore recruited as controls, 22 of whom were recruited at the Royal London 
Hospital, and 4 recruited in a school via media work; 1 was excluded after informed 
consent due to poor sputum induction technique.  Of the 25 children, 11 (44%) were 
male, 14 (56%) were female, and ages ranged from 2 to 14 years. Figure 3.2 gives an 
overview of healthy children’s recruitment and participation in various parts of the 
study. 
Figure 3.2. Flow diagram of healthy children’s recruitment. 
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A total of 60 children were recruited following written informed assent (where old 
enough) and consent from the primary caregiver. Healthy controls were matched in 
age brackets to patients with CF, ranging from 2 to 16 years, median (IQR) ages of 
CF and control groups were 11.0 (4.0 – 15.0) years and 8.5 (7.0 – 11.0) years 
respectively (p=0.35, figure 3.3). 
Figure 3.3 Age distribution of CF and control participants. Comparison by Mann-















3.4. Pollution exposure monitoring 
3.4.1. Modelled exposure at home address 
Using the LAQT provided by King’s College London, participants’ pollution exposure 
12 months prior to participation in the study was modelled based on their home 
address. There was no significant difference between the CF and control groups in 
terms of their long-term annual exposure to NO2, PM10 and PM2.5. Data are presented 
as median (IQR). Median NO2 exposure for CF vs control groups were 34.84 (31.24 – 
37.43) µg/m3 vs 37.07 (32.14 – 40.96) µg/m3 (p=0.09, figure 3.4). Notably, 4 
participants from each of the two groups live in areas with annual NO2 levels above 









Figure 3.4. Modelled exposure to NO2 of CF and control groups, 12 months before 
their participation in the study, based on their home addresses. Comparison by Mann-
Whitney test. Bars represent median. The red line indicates WHO guidelines for 





























Median PM10 exposure for CF vs control groups were 26.54 (24.53 – 27.26) µg/m3 vs 
25.41 (24.09 – 26.36) µg/m3 (p=0.42, figure 3.5). All participants live in areas with 
annual PM10 levels above the WHO guidelines. 
Figure 3.5. Modelled exposure to PM10 of CF and control groups, 12 months before 
their participation in the study, based on their home addresses. Comparison by Mann-
Whitney test. Bars represent median. The red line indicates WHO guidelines for 


























Median PM2.5 exposure were 16.81 (15.65 – 17.44) µg/m3 vs 15.19 (14.65 – 16.86) 
µg/m3 (p=0.22, figure 3.6). All participants live in areas with annual PM2.5 levels above 









Figure 3.6. Modelled exposure to PM2.5 of CF and control groups, 12 months before 
their participation in the study, based on their home addresses. Comparison by Mann-
Whitney test. Bars represent median. The red line indicates WHO guidelines for 
annual PM2.5 exposure. 
 
3.4.2. Black carbon exposure 
25 children with CF and 21 healthy controls took part in personal black carbon 
monitoring. Black carbon exposure was measured by portable aethalometers set to 
provide a reading every 60 s at a flow rate of 100 mL/min. Each participant carried an 
aethalometer for 2 typical school days, changing the filter every 24 h to ensure 
adequate device calibration.  
 
Representative annotated graphs of two of the participants’ aethalometer data are 
shown in figures 3.7 a and b. The baselines of the graphs are in the low-hundreds 
range, representing indoor levels of black carbon. Spikes are seen during participants’ 
outdoor activities (e.g. commute and play-time). 

























To further examine the causes of high spikes, an aethalometer was carried along 
some of London’s busiest roads (e.g. Oxford Street, Marylebone Road, The Strand), 
while the journey was filmed using a GoPro action camera. BC peaks were associated 
with idling vehicles or heavy vehicles (e.g. lorries, vans) passing by. Figure 3.8 shows 
some snapshots of the footage matched with the aethalometer BC peaks. 
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Figure 3.7a. Aethalometer reading of a participant’s typical school day, showing spikes in black carbon levels during outdoor activities 
including walking to and from school, and walking between school buildings during lunch and in between periods. 
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Figure 3.7b. Aethalometer reading of another participant’s 2 typical school days, showing spikes of black carbon levels during outdoor 
activities including walking to and from school, and walking between school buildings during lunch and in between periods. 
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Figure 3.8. Aethalometer readings matched with GoPro camera footage to demonstrate 




























































































































































































The mean black carbon per minute across the 2 days for each child was determined 
by dividing the cumulative black carbon concentrations over the sampling period (2 
days) by the number of sampling minutes. The median of these were compared 
between the two groups. In line with the modelled pollution data, there was no 
significant difference between the two groups. The median (IQR) of the mean black 
carbon per minute for CF and control groups were 1394 (828 – 3547) ng/m3 (n=25) 
and 1587 (725 – 4392) ng/m3 (n=21) respectively (p=0.83, figure 3.9). 
Figure 3.9. Personal black carbon exposure: each data point represents the mean 
per minute across 2 typical school days (cumulative black carbon concentrations of 
the 2 days divided by the number of sampling minutes). Comparison by Mann-
Whitney test. Bars represent median. 
The daily personal BC exposure data were shared with the participants in graphic 
form, in order to examine the pollution levels during their daily routine.  
23 participants, combining CF and control groups, completed their activity diaries in 
detail. Their daily exposures to BC were categorised into 3 periods: i) home (indoor), 
ii) school (indoor) and iii) outdoor. The pollution peaks were identified; their
























On average, children spent 23.5%, 66.4% and 10.1%, of their day indoors in school, 
home, and outdoors, respectively. The mean ± SEM daily cumulative BC 
concentrations were 1.4 x 106 ± 4.3 x 105 ng/m3 (indoor school), 1.5 x 106 ± 2.1 x 
105 ng/m3 (indoor home), and 7.0 x 105 ± 1.9 x 105 ng/m3 (outdoor). On average, the 
three microenvironments (school, home and outdoor) contributed to 29.6%, 52.0% 
and 18.4% of total daily BC exposure respectively (table 3.2). These results showed 
that children spent most of their time (66.4%) indoors at home, however, the 
cumulative BC exposure from this microenvironment was not significantly higher than 
the other two microenvironments. In fact, the cumulative BC concentration from home 
is similar to that from school, despite children spending approximately 3 times longer 
at home than in school. This suggested that the home environment was much cleaner 
than school. Similarly, while children only spent about 10.1% of the time outdoors 
(approximately one-sixth of their time at home), their cumulative BC concentration 
from the outdoor environment was almost half of that from home, suggesting the 
outdoor environment was the most heavily polluted amongst the microenvironments. 
 
Table 3.2. Summary of children’s BC exposure in each microenvironment – 
combining data from both CF and control groups, only including children who 






Mean duration  
(% of a day) 
23.5% 66.4% 10.1% 
Mean ± SEM of 
daily cumulative 
BC concentration 
1.4 x 106 ± 
4.3 x 105 
ng/m3 
1.5 x 106 ±  
2.1 x 105  
ng/m3 
7.0 x 105 ±  
1.9 x 105 
ng/m3 
Mean contribution 
of cumulative daily 
BC exposure 
29.6% 52.0% 18.4% 
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3.4.3. Nitrogen Dioxide Exposure 
NO2 levels were measured using diffusive samplers. Taking into account the air flow 
and average temperature during the monitoring period, the mean NO2 levels over 2 
weeks were determined. 
3.4.3.1. Indoor Nitrogen Dioxide Exposure 
Indoor levels of NO2 were measured by placing a diffusive sampler in a room in the 
house (except the bedroom) where the participant spent most time. Once again, there 
was no significant difference between the two groups. The mean indoor NO2 over 2 
weeks was determined for each child. The median (IQR) of was compared between 
the two groups: 23.45 (14.00 – 31.75) µg/m3 standard temperature and pressure 
(STP) for CF group (n=22), and 24.80 (21.30 – 47.50) µg/m3 STP for control group 
(n=17), p=0.21 (figure 3.10). It is unclear what was responsible for the CF outlier, an 
electric cook stove was used at home. For the control outlier, a gas cook stove was 
used and the kitchen was open-planned, the family burned candles 3 to 4 times a 
week; no other unusual activities were identified. 
Figure 3.10. Indoor NO2 levels: each data point represents the mean across 2 weeks 























There was no significant difference in indoor NO2 levels between participants 
(combined CF and controls) using gas (n=29) or electric (n=10) cook stoves, with 
median (IQR) of 24.80 (19.40 – 36.20) µg/m3 STP vs 23.45 (15.40 – 29.48) µg/m3 
STP respectively, p=0.45 (figure 3.11). 
Figure 3.11. Indoor NO2 levels for gas vs electric cook stoves, combining data from 
CF and control groups. Comparison by Mann-Whitney test. Bars represent median. 
3.4.3.2. Personal Nitrogen Dioxide Exposure 
Personal NO2 exposure was measured by the participant wearing a diffusive sampler 
on their person during the 2 week monitoring period – a mixture of indoor and outdoor 
exposure. The calculations were based on a rough estimation of participants 
spending 4 h per day outdoor, and 20 h per day indoor. This estimation was kept 
constant for all participants. For the participants who did not damage or lose the NO2 
samples, the mean personal NO2 exposure over 2 weeks was determined for each 
child. The median (IQR) of these were compared between the two groups: 19.60 
(14.90 – 29.40) µg/m3 STP for CF group (n=21), and 25.20 (17.33 – 36.00) µg/m3 
STP for control group (n=18), p=0.20 (figure 3.12). The CF outlier corresponds to the 





















Figure 3.12. Personal NO2 levels: each data point represents the mean across 2 
weeks for each participant. Comparison by Mann-Whitney test. Bars represent 
median. 
Using combined data from both CF and control groups (n=39), when the aethalometer 
readings (mean black carbon exposure per minute, over 2 typical school days) were 
compared to the personal NO2 levels (mean NO2 exposure over 2 weeks), no 
significant correlation was seen (r=0.28, p=0.08) (figure 3.13). 
Figure 3.13. Spearman correlation between mean black carbon per minute over 2 
days and mean personal nitrogen dioxide over 2 weeks, r=0.28, p=0.08. 
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3.5. Assessment of internal dose of air pollution: alveolar 
macrophage black carbon  
Using image analysis of cytospin slides from both CF and control groups, mean 
alveolar macrophage black carbon (AMBC) of 50 randomly selected alveolar 
macrophages (AMs) from each participant was determined and the median of these 
were compared.  AMBC of the CF group was significantly reduced compared to the 
control group, with median (IQR) of CF (n=19) vs controls (n=21) being 0.12 (0.05 – 
0.24) µm2 vs 0.30 (0.20 – 0.52) µm2, p<0.001 (figures 3.14).  
 
Figure 3.14. Alveolar macrophage black carbon (AMBC): each data point represents 
the mean of 50 randomly selected AMs from each participant. Comparison by Mann-






























  *** p<0.001
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Figure 3.15 shows the 50 AMs analysed from a randomly selected participant from 
the CF (figure 3.15a) and control (figure 3.15b) groups. Notably, there were more 
“clean” cells (i.e. cells with no black carbon within its cytoplasm) in the CF group 
compared to control group. There were also differences in cell morphology between 
the groups: CF AMs were generally smaller (as described in the literature), with more 
vacuoles within the cytoplasm, and cell membranes were more ragged and irregular 
– potentially due to imminent cell death. There were more prominent pseudopodia
observed in CF AMs, possibly reflecting more active phagocytosis. These 
morphological differences suggest that CF AMs may be under more stress in vivo.  
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Figure 3.15a. 50 AMs with phagocytosed black carbon (arrows) from a CF participant - 




Figure 3.15b. 50 AMs with phagocytosed black carbon (arrows) from a healthy participant. 




3.5.1. Second observer for alveolar macrophage black carbon 
Due to the temporal nature of participants’ recruitment, where children from each 
group were recruited in batches, it was difficult to blind image analysis of AMBC. In 
order to limit unconscious bias, a second observer who was blinded to the 
participants’ health status (CF vs control) performed the AMBC analysis on 11 
randomly selected samples independently, followed by Bland-Altman analysis. Bias 
± SD was 0.09 ± 0.19 with a 95% limits of agreement from -0.29 to 0.47 (figure 3.16). 
Figure 3.16. Bland-Altman: difference vs average. Bias and agreement of AMBC of 
11 participants (CF and controls) by two independent observers – where the second 
observer was blinded to the participants’ health status. 
Generally, smaller differences are seen in the analyses of the CF group, where AMBC 

















1 5 6  
3. 5. 2. R el ati o n s hi p b et w e e n al v e ol a r m a c r o p h a g e bl a c k c a r b o n a n d 
p er s o n al bl a c k c a r b o n e x p o s ur e 
T h er e w a s n o si g nifi c a nt c orr el ati o n b et w e e n A M B C a n d p er s o n al bl a c k c ar b o n 
e x p o s ur e (fr o m a et h al o m et er m o nit ori n g) f or b ot h C F (r =- 0. 5 1, p = 0. 0 6, fi g ur e 3. 1 7 a) 
a n d c o ntr ol (r =- 0. 1 8, p = 0. 4 9, fi g ur e 3. 1 7 b) gr o u p s. 
Fi g ur e 3. 1 7.  S p e ar m a n c orr el ati o n b et w e e n al v e ol ar m a cr o p h a g e bl a c k c ar b o n a n d 
m e a n bl a c k c ar b o n p er mi n ut e o v er 2 d a y s f or C F ( a) a n d c o ntr ol ( b) gr o u p s.   
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3.6. Alveolar macrophages in vitro uptake of diesel exhaust 
particles 
Enriched AMs were exposed to 10 µg/mL of diesel exhaust particles (DEP) for 2 hr 
before AMBC analysis. It was difficult to achieve overnight cell adhesion of 50 cells 
per sample due to the variable and limited numbers of AMs extracted from each 
sputum induction session, coupled with inevitable cell loss during the enrichment 
process. Therefore, for each participant, equal numbers of AMs from each culture 
(unexposed vs exposed to DEP) were used for AMBC analysis. Table 3.3 depicts the 


















1 50 1 50 
2 50 2 10 
3 50 3 50 
4 50 4 16 
5 50 5 24 
6 50 6 17 
7 15 7 50 
8 20 8 50 
9 32 9 30 
10 22 10 50 
11 10 11 50 
12 50 12 50 
13 48 13 19 
14 25 14 50 
15 17 15 23 





Table 3.3. Summary of the number of alveolar macrophages available from each 
participant after cell enrichment and overnight adhesion, for the DEP in vitro assay. 
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Comparing the number of AMs extracted from each participant, there was no 
significant difference between the CF and control groups. Median (IQR) number of 
AMs for CF and control were 40 (18 – 50) and 50 (23 – 50) respectively (p=0.49, 
figure 3.18).  
Figure 3.18. Number of alveolar macrophages available following cell enrichment 
and overnight adhesion for both CF and control groups. Comparison by Mann-
Whitney tests. Bars represent median.  
For the first time, image analysis of enriched primary AMs was performed in this 
project. The median of differences of AMBC for the CF group was 9.20 µm2, p<0.0001 
(n=16, figure 3.20a), increased by a median (IQR) fold change of 72 (48–238) 
(p<0.0001, figure 3.20c); the median of differences of AMBC for the control group 
was 11.53 µm2, p<0.0001 (n=20, figure 3.20b), increased by a median (IQR) fold 
change of 40 (20 – 81) (p<0.0001, figure 3.20d).  
Multiple comparisons showed a mean difference ± SE between CF unexposed cells 
and CF exposed cells of 13.81 ± 4.00 µm2, p=0.003; a mean difference ± SE between 































These results demonstrate that DEP exposed cells from both CF and control groups 
contained comparable amount of black carbon, suggesting AMs from both CF and 
control groups had similar phagocytic ability in vitro (figure 3.19).  
Figure 3.19. Alveolar macrophages from children with CF (a) and healthy controls 
(b), following exposure to diesel exhaust particles. 
a1 a2 a3 
b1 b2 b3 
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C o ntr ol s
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Figure 3.20. Alveolar macrophage black carbon (AMBC) of alveolar macrophages 
extracted from CF (a) and control (b) participants, unexposed to diesel exhaust 
particles (DEP -) vs exposed (DEP+); presented in log scale and compared by 
Wilcoxon test. Data transformed into fold change in (c) and (d); compared by Mann-
Whitney test, bars represent median. (e) Comparison of AMBC of unexposed (DEP -
) alveolar macrophages from CF group, exposed (DEP +) alveolar macrophages from 
CF group, and exposed (DEP +) alveolar macrophages from control group; using 
one-way ANOVA Tukey’s multiple comparisons test, bars represent SE.  
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3.7. Incidental findings - intracellular bacterial clusters 
While many AMs examined, from both CF and control groups, contained scattered 
phagocytosed bacteria, it was noted that clusters of bacteria were occasionally seen 
in AMs from children with CF, a phenomenon not observed in the control group. 13 
CF sputum samples were examined, using 50 randomly selected AMs from each 
sample. 5 of the 13 samples contained clusters of bacteria (rods or cocci, figure 3.21), 
with a mean ± SEM area occupied by bacteria of 2.41 ± 0.81 µm2.  
Figure 3.21. Alveolar macrophages from children with CF showing clusters of 
intracellular bacteria.  
Of these 5 children, from their routine hospital sputum cultures at the time of research 
sputum induction, 3 samples yielded no growth, 1 child was colonised with 
Pseudomonas aeruginosa, and 1 was colonised with Achromobacter xylosoxidans. 
In view of these incidental findings, further sputum samples from 2 of these children 
were obtained for repeat microbiology culture.  Sputum induction was performed as 
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described in section 2.6.2. Half the sample was unprocessed and sent for prolonged 
routine hospital sputum culture. Briefly, an equal volume of 0.1% dithiothreitol was 
added to the sputum sample, followed by agitation and incubation at 37oC for 30 min. 
100 µL of the homogenised sputum was added to a sterile tube containing 900 µL of 
sterile distilled water. Serial 1:10 dilution was carried out down to 1/100000. Dilution 
concentrations of 1/10, 1/1000 and 1/100000 were plated on different media: blood 
agar, chocolate agar and Sabouraud Dextrose Agar. The other half of the sputum 
sample was processed (as per section 2.7.1.) in order to enrich for AMs, followed by 
microbiology culture as described above. Culture results are summarised in table 3.4. 
The significance of these results is discussed later in this chapter. 



































Table 3.4. Summary of induced sputum prolonged cultures results: enriched alveolar 




This chapter demonstrates clear evidence of reduced in vivo alveolar macrophage 
black carbon in the CF group compared to healthy controls. This does not appear to 
be due to differences in pollution exposure between the groups, as all participants 
were school children residing in London. Both modelled exposure and personal 
monitoring data showed that they were exposed to similar levels of pollution (NO2, 
PM10, PM2.5, and black carbon – the core of PM). Therefore, the differences between 
the two groups are suggestive of functional phagocytic disparities, supporting the 
initial hypothesis of this project. That is, the lower amount of black carbon 
phagocytosed by AMs from children with CF implies impaired phagocytosis in this 
group. A similar phenomenon was seen by Brugha et al. 102 in children with moderate 
to severe asthma, who had 51% less AM carbon compared to healthy children. 
Macrophage dysfunction in CF is long established in the literature. For example, 
Brusica et al. 120 stated that CF macrophages can undergo phenotype change during 
disease processes, altering their ability to regulate inflammatory response, remove 
invading materials and repair tissue damage; while Alexis et al. 122 described altered 
CF phagocytes surface markers expressions, leading to impaired host defence and 
clearance of invading materials. It was therefore anticipated that there would be 
reduced levels of black carbon phagocytosed in AMs from children with CF.  
Given that AMs from both groups exhibited similar in vitro phagocytic abilities when 
exposed to DEP, it is therefore reasonable to assume that impaired phagocytosis in 
CF is due to the unique environment of the CF airways. Viscous CF airway mucus 
might hinder AM movements, thereby limiting their access to and uptake of inhaled 
carbonaceous particles. Additionally, the pro-inflammatory environment in the CF 
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airway might have inhibitory effects on AM function – this will be explored in the 
subsequent chapter.  
 
Traditional beliefs of airway inflammation in CF being caused by respiratory infections 
have changed over time – with airway inflammation now believed to be a primary 
event in CF, existing even without evidence of infections as early as fetal and infancy 
stages, as demonstrated by Hubeau et al. 179, when a larger population of AMs was 
seen in CF airways compared to healthy controls. Brennan et al. 180 also saw a larger 
number of AMs in bronchoalveolar lavages in children with CF compared to a non-
CF group. These suggest that, as part of the disease process in CF, the absolute 
number of AMs are higher, in which case the reduced levels of AMBC could be 
explained by the BC load being shared amongst more AMs.  
 
In this work, intracellular clusters of bacteria were incidentally observed in AMs 
isolated from children with CF, a phenomenon not seen in the healthy group. Given 
that these children were clinically well at the time of sampling, with no evidence of 
lung function decline, new onset respiratory symptoms or active chest infections, it 
was reasonable to assume that these organisms were residing within the host, 
concealed from the immune system – once again suggesting altered function of AMs 
in CF, and this could be problematic in CF. For example, Burkholderia cepacia is 
reported to survive inside phagocytic cells 131, and Burkholderia cepacia infection is 
particularly deleterious in CF as it is highly resistant to antibiotics. Another pathogen 
of concern in CF is non-tuberculous mycobacteria (NTM), prevalence of which has 
increased over the last 4 decades, potentially because of increased environmental 
exposures and antibiotic usage 181. NTM can cause progressive lung damage and 
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require prolonged courses of antibiotic treatments, but diagnosis is often challenging 
due to its slow growth and the fact that NTM can exist naturally in the environment 
182. NTM isolation should therefore be ideally from sterile respiratory specimens,
which are difficult to obtain in clinical settings. However, culturing the contents of 
enriched AMs will allow for detection of any concealed pathogens in an environment 
free from respiratory secretions and saliva, and can therefore be beneficial in the 
management of CF. 
While patients with CF are often admitted to the hospital due to acute chest 
exacerbations, a portion of them will be asymptomatic and/or are admitted purely due 
to lung function decline. However, their sputum and cough swab sample cultures 
often yield no significant bacterial growth, in which case antibiotic treatments are 
empirical. With regards to prolonged sputum microbiology culture results in this 
research, whilst most organisms identified in enriched AM cultures but not 
unprocessed cultures were commensal flora found in the oral cavity 
(Capnocytophaga ochracea, Streptococcus mitis, Streptococcus salivarius), 
respiratory tract (Neisseria flavescens) and skin (Staphylococcus epidermidis, 
Staphylococcus aureus), some of these organisms could cause opportunistic 
infections in an immune compromised host. For example, Streptococcus mitis can 
cause infective endocarditis, and Staphylococcus aureus can cause problematic 
chest infections in CF, usually requiring antibiotic treatment. Therefore, using 
enriched AMs could offer a novel method of microbiology culturing, revealing any 
concealed pathogens and offering tailored antibiotic treatments. 
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3.8.1. Strengths 
Aethalometers and diffusive samplers are gold standard methods of personal 
pollution monitoring, and are user friendly; whereas exposure modelling using the 
London Air Quality Toolkit is also well established. With participants from both CF 
and control groups being age-matched and all residing in London, their daily school 
activities and air pollution sources and levels were similar. This allowed for fair 
comparisons of AMBC findings – any differences in AMBC between the two groups 
were likely to be secondary to AM functional disparities. A second observer 
performing blinded image analyses on randomly selected samples from both groups 
helped maintain objectivity and reduce bias. Sputum induction is non-invasive and 
usually well tolerated, allowing for experimentations using primary AMs from both CF 
and control groups. The AM enrichment method allows for clear visualisation of AM 
content, and experimentations with primary AMs, without the influence of other airway 
cells and mucus. 
3.8.2. Limitations 
Personal exposure monitoring was only carried out for a limited period of time (2 days 
for BC monitoring, and 2 weeks for NO2 monitoring). Air pollution levels change with 
season and weather (temperature, wind speed, humidity, etc). 8 aethalometers were 
available for use during the study period, as a result, participants were monitored on 
different school days, spanning across all seasons and weather variations.  
Aethalometer use was limited by its battery life of up to 24 h. As a result, varying 
durations of data were obtained from each participant (ranging from 20 to 24 h per 
monitoring day). Data were therefore expressed as mean BC level per minute across 
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the monitoring period. Data interpretation relied heavily on participants’ accurate 
recording of their activities in the diary, the quality of recordings were variable. NO2 
diffusive samplers were small and prone to loss and damage. Consequently, not all 
participants completed the NO2 monitoring exercise.  
It was challenging to quantify and compare the amount of AMs present in the CF vs 
control airways, as the AM yield from sputum induction was not directly proportional 
to their in vivo quantities. Yield was very dependent on the participant’s induction 
technique and could vary even within the same individual on different occasions. As 
previously discussed, the variable absolute numbers of AMs in CF and controls could 
affect the interpretation of AMBC results.  
While sputum induction is a non-invasive and well tolerated, techniques vary amongst 
children, resulting in differing amount of AMs extracted from each participant. This 
was particularly troublesome in the CF cohort, as CF airway secretions are viscous, 
making cell expectoration difficult; many patients have been labelled as “dry” and 
have struggled to expectorate samples over the years, whilst others tend to swallow 
sputum. As a result, the in vitro work was limited by the number of AMs available from 
each participant at each sputum induction session. 
3.8.3. Summary 
This chapter demonstrated that despite exposure to similar levels of air pollution, 
there was less phagocytosed black carbon in vivo in AMs isolated from children with 
CF, compared to their healthy counterparts. However, the AM phagocytic ability from 
both groups was similar in vitro. Putative explanations include the presence of 
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phagocytic-inhibitory substances within the CF airway, or an increased amount of 
AMs in CF, sharing out the load of inhaled BC. Nevertheless, the bacterial clusters 
seen in CF AMs, along with evidence in the literature, suggest AM function in CF is 
altered, thereby supporting the former explanation. The next chapter will discuss the 
cause of impaired AM function in CF, and in particular the potential role of 
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4. Role of prostaglandin E2 in alveolar macrophage
function in cystic fibrosis
4.1. Background 
The previous chapter demonstrated that despite exposure to similar levels of air 
pollution, black carbon loading was reduced in alveolar macrophages isolated from 
children with cystic fibrosis, compared to their healthy counterparts. One obvious 
explanation is phagocytic impairment in CF. As highlighted in section 3.8, this could 
be due to altered alveolar macrophage morphology and size, and reduced receptor 
expression; it could also be due to the presence of a larger population of alveolar 
macrophages in CF, so the inhaled black carbon load is shared between more 
phagocytes. However, it is well recognised that inflammation characterises the 
airways of patients with CF. As discussed in section 1.7.2, there is increased 
recruitment of inflammatory cells, and increased production of cytokines and 
prostaglandins within the CF airways; CFTR dysfunction can also affect 
macrophage polarisation, contributing to inflammatory responses. Inflammation is 
particularly worse during exacerbations, but can also be present when patients are 
clinically well without any evidence of infections.  
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4.2. Aims 
In this chapter, the hypotheses tested are: 
o Children with CF have higher levels of prostanoids – specifically, increased
levels of prostanoids and metabolites in the respiratory secretions and urine.
o Prostaglandins, specifically PGE2, exert inhibitory effects on alveolar
macrophage phagocytosis.
o There is increased expression of cyclooxygenase-2 in alveolar macrophages
isolated from children with CF.
o Prostanoid production can be reduced by cyclooxygenase inhibitors (e.g.
Ibuprofen).
Firstly, in vivo markers of inflammation including cyclooxygenase 2 (COX-2) and 
prostaglandins (PGs) metabolites were measured and compared in both CF and 
control groups. COX-2 expression in AMs was measured using flow cytometry, while 
urinary metabolites of prostanoids were used as a reflection of endogenous PGs 
synthesis due to its chemical instability, as discussed in section 2.8. Secondly, the 
inhibitory effect of prostaglandin, in particular PGE2, on AM function was modelled 
in vitro; along with the demonstration of how PGE2 blockade with an EP2 antagonist 
could restore AM phagocytosis. To further demonstrate the association, the effect 
of CF airway secretions on responder AM function (cells isolated from healthy 
controls) was also modelled.  
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4.3. Cyclooxygenase 2 expression in alveolar macrophages 
Relative median fluorescence intensities (MFI) of COX-2 expression in enriched 
AMs were higher in the CF group (n=20) compared to the control groups (n=17). 
Median (IQR) MFI was 10217 (8092 – 16126) vs 8142 (6536 – 10209) for CF and 











Figure 4.1. Median fluorescence intensities (MFI) for COX-2 expression in alveolar 
macrophages isolated from CF and control groups. Comparison by Mann-Whitney 
test. Bars represent median.  
 
4.3.1. Blinded analysis of COX 2 expression in alveolar macrophages 
8 samples (mixed CF and control groups) were randomly selected, different sample 
identification numbers were re-assigned by an independent researcher, thereby 
blinding the analyst from the participants’ health status, followed by re-analysis by 
the original analyst (myself), using the same flow cytometry gating strategy. The 
bias and agreement of the median MFI for COX-2 expression from the two sets of 


































results were compared by Bland-Altman method. Bias ± SD was 1936 ± 8399 with 









Figure 4.2. Bland-Altman: difference vs average. Bias and agreement of median 
MFI for COX-2 expression in AMs from 8 participants (CF and controls) by the same 


























4.4. Prostanoid profiles in cystic fibrosis compared to 
healthy controls 
4.4.1. Indirect measurement of prostanoid production – urinary profiles 
Urinary metabolites of prostaglandin E2 (13,14-dihydro-15-keto-E2; 13,14-dihydro-
15-keto-tetranor-PGE2 and tetranor-PGE-M), prostaglandin D2 (13,14-dihydro-15-
keto-tetranor-PGD2, tetranor-PGD-M, and 9a,11b-PGF2), and prostaglandin J2 
(15-doexy-delta12,14-PGJ2) were higher in the CF group (n=24) than the control 
group (n=20), after correction for urinary creatinine levels (median (IQR) creatinine 
for CF and controls were 4987 (1847 – 8478) µmol/L vs 12291 (8227 – 16559) 
µmol/L respectively, p<0.001). 
4.4.1.1. Prostaglandin E2 
For urinary metabolites of PGE2, median (IQR) urinary 13,14-dihydro-15-keto-E2 
were 1490 (773 – 2675) pg/mg creat vs 928 (478 – 1376) pg/mg creat (p=0.04, 
figure 4.3). 
Figure 4.3. Urinary metabolite of prostaglandin E2: 13,14-dihydro-15-keto-E2 for 
CF and control groups, presented in log scale. Comparison by Mann-Whitney test. 
































Median (IQR) urinary 13,14-dihydro-15-keto-tetranor-E2 for CF vs controls were 511 
(249 – 788) pg/mg creat vs 214 (96 – 323) pg/mg creat (p=0.003, figure 4.4). 
Figure 4.4. Urinary metabolite of prostaglandin E2: 13,14-dihydro-15-keto-tetranor-
E2 for CF and control groups, presented in log scale. Comparison by Mann-Whitney 
test. Bars represent median. 
 Median (IQR) urinary tetranor PGEM, the main metabolite of PGE2, were 35965 
(22915 – 101316) pg/mg creat vs 15873 (10150 – 24733) pg/mg creat (p<0.001, 
figure 4.5). 
Figure 4.5. Urinary metabolite of prostaglandin E2: tetranor-PGE-M for CF and 






























































Since airway inflammation can progressively deteriorate with time in CF, the main 
metabolite of PGE2 (urinary tetranor-PGE-M) was examined further in relation to the 
participants’ age. All participants were clinically stable at the time of sampling. There 
was no relationship between urinary tetranor-PGEM and age of the children from 
the CF group (r=0.16, p=0.50) (figure 4.6).  
Figure 4.6. Spearman correlation: relationship between urinary tetranor PGEM and 
age of children with CF, r=0.16, p=0.50. 
Lung function also deteriorates over time in CF, therefore, urinary tetranor-PGE-M 
levels of children with CF were compared to their spirometry results at the time of 
sampling, while clinically stable. There was no apparent relationship between 
urinary tetranor-PGE-M and FEV1 predicted (r=0.26, p=0.42), (figure 4.7); nor was 
there a relationship between urinary tetranor-PGE-M and FVC predicted (r=0.35, 
p=0.21), (figure 4.8).  


























Figure 4.7. Spearman correlation: relationship between urinary tetranor-PGE-M 
and FEV1 predicted (%) in children with CF, r=0.26, p=0.42. 
Figure 4.8. Spearman correlation: relationship between urinary tetranor-PGE-M 
and FVC predicted (%) in children with CF, r=0.35, p=0.21. 



















































4.4.1.2. Prostaglandin D2 
With regard to PGD2 metabolites, median (IQR) urinary 13,14-dihydro-15-keto-D2 











Figure 4.9. Urinary metabolite of prostaglandin D2: 13,14-dihydro-15-keto-D2 for 
CF and control groups, presented in log scale. Comparison by Mann-Whitney test. 








































Median (IQR) urinary 13,14-dihydro-15-keto-tetranor-PGD2 for CF vs controls were 
680 (443 – 889) pg/mg creat vs 233 (170 – 405) pg/mg creat (p<0.0001, figure 4.10). 
Figure 4.10. Urinary metabolite of prostaglandin D2: 13,14-dihydro-15-keto-
tetranor-PGD2 for CF and control groups, presented in log scale. Comparison by 
Mann-Whitney test. Bars represent median. 
Median (IQR) urinary tetranor-PGD-M, the main metabolite of PGD2, were 8003 
(3817 – 12173) pg/mg creat vs 3219 (2567 – 5150) pg/mg creat (p<0.001, figure 
4.11) 
Figure 4.11. Urinary metabolite of prostaglandin D2: tetranor-PGD-M for CF and 































































Median (IQR) urinary 9a,11b-PGF2 were 868 (572 – 1453) pg/mg creat vs 583 (469 
– 787) pg/mg creat (p=0.008, figure 4.12).
Figure 4.12. Urinary metabolite of prostaglandin D2: 9a,11b-PGF2 for CF and 
control groups, presented in log scale. Comparison by Mann-Whitney test. Bars 
represent median. 
4.4.1.3. Other eicosanoids 
The median (IQR) of PGJ2 metabolite, urinary 15-doexy-delta12,14-PGJ2, in CF 
and controls were 4.3 (2.3 – 13.3)  vs 2.9 (1.6 – 3.3) pg/mg creat. (p=0.02, figure 
4.13). 
Figure 4.13. Urinary metabolites of prostaglandin J2: 15-doexy-delta12,14-PGJ2, 
of CF and control groups, presented in log scale. Comparison by Mann-Whitney 



















































Urinary leukotriene E4 (LTE4) levels were similar in both CF and control groups, 
with median (IQR) being 109 (51 – 181) pg/mg creat and 89 (50 – 112) pg/mg creat 










Figure 4.14. Urinary leukotriene E4 (LTE4) of CF and control groups, presented in 
log scale. Comparison by Mann Whitney test. Bars represent median. 
 
Collectively, these findings show that the urinary metabolites for PGE2, PGD2, and 
PGJ2 are higher in the CF group compared to healthy controls, supporting the 





















4.4.2. Direct measurement of prostanoid production – sputum 
supernatant profiles 
Supernatant from induced sputum from both CF (n=7) and control (n=9) groups 
showed that the CF group had higher levels of PGE2. Median (IQR) were 989 (723 
– 1118) pg/mg protein vs 690 (565 – 800) pg/mg protein, p=0.04 (figure 4.15).
Figure 4.15. Sputum supernatant PGE2 levels of CF and control groups. 


































1 8 4  
4. 5. Eff e ct s of pr o st a gl a n di n o n i n vitr o al v e ol ar m a cr o p h a g e 
f u n ctio n  
A s di s c u s s e d i n s e cti o n 1. 7. 2. 1, a n d s u p p ort e d b y t h e st u di e s s u m m ari s e d i n 
a p p e n di x 2, pr o st a gl a n di n E 2 i s k n o w n t o i n hi bit m a cr o p h a g e f u n cti o n. T hi s st u d y 
u s e d e nri c h e d pri m ar y h u m a n A M s t o r e pli c at e t hi s eff e ct f or t h e fir st ti m e. I n d e e d, 
pr o st a gl a n di n E 2 w a s s h o w n t o i n hi bit pri m ar y A M p h a g o c yt o si s of di e s el e x h a u st 
p arti cl e s i n vitr o.  
F oll o wi n g e x p o s ur e of A M s  i s ol at e d fr o m C F p arti ci p a nt s ( n = 6) t o D E P i n t h e 
a b s e n c e a n d pr e s e n c e of P G E 2 , t h e m e a n diff er e n c e ± S E b et w e e n c o ntr ol c ult ur e s 
a n d t h o s e e x p o s e d t o D E P al o n e w a s 1 2. 4 9 ± 2. 7 9 µ m 2 , p = 0. 0 1; a n d t h e m e a n 
diff er e n c e ± S E b et w e e n c ult ur e s e x p o s e d t o D E P al o n e a n d t h o s e e x p o s e d t o D E P 
a n d P G E 2  w a s - 5. 8 1 ± 2. 3 2 µ m 2 , p= 0. 0 5 (fi g ur e 4. 1 6). 
Fi g ur e 4. 1 6.  U si n g A M s fr o m C F p arti ci p a nt s: c o m p ari s o n of al v e ol ar m a cr o p h a g e 
























































) C y sti c Fi br o si s A M s
*p = 0. 0 1 *p = 0. 0 5
. 
C o m p ari s o n b y o n e- w a y A N O V A. 
1 8 5  
U si n g r e s p o n d er A M s i s ol at e d fr o m h e alt h y c o ntr ol s ( n = 1 4), c ell s w er e e x p o s e d t o 
D E P i n t h e a b s e n c e a n d pr e s e n c e of P G E 2 . T h e m e a n diff er e n c e ± S E b et w e e n 
c o ntr ol c ult ur e s a n d t h o s e e x p o s e d t o D E P al o n e w a s 9. 8 9 ± 1. 1 7 µ m 2 , p < 0. 0 0 0 1; 
w hil e t h e m e a n diff er e n c e ± S E b et w e e n c ult ur e s e x p o s e d t o D E P al o n e a n d t h o s e 
e x p o s e d t o D E P a n d P G E 2  w a s - 3. 8 8 ± 0. 7 4 µ m 2 , p < 0. 0 0 1 (fi g ur e 4. 1 7). 
Fi g ur e 4. 1 7.  U si n g r e s p o n d er A M s fr o m h e alt h y c o ntr ol s: c o m p ari s o n of al v e ol ar 
m a cr o p h a g e bl a c k c ar b o n i n c ult ur e s: c o ntr ol ( n o D E P or P G E 2 ) v s D E P v s D E P 
























































****p < 0. 0 0 0 1 ***p < 0. 0 0 1
R e s p o n d er A M s
. C o m p ari s o n b y o n e- w a y A N O V A. 
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4.5.1. Reversal of prostaglandin effects on alveolar macrophage 
function with EP2 antagonist 
Using responder AMs from healthy controls (n=5), 75 µM of EP2-receptor antagonist 
was used to block the action of PGE2 in the cell-DEP-PGE2 culture. Firstly, it was 
demonstrated that EP2 antagonist alone did not affect AM phagocytosis, the mean 
difference ± SEM in AMBC between cell-DEP and cell-DEP-EP2 cultures was 0.42 
± 0.69 µm2, p=0.57 (figure 4.18).  
Figure 4.18. Alveolar macrophage black carbon of cell-DEP cultures with and 
without EP2 antagonist, using responder alveolar macrophages from healthy 




































1 8 7  
A s s h o w n i n fi g ur e 4. 1 9, t h e E P 2 a nt a g o ni st r e v er s e d t h e a cti o n of P G E 2 , r e s ulti n g 
i n a m e a n diff er e n c e ± S E i n A M B C b et w e e n c ult ur e s tr e at e d wit h D E P al o n e a n d 
t ho s e tr e at e d wit h D E P a n d P G E 2  of - 2. 6 2 ± 0. 7 4 µ m 2  (p = 0. 0 5); w hil e m e a n 
diff er e n c e ± S E i n A M B C b et w e e n c ult ur e s tr e at e d wit h D E P a n d P G E 2  a n d t h o s e 
tr e at e d wit h D E P, P G E2  a n d E P 2 w a s 1. 7 7 ± 0. 3 0 µ m 2  (p = 0. 0 1). T h er e w a s n o 
si g nifi c a nt diff er e n c e i n A M B C b et w e e n c ult ur e s tr e at e d wit h D E P al o n e a n d t h o s e 
tr e at e d wit h D E P, P G E2  a n d E P 2 ( m e a n diff er e n c e 0. 8 6 ± 0. 8 1 µ m 2 , p = 0. 5 9). 
T h e s e r e s ult s o n c e a g ai n d e m o n str at e t h e i n hi bit or y eff e ct of P G E 2  o n A M 
p h a g o c yt o si s, a s s e e n i n fi g ur e s 4. 1 6 a n d 4. 1 7. T h e y al s o pr o v e t h at bl o c k a d e of 
E P 2 r e c e pt or s c a n pr o hi bit P G E 2  a cti vit y o n A M p h a g o c yt o si s.  
Fi g ur e 4. 1 9.  U si n g r e s p o n d er al v e ol ar m a cr o p h a g e s fr o m h e alt h y c o ntr ol s: al v e ol ar 


































































**p = 0. 0 1
p = 0. 5 9
* p = 0. 0 5
 a n d/ o r 
E P 2 a nt a g o ni st. C o m p ari s o n b y o n e- w a y A N O V A.    
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4.6. Effects of CF airway secretions on alveolar 
macrophage function 
In order to further investigate if PGE2 in CF airway secretions is indeed the cause of 
impaired AM phagocytosis, sputum supernatant from CF participants was added to 
the cell-DEP culture to assess responder AM function.  
 
CF sputum supernatant (i.e. diluted cell-free airway secretion) demonstrated 
inhibitory effects on diesel exhaust particles phagocytosis by responder AMs 
isolated from healthy controls (n=14). The median of differences (IQR) in AMBC 
between cell-DEP cultures untreated and treated with CF supernatant was -3.82 (-












Figure 4.20. Comparison of alveolar macrophage black carbon in cell-DEP cultures 
untreated (-) and treated (+) with CF supernatant, using responder alveolar 















































1 8 9  
4. 6. 1. R e v e r s al of C F air w a y s e c r eti o n s’ eff e ct s o n al v e ol a r 
m a c r o p h a g e f u n cti o n wit h E P 2 a nt a g o ni st 
7 5 µ M of E P 2-r e c e pt or a nt a g o ni st w a s u s e d t o bl o c k t h e p ot e nti al a cti o n of P G E 2  i n 
t h e C F s u p er n at a nt. E P 2 a nt a g o ni st w a s a bl e t o r e st or e r e s p o n d er A M p h a g o c yt o si s 
of di e s el e x h a u st p arti cl e s. T h e m e a n diff er e n c e ± S E i n A M B C b et w e e n c ult ur e s 
e x p o s e d t o D E P i n t h e a b s e n c e a n d pr e s e n c e of C F s u p er n at a nt w a s - 2. 7 8 ± 0. 9 3 
µ m 2 , p = 0. 0 4; t h e m e a n diff er e n c e ± S E i n A M B C b et w e e n c ult ur e s e x p o s e d t o D E P 
a n d tr e at e d wit h C F s u p er n at a nt, i n t h e a b s e n c e a n d pr e s e n c e of E P 2 a nt a g o ni st, 
w a s 1. 6 6 ± 0. 5 3 µ m 2 , p = 0. 0 4. T h er e w a s n o si g nifi c a nt diff er e n c e i n A M B C b et w e e n 
e x p o s e d c ult ur e s i n t h e a b s e n c e of C F s u p er n at a nt a n d E P 2 a nt a g o ni st, a n d t h o s e 
i n t h e pr e s e n c e of C F s u p er n at a nt a n d E P 2 a nt a g o ni st ( m e a n diff er e n c e ± S E of 
1. 1 2 ± 1. 0 6 µ m 2 , p = 0. 5 7), fi g ur e 4. 2 1. 






























































































) p = 0. 5 7
*p = 0. 0 4 * p = 0. 0 4
U si n g r e s p o n d er al v e ol ar m a cr o p h a g e s fr o m h e alt h y c o ntr ol s: al v e ol ar 
m a cr o p h a g e bl a c k c ar b o n i n c ell- D E P c ult ur e s tr e at e d wit h or wit h o ut C F 
s u p er n at a nt a n d/ or E P 2 a nt a g o ni st. C o m p ari s o n b y o n e- w a y A N O V A.    
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4.7. Effects of Cyclooxygenase inhibitor on Prostanoid 
Profiles 
Urinary PGE2 metabolite levels were measured in a random selection of children 
with cystic fibrosis before and after a 3-day course of over-the-counter-dose of 
Ibuprofen. Their lung function (FEV1 predicted) at the beginning of Ibuprofen course 
is listed in table 4.1. 








Table 4.1. Lung function (forced expiratory volume in 1 second, FEV1 % predicted) 
of CF participants at the beginning of the 3-day Ibuprofen course. 
For urinary 13,14-dihydro-15-keto-PGE2, the median of difference (IQR) between 
pre- and post- Ibuprofen was -2286 (-4500 to -351) pg/mg creat. (p=0.03, n=6) 
(figure 4.22). 
Figure 4.22. Urinary 13,14-dihydro-15-keto-PGE2 of children with cystic fibrosis, 
before and after a 3-day course of standard dose Ibuprofen, presented in log scale. 









































For urinary 13,14-dihydro-15-keto-tetranor PGE2, the median of difference between 












Figure 4.23. Urinary 13,14-dihydro-15-keto-tetranor PGE2 of children with cystic 
fibrosis, before and after a 3-day course of standard dose Ibuprofen, presented in 



























































For urinary tetranor PGE-M (main metabolite of PGE2), the median of difference 
(IQR) between pre- and post- Ibuprofen was -70989 (-107711 to -281) pg/mg creat. 
(p=0.04, n=7) (figure 4.24). 
Figure 4.24. Urinary tetranor PGE-M of children with cystic fibrosis, before and after 
a 3-day course of standard dose Ibuprofen, presented in log scale. Comparison by 
Wilcoxon test.  
These results suggest that a short 3-day course of standard dose Ibuprofen can 
lower urinary metabolites of PGE2 in children with CF, suggesting systemic 
reduction in PGE2 production.  
In this work, sputum concentrations of PGE2 were not measured pre- and post- 
Ibuprofen course due to time constraints. AMBC was also not determined pre- and 
post- Ibuprofen course because the turnover time for AMs is approximately 3 
months, therefore participants will have to be on a longer course of Ibuprofen in 



































When the urinary PGE2 metabolite levels of children with CF after a 3-day course of 
Ibuprofen were compared with the metabolite levels from healthy controls (baseline 
levels with no Ibuprofen), Ibuprofen seemed to be able to reduce the CF urinary 
metabolites to comparable levels as controls for two of the three PGE2 metabolites 
measured.   
For urinary 13,14-dihydro-15-keto-E2, the median (IQR) for CF (post-Ibuprofen) vs 
control were 985 (509 – 5301) pg/mg creat. (n=6) vs 928 (478 – 1376) pg/mg creat. 
(n=20) (p=0.61) (figure 4.25). 
Figure 4.25. Urinary 13,14-dihydro-15-keto-E2 of children with CF after a 3-day 
course of Ibuprofen and healthy controls. Comparison by Mann-Whitney test. Bars 









































For urinary 13,14-dihydro-15-keto-tetranor E2, the median (IQR) for CF (post-
Ibuprofen) vs control were 270 (53 – 554) pg/mg creat. (n=7) vs 214 (96 – 323) 













Figure 4.26. Urinary 13,14-dihydro-15-keto-tetranor E2 of children with CF after a 
3-day course of Ibuprofen and healthy controls. Comparison by Mann-Whitney test. 




















































For urinary tetranor PGEM, the median (IQR) for CF (post-Ibuprofen) vs control 
were 34851 (30579 – 239795) pg/mg creat. (n=7) vs 15873 (10150 – 24733) pg/mg 
creat. (n=20) (p<0.001) (figure 4.27). 
Figure 4.27. Urinary tetranor PGEM of children with CF after a 3-day course of 
Ibuprofen and healthy controls. Comparison by Mann-Whitney test. Bars represent 
median.  
For urinary tetranor PGEM, the furthest outlier in the CF group corresponds to the 
participant with the lowest lung function (FEV1 predicted) at the beginning of the 
Ibuprofen course (table 4.1). 
These results show that, apart from urinary tetranor PGEM, a 3-day course of 
Ibuprofen was able to reduce urinary 13,14-dihydro-15-keto-E2 and 13,14-dihydro-




































The results of the previous chapter suggested that AM phagocytosis impairment in 
CF is likely to be secondary to inhibitory substances present in CF airway secretions, 
with PGE2 suspected to be one of the mediators. As mentioned in section 1.7.2., CF 
airways are known to contain excessive cytokines and PGs; BAL, sputum, exhaled 
air and saliva from patients with CF do indeed contain higher levels of PGE2 144-148. 
Chen et al. 137 described CFTR as a regulator of the PGE2-mediated inflammatory 
response; that a lack of functional CFTR could lead to heightened inflammatory 
signalling.  
The results from this chapter confirm that PG production is increased in CF, reflected 
by higher levels of urinary metabolites of PGE2, PGD2 and PGJ2, and supported by 
the increased COX-2 expression in AMs isolated from the CF group. These findings 
are in agreement with the upregulation of COX-2 in CF nasal polyps reported by 
Roca-Ferrer et al. 140. Besides, the higher concentration of PGE2 in CF sputum 
supernatant compared to the control group, also supports that PGE2 production is 
amplified in CF. 
Aronoff et al. 141 described that PGE2 could inhibit AM phagocytosis in a dose-
dependent manner, as demonstrated in the findings from this study. Domingo-
Gonzalez et al.183 also reported in an animal model that there was an impaired 
innate immune response driven by elevated PGE2 after bone marrow transplant; 
and treatment with PGE2 could result in altered bacterial phagocytosis due to 
changes in the AM scavenger receptor profile. The in vitro model in this study 
demonstrated the inhibitory effect of PGE2 on responder AM (those extracted from 
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healthy controls) phagocytosis, which was restored by an EP2 receptor antagonist. 
Interestingly, cell-free CF sputum supernatant, containing CF airway secretions and 
mucus, also exerted inhibitory effects on responder AM phagocytic function. Since 
PGE2 was the suspected inhibitory factor in CF airway secretions, an EP2 receptor 
antagonist was used to show any potential reversal of AM phagocytosis inhibition 
by CF sputum supernatant. Indeed, the EP2 antagonist restored responder AM 
function despite the presence of CF secretions, suggesting PGE2 does play a role 
in phagocytic impairment in CF.  
Ibuprofen is a non-steroidal anti-inflammatory drug, which acts by inhibiting COX-1 
and COX-2. Clinical trials have shown that high-dose ibuprofen can reduce 
inflammation and slow the disease progression in CF, especially in children 184,185; 
however, ibuprofen used at high dose has side effects. A low over-the-counter dose 
of ibuprofen was used in this work, and a reduction in systemic PG production was 
demonstrated only after a short 3-day course. Interestingly, for two of the three PGE2 
metabolites examined, Ibuprofen was able to reduce the urinary PG metabolite 
levels of the CF group to that similar of the control group – although the short course 
of Ibuprofen did not lower CF urinary tetranor-PGEM to levels comparable to control 
group, its production was still reduced, whether a longer course would be able to 
lower its production further is yet to be explored. 
Considering the inhibitory effects of PGE2 on AM function, as demonstrated in this 
chapter, less systemic PGE2 production could potentially lead to improved AM 
phagocytosis, thereby reducing the vulnerability of children with CF to inhaled 
particulate matter. 
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Although a short course of Ibuprofen at a low dose may not affect CF disease 
progression as such, longer term usage may offer potential therapeutic benefits in 
improving AM function in face of air pollutants.  
4.8.1. Strengths 
COX-2 expression in AMs from CF and control groups were determined using flow 
cytometry. Flow cytometry allows for elimination of cell debris and dead cells during 
analysis. The cell populations presented for flow cytometry were enriched sputum 
samples consisting mostly of AMs; the cells were further marked with a macrophage 
marker in order to enhance flow cytometry gating. Prostaglandins were measured 
both in the urine (a traditional approach, indirect measure of PG production) and 
sputum supernatant (direct measure of PG production), to confirm that PGs, 
particularly PGE2, were indeed present in higher quantities in CF.  
4.8.2. Limitations 
Monocytes tend to be adhesive, making flow cytometry slow and difficult at times. 
Vigorous agitation of samples before flow cytometry was therefore required. As 
before, the in vitro assays were limited by the number of AMs available for each 
experiment due to varying participants’ sputum induction techniques, and inevitable 
cell loss during processing and experimentation. Due to limited number of cells for 
flow cytometry, any variation in gating strategy could result in drastic changes in 
median MFI, making gating by a second observer challenging. In order to address 
this and limit bias, blinded re-analyses were performed by the same researcher 
(myself) and results from the blinded and unblinded analyses were compared. 
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The data presented in this chapter are limited in power due to the small number of 
participants who underwent repeated sputum induction for the PG experiments. 
 
Since CF airway secretions are thick, the reduction in responder AM phagocytic 
ability when exposed to CF sputum supernatant could be secondary to its viscosity, 
impeding AM access to DEP. However, the successful reversal of phagocytic 
function using an EP2 antagonist suggested such functional impairment was related 
to PGE2.  
 
Ibuprofen was used at a standard over-the-counter course for 3 days. While this 
showed a reduction in PG metabolites in the urine, whether this would in fact 
improve AM function remains unclear. With the average clearance half-life of AMBC 
reported to be 53 to 116 days by Bai et al. 104, children will have to take daily 
Ibuprofen for at least 3 months (the “wash-out” period) before any changes in AMBC 
can be seen. This was not done in this study because of time limitation, but would 
certainly be an interesting area to explore in the future.  
 
4.8.3. Summary 
The results from this chapter confirm the increased production of PGs in CF, 
secondary to increased expression of COX-2 in AMs in this group. Using responder 
AMs from healthy controls, PGE2 was shown to have an inhibitory effect on AM 
phagocytosis in vitro, which was successfully restored by an EP2 antagonist. 
Interestingly, a similar phagocytic-inhibitory effect was seen with cell-free sputum 
supernatant from children with CF, this was also restored by an EP2 antagonist. 
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This strongly suggests that PGE2 is indeed the mediator responsible for impaired 
AM phagocytosis in vivo in CF. So far, this thesis has demonstrated that AM 
phagocytosis of BC is impaired in CF, likely secondary to increased levels of PGs 
in the CF airway. In the next chapter, the consequence of such AM functional 
impairment will be explored. 
201 
Chapter 5: 
Modelling the effects of 
impaired alveolar 
macrophage 
phagocytosis caused by 
prostaglandin E2 
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5. Modelling the effects of impaired alveolar macrophage 
phagocytosis caused by prostaglandin E2 
5.1. Background 
With reduced AM functional capacity, non-phagocytosed inhaled carbonaceous 
particulate matter may remain in the airway and exert its adverse effects on other 
airway cells such as epithelial cells. These effects are typically pro-inflammatory. 
Indeed, as discussed in section 1.4.2, upon exposure to insults such as diesel 
exhaust particles, the airway epithelium contributes to inflammatory cytokine 
release, inflammatory cell differentiation and activation – a phenomenon that is 
already intrinsically prominent in the CF airway even without the presence of air 
pollution, as mentioned in section 1.7.2. Chronic airway inflammation is the driver of 
structural lung damage and lung function decline in CF, which could be worsened 
by exposure to air pollution.  
 
In sections 1.2.1.1. and 1.4.3., the effects of air pollutants on epithelial cells were 
explored. Other than mediating inflammation, DEP and NO2 can also affect epithelial 
ciliary movements, alter cell integrity and increase cell permeability; increasing the 
chance of particle translocation by passive diffusion. In addition, uptake of 








In this chapter, the hypothesis tested is: 
o In the absence of functional alveolar macrophages, particulate matter
invades other airway cells such as epithelial cells, inducing pro-inflammatory
cascades and the release of cytokines such as IL-8.
The consequences of non-phagocytosed diesel exhaust particles remaining in the 
airway are explored. The potential for diesel exhaust particles to invade epithelial 
cells is investigated, using an epithelium-macrophage in vitro model (figure 5.1), 
containing A549 adenocarcinomic human alveolar basal epithelial cells and 
responder alveolar macrophages from healthy participants. The concept of how 
functional alveolar macrophages are important to protect epithelial cells and the 
lungs, is demonstrated using this model followed by image analysis. Cytokine (IL-8) 
release from A549 epithelial cells when exposed to DEP is also examined. 
Figure 5.1. Epithelium-macrophage in vitro model: A549 epithelial cells adhered to 
the well overnight, followed by addition of primary responder alveolar macrophages 
and DEP. Functional alveolar macrophages will phagocytose DEP and protect 
against invasion of epithelial cells. 
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5.3. Epithelial cell model 
5.3.1. Diesel exhaust particle invasion into epithelial cells 
In the absence of alveolar macrophages, diesel exhaust particles were able to 
invade A549 epithelial cells during the exposure period (figure 5.2). 
Figure 5.2. Light microscopy of A549 epithelial cells following exposure to diesel 
exhaust particles, showing particle invasion into the cells.  
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5.3.2. Protective role of airway macrophages 
Compared with pure epithelial cultures, the area of epithelial black carbon was 
significantly reduced in the presence of responder AMs. Examining 50 randomly 
selected epithelial cells per culture, mean ± SEM epithelial BC were 12.80 ± 2.45 
µm2 vs 3.19 ± 1.17 µm2 for control cultures (no AMs) and cultures with AMs 
respectively, with a median of difference (IQR) of -9.50 (-13.10 to -4.94) µm2 (n=6, 
p=0.03, figure 5.3a), and a mean ± SEM percentage reduction of -75.12 ± 8.85%. 
Digital images showed that the majority of carbon in mixed epithelial-macrophage 
cultures was phagocytosed by adjacent AMs (figure 5.3b). 
 
 
Figure 5.3. (a) Area of black carbon in A549 epithelial cells with and without alveolar 
macrophages. Comparison by Wilcoxon test. (b) A549 epithelial cell (E) and a 
neighbouring primary alveolar macrophage (AM) which has phagocytosed black 


















































5.3.3. Effects of prostaglandin E2 on the function of alveolar 
macrophages 
The results in section 4.5. showed the inhibitory effect of PGE2 on AM function. 
Black carbon associated with A549 cells were increased in the epithelial-
macrophage cultures with PGE2, compared to those without PGE2. The median of 
difference (IQR) was 0.64 (0.36 – 6.59) µm2 (n=6, p=0.03, figure 5.4).  
Figure 5.4. Area of black carbon in A549 epithelial cells in the presence of alveolar 





















































5.4. Cytokine release from epithelial cells following diesel 
exhaust particles exposure 
Interleukin 8 (IL-8) levels between cultures of i) controls (A549 cells only); and ii) 
A549 cells and 10 µg/ml of DEP, were compared. ELISA standard curve shown in 
figure 5.5. 
Figure 5.5. Standard curve created using a curve-fitting software, subtracting the 




















The median of difference (IQR) IL-8 levels for A549 only vs A549 exposure to DEP 
was 49.79 (24.07 – 96.10) pg/ml (n=9, p=0.004) (figure 5.6a). Similar trend was 
seen when data were transformed into fold change. The median (IQR) fold change 
between control cultures of A549 alone and cultures treated with DEP was 2.16 
(1.27 – 2.97), n=9, p<0.0001 (figure 5.6b). 
 
 
Figure 5.6. (a) Interleukin 8 (IL-8) levels: cultures of A549 epithelial cells with and 
without 10 µg/ml DEP. Comparison by Wilcoxon test. (b) Fold change in IL-8 release 
in epithelial cell cultures exposed to DEP, compared to those unexposed. 









































































With impaired AM phagocytosis, inhaled carbonaceous particles may remain in the 
airway and exert their detrimental effects on epithelial cells. As discussed in section 
1.2.1, the airway epithelium is an important part of the immune defence against 
foreign insults. It acts as a physical barrier, and is a medium for ciliary action and 
mucociliary clearance. Its role in inflammatory and antimicrobial activities is by virtue 
of the production of cytokines. Rezaee et al. 186 suggested that CFTR may be 
involved in regulating apical membrane proteins, and may therefore have a role in 
epithelial barrier function – i.e. defective CFTR increases epithelial permeability, 
thereby increasing the CF host’s susceptibility to invading pathogens and particles. 
Previous research indicated that DEP not only increases cytokine production by 
human bronchial epithelial cells, but also reduces the cytoskeletal stiffness and cell-
matrix adhesion molecule, allowing for epithelial cells detachment 187.  
As demonstrated by Stearns et al. 87, nanoparticles could adhere to and invade 
epithelial cells, altering their permeability and integrity. Indeed, the results from this 
chapter have shown that diesel exhaust particles can invade epithelial cells. This is 
particularly problematic for individuals with impaired macrophage function such as 
children with CF. The protective role of alveolar macrophages was demonstrated in 
the epithelium-macrophage in vitro model, where AM phagocytosis of DEP resulted 
in less epithelial cell invasion. The addition of PGE2 to the epithelium-macrophage 
model was an attempt to mimic the CF airway to an extent, the subsequent increase 
in DEP invasion of epithelial cells demonstrated the potential consequence of non-
phagocytosed PM in the CF airways.  
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It is known that the CF airway is overwhelmed by inflammation caused not only by 
recurrent infections, but also as part of the disease pathogenesis. CFTR defects can 
cause abnormal signalling in epithelial cells; while accumulation of defective CFTR 
can trigger apoptosis and dysregulated immune function, resulting in amplified but 
ineffective airway inflammation 188. In CF, reduced airway surface liquid and 
impaired mucociliary function encourage bacterial growth, leading to neutrophil-
driven inflammatory responses. Many studies have found increased levels of IL-8, 
a neutrophil chemokine, in the CF airway 189. For example, Sagel et al. 190 reported 
increased neutrophil counts, IL-8 levels, and neutrophil elastase activity in sputum 
from children with CF compared to healthy controls. Furthermore, IL-8 can also be 
used as a biomarker for disease severity in CF, as Mayer-Hamblett et al. 191 found 
a negative correlation between IL-8 and lung function.  
 
The ELISA results in this chapter showed that IL-8 release by A549 epithelial cells 
was increased in the presence of DEP, supporting the hypothesis that epithelial 
inflammation is aggravated by DEP exposure, thereby potentially worsening disease 
progression in CF, where AM function is impaired. 
 
Of note, Massengale et al. 192 proposed that IL-8 release by CF airway epithelial 
cells was defective, and may contribute to bacterial colonisation in the airway – they 
found that IL-8 secretion and IL-8 mRNA were lower in CF epithelial cell line 
compared to normal epithelial cell line, or CF phenotypically corrected cell line. This 
was in contrast to other publications which stated that IL-8 secretions were higher 
in CF cell line compared to CF corrected cell line 193; the deduction was that this 
was due to differences in CF genotype or CFTR expression.  
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5.5.1. Strengths 
The lower airway was modelled using A549 epithelial cells and primary AMs from 
participants. The addition of PGE2, though at a higher than physiological 
concentration, mimicked the CF airway to a certain extent. This model demonstrated 
the invasion of DEP into epithelial cells without the protection from functional AM, 
along with subsequent inflammatory cytokines release. AMs used were enriched, 
with saliva and mucus removed – since saliva contains lower levels of IL-8 




A549 cell lines were used as opposed to primary epithelial cells. The phenotype, 
architecture, and properties of the cell line may not be truly representative of its 
primary counterpart. Apart from the limited and variable number of AMs available 
from each participant, the lack of other inflammatory cells and mucus mean that the 
epithelium-macrophage model is not an accurate representation of the airway, 
which is a lot more complex in reality, with many other inflammatory cells and 
cytokines being activated and interacting with each other – these were not 
addressed by the model in this work. The results for the epithelium-macrophage 
assays were obtained from a small number of children, the conclusions drawn are 
therefore limited by the risk of type 1 and type 2 errors.  
 
5.5.3. Summary 
The results from this chapter demonstrate the protective role of functional AMs on 
epithelial cells, and that non-phagocytosed carbonaceous PM can indeed invade 
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epithelial cells. As highlighted in previous chapters, in vivo function of AMs in CF 
appears to be impaired, rendering patients more susceptible to the effects of non-
phagocytosed PM within the airway. The increase in IL-8 release when A549 
epithelial cells were exposed to DEP, supports the hypothesis that non-
phagocytosed PM can induce epithelial cytokine release. After demonstrating the 
potential for non-phagocytosed particles to invade airway epithelial cells, the next 
chapter will look into potential translocation of non-phagocytosed ultrafine particles, 



























6. Translocation of air pollution particles
6.1. Background 
Having demonstrated that non-phagocytosed ultrafine particulate matter may be 
taken up by airway epithelial cells, leading to local inflammation, this chapter will 
explore the potential for any residual inhaled ultrafine or nano particles to translocate 
across tissue barrier and travel through the circulation to distant organs.  
The placenta is a temporary organ formed during pregnancy, and is naturally 
expelled following childbirth. Therefore, not only can the placenta be used as a proxy 
for distant organs without the need for surgery or autopsy, any evidence of particle 
translocation to the placenta may also explain how placental function and fetal 
development are affected by air pollution. 
It is known that apart from the lungs, air pollution can also affect other organs, and 
that maternal exposure to air pollution can result in adverse birth outcomes such as 
low birth weight and preterm delivery. While the mechanisms of how pollutants affect 
distant organs and fetal development are undoubtedly manifold, one of the putative 
explanations is translocation of pollutants via the circulation, allowing them to exert 
their toxic effects directly on other organs such as the placenta and fetus.  
As discussed in section 1.4.4, ultrafine and nano particles are able to enter the 
circulation in animal models, whereas ex vivo models have shown the possibility of 
nanoparticles crossing the placental barrier. In order to seek evidence of extra-
pulmonary particles in the body, microscopy can be used to visualise any particles 
phagocytosed by local macrophages. 
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6.2. Aims 
In this chapter, the hypothesis tested is: 
o Carbonaceous particulate matter is present in placental tissues, having 
translocated from the maternal lung after by-passing the maternal first line of 
respiratory defence.  
 
The possibility of particle translocation from the lung to distant organs is explored. 
Personal air pollution exposure of the recruited pregnant women were modelled 
using their home addresses. Evidence of black carbon in placental macrophages 
was sought using light and electron microscopy.  
 
 
To investigate the potential for non-phagocytosed inhaled carbonaceous PM to 
translocate from the lung to distant organs via the systemic circulation, placentas 
were used. The placenta is a temporary organ which is delivered in the third stage 
of labour. In a healthy pregnancy followed by the delivery of a healthy term infant, 
the placenta is usually discarded after delivery. It is therefore a non-invasive way to 









6.3.1. Ethical approval 
The project protocol was reviewed and approved by the Joint Research 
Management Office for Barts Health NHS Trust and Queen Mary University of 
London. 
Ethical approval to recruit women was granted by the NHS Research Ethics 
Committees (REC, REC references 17/NW/0092, IRAS project ID 219053) in 
February 2017, following a full ethical review. Health Research Authority (HRA) 
approval was obtained in March 2017. See appendix 8 for the latest version of the 
study protocol. 
Three subsequent amendments were approved for the following reasons: 
I. To expand the number of participants, and include personal nitrogen dioxide
monitoring in participants.
II. To change the timeframe between information sheet dissemination to
consent from at least 24 hours to the morning of elective caesarean sections.
III. To extend the study date for another year.
See appendix 11 for all correspondences with the ethics committee. 
6.3.2. Participants 
Healthy pregnant women were recruited from the Royal London Hospital tertiary 
maternity unit. They were healthy women who were booked for elective Caesarean 
sections (C-sections) to deliver a healthy singleton infant. Elective C-section was 
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the chosen mode of delivery for this study due to the possibility to time delivery and 
placenta processing accordingly.  
 
6.3.2.1. Inclusion criteria 
I. Term pregnancy (≥37 week gestation)  
II. Live birth delivery by elective Caesarean section   
III. Maternal age 18-50 years 
 
6.3.2.2. Exclusion criteria 
I. Complicated pregnancy  
II. Oligohydramnios  
III. Pre-eclampsia  
IV. Intra-uterine growth restriction (IUGR)  
V. Abnormal placental perfusion – reduced, absent or reversed end diastolic 
flow on Doppler study  
VI. Active smoker 
VII. Maternal request to take placenta home  
 
6.3.3. Recruitment process 
Potential participants were approached by the research team. Previously, women 
undergoing elective Caesarean sections at the Royal London Hospital were invited 
to attend an antenatal clinic appointment 4 to 10 weeks before the operation date. 
Participants were approached and information sheets were disseminated at the 
clinic, followed by informed consent on the day of operation (information sheet and 
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consent form can be found in appendices 9 and 10 respectively). This antenatal 
clinic was discontinued during this study, so a different strategy was employed. With 
guidance from the Obstetrics team, the researcher approached and consented 
eligible participants on the morning of elective Caesarean sections. 
6.3.4. Personal exposure to air pollution 
6.3.4.1. Modelled exposure at home address 
Using the LAQT as before, colleagues at King’s College London estimated the mean 
PM and NO2 concentrations based on participants’ home postcodes, 12 months 
prior to the date when participants underwent elective Caesarean sections.  
6.3.5. Placenta processing 
Placentas were acquired immediately after the third stage of labour, following 
placental inspection by the attending midwife, to check for abnormalities. Placentas 
were transported on ice to the laboratory for immediate processing to ensure cell 
viability. Blood was aspirated from the umbilical cord for erythrocyte extraction using 
a density gradient medium, as described above (section 2.7.1). Placental tissue was 
separated from the membrane using a scalpel, and dissected into pieces of roughly 
3 x 3 x 3 cm. Placental tissues were rinsed first in ultrapure ddH2O (Barnstead™ 
NANOpure Diamond Life Sciences, California, USA), then in DPBS, followed by 
vigorously agitating in 6-well cell culture plates (Corning® Costar® , Corning, USA). 
Tissues were incubated in trypsin (Santa Cruz biotechnology, USA) and dispase 
(Sigma-Aldrich, Poole, UK) for 3 h at 37°C, 5% CO2. Hyaluronidase (Sigma-Aldrich, 
Poole, UK) was added to the digestion mixture for the final 1 h. Digested placental 
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tissues passed through a 36 μm gauze (NITEX 03-36/28, Sefar, Switzerland), and 
were diluted with 1:1 DPBS and washed 3 times in DPBS. Finally, cells were 
resuspended in PBS/FBS (2%), according to consistency, for placental macrophage 
(PMac) extraction, using the human monocyte enrichment cocktail and cell-depleted 
erythrocytes as described previously (section 2.7.1.). Following enrichment, PMacs 
were resuspended in appropriate cell culture medium for investigation. 
6.3.6. Presence of inhaled pollutants within the placenta 
6.3.6.1. Placental macrophage black carbon analysis 
As with alveolar macrophages, cytospin slides of PMacs were generated and 
analysed using the same image analytical method, under light microscopy. 1000 
randomly selected PMacs from each sample were examined, and the mean BC 
content quantified using ImageJ, as described before (section 2.6.4.). 
6.3.6.2. Electron microscopy of placental macrophages 
Specimens for electron microscopy (EM) were fixed in phosphate buffered 4% 
glutaraldehyde (Agar Scientific, UK) then centrifuged at 2000 rpm (314 x g) for 10 
min.  The supernatant was discarded, the pellet was re-suspended in 1:1 2% low 
gel temperature agarose (VWR International, Pennsylvania, USA).  Once the 
agarose had solidified, the block was cut into cubes of approximately 1 x 1 x 1 mm 
which were washed overnight in phosphate buffer.  They were then post-fixed in 1% 
osmium tetroxide (Agar Scientific, Essex, UK), washed in phosphate buffer, 
dehydrated through graded ethanol, cleared in propylene oxide (Agar Scientific, 
Essex, UK) and embedded in Araldite epoxy resin (Agar Scientific, Essex, UK). 
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For light microscopy, semi-thin (0.5 mm) sections were mounted onto slides and 
stained with 1% toluidine blue in 1% borax (Atom Scientific, Cheshire, UK).  For EM, 
ultrathin sections (60 – 90 nm) were mounted on grids and stained with saturated 
aqueous uranyl acetate (Agar Scientific, Essex, UK) followed by Reynold’s lead 
citrate.  The ultrathin sections were examined with a Jeol JEM1230 electron 
microscope and digital images captured on a SIS Morada camera. At least 20 
individual PMacs were examined under EM per sample, images of cells with 
suspected intracellular carbonaceous material were captured for expert analysis. 
EM was conducted by a biomedical scientist at the Royal London Hospital.  
6.3.6.2.1. Investigation of intravacuolar particles 
EM images with suspicious black inclusions compatible with the appearance of 
carbonaceous PM were examined and analysed by Dr Carolyn Jones, an honorary 
research fellow and an experienced electron microscopist, specialising in the 
placenta, at St Mary’s Hospital, Manchester, UK.   
6.3.7. Placental macrophages function 
To determine in vitro phagocytic ability of PMacs, enriched PMacs were exposed to 
diesel exhaust particle (SRM 2975, NIST, USA) as with alveolar macrophages.  
6.3.7.1. Placental macrophage uptake of diesel exhaust particles 
Nunc™Lab-Tek™ cell culture chambers (ThermoFisher Scientific, UK) were pre-
coated in 1:10 collagen for at least 30 min at 37°C. The concentration used was 
lower than that for alveolar macrophage experiments due to the abundance of 
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PMacs available from each placenta. Enriched PMacs were washed and 
resuspended in complete RPMI before allowing to adhere in chamber wells 
overnight at 37oC, 5% CO2. PMacs were washed in incomplete RPMI the next day. 
Experimental chamber wells were exposed to 2 µg/mL of diesel exhaust particles 
(DEP) (SRM 2975, NIST, USA) for 2 h at 37°C, 5% CO2; control wells were 
unexposed. Chamber wells were washed and stained as described before (section 
2.7.2.). Light microscopy and image analysis of PMacs were performed using 20 
randomly selected cells per culture (i.e. unexposed and exposed to DEP).  
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6.4. Results – Translocation of air pollution particles  
6.4.1. Modelled exposure at home address 
The participants all resided in east London and had similar exposure to air 
pollutants. Using the LAQT, the participants’ (n=13) mean  SEM annual PM10 and 
PM2.5 exposure in the 12 months prior to delivery were 27.22  0.60 µg/m3 and 16.94 
 0.38 µg/m3 respectively (figure 6.1). 
 
Figure 6.1. Modelled annual mean PM10 and PM2.5 levels 12 months prior to delivery 
date, based on participants’ home addresses. Bars represent standard error of 
mean. 
 
Monitoring of personal air pollution exposure using aethalometers and nitrogen 
dioxide samplers was not performed for this part of the study – this is because 
participants were recruited on the day of delivery, rendering pre-delivery monitoring 
impossible; and their daily routines were greatly altered post-delivery. Nitrogen 
dioxide samplers were distributed to participants after delivery, with the instructions 
to carry them on their persons once normal daily routines had resumed, however, 









































6.5. Presence of inhaled pollutants within the placenta 
6.5.1. Placental macrophage black carbon Analysis 
Randomly selecting 1000 placental macrophages (PMacs) per placenta, a total of 
15000 PMacs from 15 placentas were examined. All placentas contained suspicious 
black inclusions in at least 3 of the 1000 cells per placenta (figure 6.2, table 6.1). 
Mean  SEM placental macrophage black carbon (PMacBC) was 0.02  0.02 µm2. 
Figure 6.2. Selected light microscopy images of placental macrophages showing 
black inclusions (red arrows) compatible with the appearances of phagocytosed 


























1 17 18 0.0044 28.43 18.81 
2 10 11 0.0052 27.59 17.77 
3 19 21 0.0129 28.56 18.23 
4 7 7 0.0030 29.64 18.26 
5 5 7 0.0014 28.97 18.25 
6 9 15 0.0022 27.24 17.38 
7 14 18 0.0028 26.07 16.59 
8 13 13 0.0027 24.08 14.62 
9 24 24 0.0068 26.13 15.53 
10 4 5 0.0038 24.81 15.28 
11 3 3 0.0015 N/A* N/A* 
12 8 11 0.0119 24.63 15.44 
13 13 17 0.0026 31.37 17.56 
14 2 2 0.0006 N/A* N/A* 
15 4 6 0.0017 26.29 16.49 
Table 6 .1. Summary of number of PMac cells with black inclusions found in each 
placenta (1000 randomly selected cells examined per placenta), with the mean 
placental macrophage black carbon and the participants’ modelled annual mean PM 
exposures.  
* Two of the participants resided in newly developed areas where postcode
modelling of PM exposure was not available.
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No evidence of correlation was seen between modelled exposures to PM and 
PMacBC, with r=0.26, p=0.44 for PM10; and r=0.24, p=0.48 for PM2.5 (figure 6.3).  
 
Figure 6.3. Spearman correlation between modelled PM (PM10 and PM2.5) and 
placental macrophage black carbon (PMacBC): r=0.26, p=0.44 for PM10; and 
r=0.24, p=0.48 for PM2.5. 
 
The poor correlation is likely to be related to the similar modelled PM exposure for 
all participants, given that they all resided in east London. The variation in PMacBC 
between participants is also small, as most PMacs reviewed contained no black 





























6.5.2. Electron microscopy of placental macrophages 
Five placentas were further examined by electron microscopy, which demonstrated 
ultrafine and nano sized black inclusions (some measuring <0.1µm) within placental 
macrophages from each placenta (figure 6.4). These black inclusions had 
appearances compatible with diesel exhaust particles seen in PMacs exposed to 
DEP in vitro (figure 6.5), they also resemble phagocytosed black carbon seen in 
alveolar macrophages, as demonstrated in chapter 3 of this thesis. 
Figure 6.4. Electron microscopy images of placental macrophages showing black 
inclusions in vacuoles compatible with diesel exhaust particles appearances. 
2 µm 
2 µm 2 µm 
2 µm 
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Figure 6.5. Electron microscopy images of placental macrophages exposed to 
diesel exhaust particles in vitro. (d) is an magnified image of (c).  
a b 
c d 
5 µm 5 µm
5 µm 2 µm
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6.6. Placental macrophage uptake of diesel exhaust particles in vitro 
Placental macrophages demonstrated phagocytic ability in vitro when exposed to 
diesel exhaust particles (figure 6.6), median of differences (IQR) in PMacBC 
between unexposed and exposed PMacs was 5.96 (4.16 – 10.55) µm2, n=13, 
p<0.001 (figure 6.7). 
Figure 6.6. Light microscopy images of placental macrophages after exposure to 












Figure 6.7. Placental macrophage black carbon in PMac cells unexposed (DEP-) 
and exposed (DEP+) to diesel exhaust particles, presented in log scale. Comparison 













































Using light microscopy, evidence of black inclusions, with appearances compatible 
with inhaled black carbon seen in alveolar macrophages, were found in placental 
macrophages, suggesting that it is indeed possible for carbonaceous particles to 
translocate from the maternal lung via the circulation to the placenta. More 
importantly, this finding was universal, i.e. all placentas had evidence of such black 
inclusions. Since it is difficult to prove the nature of the black inclusions using only 
their appearances, electron microscopy was used to pursue any such black 
materials that were phagocytosed. Using light and electronic microscopy images of 
placental macrophages exposed to diesel exhaust particles in vitro, and resources 
available in the literature, suspicious black substances compatible with diesel 
exhaust particles were seen within placental macrophage vacuoles.  
Combining both light and electron microscopy, these results strongly support that 
inhaled carbonaceous ultrafine PM can penetrate the tissue barrier of the respiratory 
system, invade the circulation and travel to distant organs. Notably, ultrafine 
particles were seen in placental macrophages – this is consistent with the findings 
from previous research that nano-sized particles are able to cross tissue barrier. As 
the amount of BC detected in the placenta is very small, whether it is adequate to 
cause significant problems in placental function and fetal development remains 
unknown. However, particles able to reach the placenta may also cross over the 
placental barrier and reach the fetus – an area which warrants future investigations. 
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6.7.1. Strengths 
For the first time, using visualisation by microscopy, this work demonstrated the 
possibility of inhaled ultrafine carbonaceous particles to escape the airway immune 
system, penetrate tissue barriers, and reach the systemic circulation, traveling to a 
distant destination in the body. This also provides a potential mechanism of how air 
pollution can affect the unborn fetus, resulting in adverse birth outcomes. Two 
different methods, light and electron microscopy, were used to confirm the nature of 
the black inclusions identified.  
 
6.7.2. Limitations 
The number of participants was small and they were exposed to similar amount of 
air pollutants as they were all residing in similar parts of London. The study would 
be strengthened by a larger number of participants, ideally from different parts of 
the country, or different countries, with different levels of air pollution. The study 
would also be improved by comparing PMacBC to maternal AMBC. Active smoking, 
but not passive smoking, was an exclusion criterion. Both active and passive 
smoking are known to have negative effects on maternal and fetal health, it would 
therefore be reasonable to consider the effects of passive smoking on placental 
macrophage function and carbon loading. 
 
6.7.3. Summary 
Using light and electron microscopy, the results from this chapter show evidence of 
carbonaceous ultrafine particles in placental macrophages in all placentas 
examined. These findings suggest it is possible for ultrafine particles to translocate 
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from the lung to distant organs, providing a potential mechanism of how air pollution 
can affect extra-pulmonary systems, and how the unborn fetus is impacted. 
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Chapter 7: Discussion 
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7. Discussion
7.1. Key findings 
In this thesis, I sought to address the mechanisms underlying the vulnerability of 
children with cystic fibrosis to air pollution. Air pollution is harmful to all individuals 
at every stage of the life course – with children, particularly those with respiratory 
conditions, being most susceptible. Phagocytosis by alveolar macrophages, a major 
route of clearing inhaled carbonaceous particulate matter, is impaired in CF. This 
was demonstrated by the reduced amount of phagocytosed black carbon observed 
in AMs from children with CF, despite children from both CF and control groups were 
exposed to similar levels of PM and NO2, as seen in their modelled and personal 
monitoring data. However, the impairment of CF AM function appeared to be only 
an in vivo problem, as AM phagocytosis of DEP in both CF and control groups were 
similar in vitro. This reinforced the hypothesis that it is the CF airway environment 
that hinders AM phagocytosis. Brugha et al. 102 suggested that impaired AM 
phagocytosis in severe asthma was likely to be secondary to increased production 
of PGE2, PGE2 was therefore speculated to be the driver of AM phagocytosis 
impairment in CF as well.  
The work in this thesis showed that not only did the CF group have higher levels of 
urinary metabolites of PGD2, PGE2 and PGJ2, reflecting increased production of 
these PGs; PGE2 level in sputum supernatant was also higher in the CF group 
compared to healthy controls. Additionally, the increased expression of COX-2 in 
CF AMs further supplemented the evidence for increased PGs production.  
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The in vitro assay showed that PGE2 did inhibit responder AM phagocytosis, which 
was reversed by blocking PGE2 with an EP2 receptor antagonist. 
Notably, CF sputum supernatant also exhibited inhibitory effects on responder AM 
phagocytosis in vitro; and reversal of this inhibition was achieved using an EP2 
receptor antagonist, strongly suggesting PGE2 as a driving factor for the functional 
impairment in CF AMs.  
This thesis then explored the consequences of impaired phagocytosis of inhaled 
PM. The protective role of functional AM was demonstrated – the absence or 
dysfunction of AMs (e.g. when responder AMs were inhibited by PGE2) allowed PM 
to invade and affect epithelial cells. While the epithelium-macrophage in vitro model 
may not be a true representation of the airway, it functioned as a proof-of-concept 
model nonetheless. The invasion of residual PM in the airway into epithelial cells 
may trigger local inflammation – as seen in the increased IL-8 release from epithelial 
cells when exposed to DEP.  
This thesis went on to investigate further consequences of non-phagocytosed PM. 
PM may remain in the airway for various reasons, such as impaired AM 
phagocytosis, or saturation of AM functional capacity in heavily polluted 
environment. Ultrafine and nano-particles have been shown to be able to penetrate 
tissue barriers in animal and human ex vivo models. The work in this thesis showed, 
for the first time, microscopy evidence of particle translocation from the lung to 
distant organ. The placenta was not only used as a proxy for distant organs, 
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presence of pollutant particles in the placenta may also explain the association 
between maternal air pollution exposure and adverse birth outcomes.  
All participating women were exposed to similar levels of pollution based on their 
modelled exposure data, and suspicious black inclusions were identified in all 
placentas. The black inclusions have appearances compatible with inhaled 
carbonaceous particles phagocytosed by AMs, as shown by the sputum work on 
AMBC in this thesis, and also in the literature 102,103. Electron micrographs of 
placental macrophages revealed black substances, which were compatible with 
carbonaceous ultrafine particles in AMs demonstrated by Bunn et al. 194. To further 
support these findings, PMacs were exposed to DEP in vitro – this demonstrated 
the phagocytic ability of PMacs, and at the same time, electron microscopy of PMacs 
exposed to DEP showed that the characters of DEP do akin to the black substances 
observed within unexposed PMac.  
 
Figure 7.1 demonstrates the overall findings of this thesis. 
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7.2. Implication for future studies 
Since it was impossible to compare the amount of AMs present in the CF vs healthy 
airways, future studies examining AMBC using bronchoalveolar lavage might be of 
interest. Lavage can be performed under a more controlled environment using a 
fixed amount of saline flush. The difficulty with this approach is that it is uncommon 
for healthy children to undergo bronchoscopy.  
To better model the CF airways, primary epithelial cells can be used. Further studies 
that explore the complex interactions of cytokines released from all airway cells 
under the influence of diesel exhaust particles are needed. 
The work in this thesis shows that a short 3-day course of Ibuprofen can reduce PG 
metabolites in the urine, reflecting a reduction in PG production. However, a longer 
term, randomised study spanning beyond the average half-life of AM will be 
beneficial and more compelling, where AMBC can be compared before and after 
intervention with Ibuprofen. While air pollution remains a global public health issue, 
and air quality improvement is slow to progress, the current generation of children 
continue to suffer the health effects of air pollution. Cyclooxygenase inhibitors such 
as Ibuprofen may offer a therapeutic option in tackling inflammation caused by air 
pollution. 
Intracellular clusters of bacteria were observed within AMs from children with CF. 
These children were clinically stable at the time and had no evidence of concurrent 
infections or exacerbations. While it is known in the literature that some bacteria are 
able to bypass the immune system and survive within macrophages, it may be 
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important to identify any concealed bacteria residing within cells, and understand 
the consequence of such uninvited residence – for example, whether these bacteria 
are driving chronic but subclinical airway inflammation. During chest exacerbations, 
patients with CF can be asymptomatic but have declined lung function. Sputum and 
cough swabs cultures often show no microbiology growth, and therefore antibiotic 
treatments are commonly empirical. Any pathogens concealed within alveolar 
macrophages might not be detected by routine hospital cultures. Using the 
monocyte enrichment method, AMs can be isolated and intracellular contents may 
be cultured. This will not only allow for more tailored antibiotic treatments, it may 
also identify patients who are asymptomatic but at risk of colonisation. Further 
studies in this area are definitely warranted. 
With the knowledge that the handling of inhaled carbonaceous particles is 
compromised in patients with CF, subsequently worsening the pre-existing chronic 
airway inflammation, it is important to raise patients’ awareness and advise them 
accordingly, so they can take appropriate measures to reduce their personal 
exposure to air pollution. While air quality activists worldwide are striving for cleaner 
air, which is an urgent matter as no child should be denied their fundamental right 
to live in a clean environment, the responsibility largely lies with policy makers and 
governmental bodies, and the process of reducing air pollutants to target levels 
could be protracted. It is therefore sensible to pursue therapeutic avenues which 
may protect vulnerable children from the harmful effects of air pollutants. With the 
techniques used in this work, it is possible to non-invasively isolate primary alveolar 
macrophages from children, allowing further studies on how to improve their 
phagocytic function.  To limit, halt, or reverse any lung damage caused by air 
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pollution, that is occurring on a day to day basis, will allow our current generation of 
children to achieve their developmental potential, lead a healthy childhood, and 
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Appendix 1 – Summary of literature review on alveolar macrophage 
function in cystic fibrosis 
Study Subjects 
(source of AM) 
Findings 




CFTR knock-out AM showed reduced 
phagocytosis of Staphylococcus aureus. 
Entezari et al., 
2012 196
Human (BAL), and 
CFTR knock-out 
mice 
High-mobility group box 1 protein (HMGB1) 
levels were elevated in CF; which impaired 
macrophage phagocytosis of 
Pseudomonas aeruginosa. 
Wright et al., 
2009 123
Human (IS) Expansion of small macrophages, with 
reduced expression of MARCO and CD206 
in CF sputum macrophages, resulting in 
reduced phagocytosis of unopsonised 
fluorescent particles. 
Di et al., 
2006 121
Human (BAL), and 
CFTR knock-out 
mice 
CFTR deficient AMs showed a loss of 
subcellular acidification, resulting in 
enhanced survival of Pseudomonas 
aeruginosa within the phagosomal 
compartment. 







Increased number of in vivo apoptotic cells 
in CF sputum, suggesting defective airway 
clearance. CF sol inhibited HMDM 
phagocytosis of apoptotic cells in vitro, 
secondary to protease cleavage of cell 
surface receptor and deficiency in 
surfactant proteins. 
Vandivier et al., 
2002 198
Human (BAL) CF airway fluids inhibited AM removal of 
apoptotic cells in vitro, mediated by 
elastase facilitated phagocyte receptor 
cleavage.   
Fick et al., 
1983 199
Human (BAL) Impaired macrophage intracellular bacterial 
killing from CF-derived opsonins, 
associated with disrupted attachment of 
antibodies to the AM membranes. 
Cassino et al., 
1980 200
Human (BAL) Phagocytic capacity of AMs when exposed 
to Candida albicans was higher in CF. 
Thomassen et al., 
1980 201
Human (BAL) Phagocytosis of Pseudomonas aeruginosa 
in normal serum was seen in both CF and 
normal AM; but phagocytosis was impaired 
when AMs were exposed to CF serum, 
except for phagocytosis of Staphylococcus. 
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Appendix 2 – Summary of literature review on the effects of 
prostaglandin E2 on alveolar macrophage function  
 
Study Subjects  
(source of AM) 
Findings 
Pereira et al., 
2018 153 
Rats PGE2 decreased phagocytosis and killing of 
serum-opsonized Histoplasma capsulatum, 
with opposite effects seen with PGD2. 
Salina et al.,  
2017 202 
Rats PGE2 produced by AMs impaired clearance 
of non-opsonized Streptococcus 
pneumoniae. 
Domingo-Gonzalez 




PGE2-driven alterations in scavenger 
receptor and miR-155 expression could 
inhibit bacterial killing, 
affecting phagocytosis of Pseudomonas 
aeruginosa and Staphylococcus aureus. 





Post BMT overproduction of PGE2 inhibited 
opsonised and unopsonised phagocytosis of 
Pseudomonas aeruginosa. 
Medeiros et al., 
2009 204 
Mice and rats Apoptotic cells suppressed in vitro AM 
phagocytosis and bacterial killing. 
Intrapulmonary administration of apoptotic 
cells led to PGE2 generation, resulting in 
impaired recruitment of leukocytes and 
clearance of Streptococcus pneumoniae 
Canetti et al., 
2007205 
Rats PGE2, by increasing the activity of 
phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) in AMs, inhibited 
AM immune signalling. PTEN inhibition 
decreased PGE2-induced suppression of 
AM killing of Klebsiella pneumoniae. 





Increased production of PGE2 post-BMT 
impaired host defence against Escherichia 
coli. 
Canning et al.,  
1991 207 
Mice PGE2 levels were increased following ozone 
exposure, associated with reduced 
phagocytosis of opsonized sheep red blood 
cells. Pre-treatment with COX-inhibitor 
(indomethacin) partially inhibited ozone-
induced suppression of AM phagocytosis.  
Laegreid et al., 
1989 208 
Cattle AMs were infected parainfluenza-3 (PI3 
virus) virus, followed by exposure to 
Staphylococcus epidermidis. PI3 virus-
infected AM had impaired bacterial killing, 
which was reversed by COX- inhibitor. In 
vitro impaired bactericidal function 
associated with virus infection of AM was 




Appendix 3 – Summary of literature review on the effects of air pollution 
on cystic fibrosis 
Study Study design Findings 
Kopp et al., 
2019 209
Cohort study of 77 children 
with CF aged <10 years. 
Children with CF who are exposed to 
second-hand smoke had altered 
arachidonic acid metabolism and 
inflammatory gene expression, resulting 
in impaired bacterial clearance. 
Psoter et al., 
2017 165
Retrospective study in 
3463 children with CF 
aged <6 years, using the 
CF Foundation Patient 
Registry. 
10 μg/m3 increase in PM2.5 exposure 
increased the risk of MRSA acquisition 
during follow up (Hazard Ratio: 1.68; 95% 
CI 1.24-2.27). 
Kunzi et al., 
2015 169
In vitro study assessing the 
response of normal, 
distressed (antibiotic 
treated), CF human 
bronchial epithelia (HBE), 
and single-cell bronchial 
epithelial cell line (BEAS-
2B), when exposed to 
gasoline-exhaust particles.  
Short-term exposure to gasoline-exhaust 
particles impaired epithelial defence 
mechanisms; promoting cell death in a 
dose-dependent manner in normal and 
diseased epithelia. Decreased cytokine 
release was seen in CF epithelia, thereby 
lowering the capacity to respond to insult. 
Jeannet et al., 
2017 170
In vitro study using normal 
and CF HBE and BEAS-2B 
cell lines, looking at cell 
death, inflammatory 
response, epithelial 
function and morphology, 
following exposure to silver 
and carbon nanoparticles.   
Nanoparticle exposure led to increased 
necrosis in CF compared to normal HBE 
and BEAS-2B cells; with no functional 
and structural alterations to the epithelia. 
Ni et al., 
2015 210
In vitro study using murine 
macrophages exposed to 
cigarette smoke extract 
and pseudomonas 
aeruginosa. 
Cigarette smoke extract exposure 
inhibited Pseudomonas aeruginosa 
phagocytosis, which was improved by 
induction of macrophage CFTR 
expression. 
Psoter et al., 
2015 164
Retrospective study of 
3575 children aged <5 
years, using the US 
registry. 
10 µg/m3 increase in PM2.5 exposure was 
associated with earlier Pseudomonas 
aeruginosa acquisition – a 24% increased 
risk of Pseudomonas acquisition during 
follow up. 
Geiser et al., 
2014167 
In vitro study using 
alveolar epithelial cells 
from CFTR mutant mice, 
exposed to iridium, 
titanium doxide, and 
carbon nanoparticles.  
CFTR mutant epithelial cells showed 
higher nanoparticle uptake. 
Farhat et al., 
2013 211
1 year prospective study of 
103 children with CF. 
An interquartile range increase (45.62 
μg/m3) in the ozone concentration had an 
256 
OR of 1.86 (95% CI 1.14-3.02) for a 2-
day delayed pulmonary exacerbation. 
Jassal et al., 
2013 212
5 year retrospective 
study of 145 patients with 
CF aged >7 years, using 
the US Cystic Fibrosis 
Foundation National 
Patient Registry. 
Correlation between pulmonary 
exacerbations and 1000 m distance to 
major arterial roads, with an OR of 6.7 
(1.23–54.9). 
Goeminne 
et al., 2013 163 
Case crossover analysis of 
215 patients with CF. 
Increasing concentrations of PM10, NO2, 
and ozone on the event day and for NO2 
on the day before were associated with 
increased risk of antibiotic use. 
OR for pulmonary exacerbation per 
10µg/m3 increase in each pollutant: 
PM10 = 1.043 (1.004–1.084) 
NO2 = 1.106 (1.05–1.166) 
O3 = 1.034 (1.003–1.067) 
Kasmdar 
et al., 2008 213 
In vitro study using CF 
HBE exposed to PM2.5. 
Oxidative stress and mitochondrial 
signalling mediated apoptosis were 
enhanced by PM, which upregulated pro-
apoptotic mediators; and had no effect on 
anti-apoptotic mediators. 
Goss et al., 
2004 166
Retrospective cohort study 
of 11484 patients with CF 
aged >6 years, using the 
Cystic Fibrosis Foundation 
National Patient Registry. 
10 µg/m3 rise in PM10 and PM2.5 was 
associated with an 8% (95% CI, 2-15%) 
and 21% (95% CI, 7-33%) increase in the 
odds of two or more exacerbations, 
respectively. 
10 ppb rise in ozone was associated with 
a 10% (95% CI, 3-17%) increase in odds 
of two or more exacerbations. 
For every 10 µg/m3 increase in PM2.5, 
there was an associated fall in FEV1 of 24 
ml (95% CI 7-40). 
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Appendix 4 – Protocol: Reducing the effects of air pollution in children 
with cystic fibrosis 
1. General Information
Full title: Reducing the effects of air pollution on children with 
cystic fibrosis 
Short title: Air pollution and Children with Cystic Fibrosis 
Sponsor: Queen Mary University of London 
Mays Jawad, R&D Operations Manager 
Joint Research Management Office 
Queen Mary Innovation Centre 
5 Walden Street, London, E1 2EF, UK 
Tel: 020 7882 7275 
Email: research.governance@qmul.ac.uk 
REC Reference: 17/EM/0023 
IRAS project ID: 215879 
Chief Investigator: Professor Jonathan Grigg 
Centre for Paediatrics, Blizard Institute 
4 Newark Street, London E1 2AT, UK 
Tel: 02078822206 
Fax: 02078825555  
Email: j.grigg@qmul.ac.uk 
Principal Investigator: Dr Norrice Liu 
Centre for Paediatrics, Blizard Institute 
4 Newark Street, London E1 2AT, UK 
Tel: 02078822616 
Email: n.liu@qmul.ac.uk 
Co-Investigators: Dr Chinedu E.C Nwokoro 
Blizard Institute 
4 Newark Street, London E1 2AT, UK 
Tel: 020 7882 8397  
Email: c.nwokoro@qmul.ac.uk 
Professor Malcolm G Semple 
Professor Kevin W Southern 
University of Liverpool 
Institute in The Park 
Alder Hey 
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Sites/ Organisations: Barts and The London School of Medicine and Dentistry 
Centre for Paediatrics  
Blizard Institute 
4 Newark Street 
London E1 2AT, United Kingdom 
Barts Health NHS Trust 
Royal London Hospital 
Whitechapel Road 
London E1 1BB, United Kingdom 




Laboratories: Blizard Institute 
4 Newark Street 
London E1 2AT 
United Kingdom 
Tel:  020 7882 2483 
Histopathology 
Alder Hey Children’s Hospital NHS Foundation Trust 
Eaton Road 
Liverpool L21 2AP 
IVL Swedish Environmental Research Institute Ltd 
P.O. Box 53021 
SE-400 14 Gothenburg Sweden 
Tel: +46 (0)10 -788 65 00 
Email: info@ivl.se 
Professor Marek Sanak 
Department of Medicine 
Jagiellonian University Medical School 
ul. św. Anny 12 
31-008 Kraków, Poland
Tel: (48 12) 422 80 42
Funder: Barts Charity 
Ground Floor 
12 Cock Lane 
London, EC1A 9BU 
Tel: 02076181717  
Fax: 02072489395 
Emails: blcharity@bartshealth.nhs.uk 
Grant Reference: MGU0312  
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2. Glossary of Terms and Abbreviations 
 
AE   Adverse Event  
AM   Airway Macrophage 
AR   Adverse Reaction 
ASR   Annual Safety Report 
BAL   Broncho-alveolar lavage 
BC   Black Carbon 
CA   Competent Authority 
CF   Cystic Fibrosis 
CI   Chief Investigator 
COX   Cyclooxygenase 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
FEV1   Forced Expiratory Volume in 1 second 
GAfREC  Governance Arrangements for NHS Research Ethics Committees 
GPS   Global Positioning System  
ICF   Informed Consent Form 
IL-9    Interleukin-8 
IS   Induced Sputum 
ISS   Induced sputum supernatant 
JRMO   Joint Research Management Office 
JRO   Joint Research and Development Office 
NHS REC  National Health Service Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
NO2   Nitrogen Dioxide 
Participant  An individual who takes part in a clinical trial or study 
PGE2   Prostaglandin E2 
PI   Principle Investigator 
PIS   Participant Information Sheet 
PM   Particulate Matter 
QA   Quality Assurance 
QC   Quality Control 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAR   Serious Adverse Reaction 
SAE   Serious Adverse Event 
SDV   Source Document Verification 
SOP   Standard Operating Procedure 
SSA   Site Specific Assessment 
TMG   Trial Management Group 
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3. SIGNATURE PAGE
Chief Investigator Agreement 
The clinical study as detailed within this research protocol (Version 1.11, dated 
19/02/2019), or any subsequent amendments will be conducted in accordance with the 
Research Governance Framework for Health & Social Care (2005), the World Medical 
Association Declaration of Helsinki (1996) and the current applicable regulatory 
requirements and any subsequent amendments of the appropriate regulations. 
Chief Investigator Name: Professor Jonathan Grigg 
Chief Investigator Site: Blizard Institute 
Signature and Date:  19/02/2019 
Principal Investigator Agreement (if different from Chief investigator) 
The clinical study as detailed within this research protocol (Version 1.11, dated 
19/02/2019), or any subsequent amendments will be conducted in accordance with the 
Research Governance Framework for Health & Social Care (2005), the World Medical 
Association Declaration of Helsinki (1996) and the current applicable regulatory 
requirements and any subsequent amendments of the appropriate regulations. 
Principal Investigator Name: Dr Norrice Liu 
Principal Investigator Site: Blizard Institute 
Signature and Date:  19/02/2019 
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4. Summary / Synopsis
Short title Air pollution and Children with Cystic Fibrosis 
Methodology Cross-sectional cohort study 
Research Sites  Barts Health NHS Trust
 Blizard Institute, Queen Mary University of London
 Alder Hey Children’s Hospital, Liverpool
Objectives/ 
Aims 
1. To determine personal exposure to air pollution in children
with cystic fibrosis;
2. To determine airway macrophage uptake of inhaled
particulate matter in cystic fibrosis children;
3. To establish whether prostaglandin E2 affects particulate







 Diagnosis of Cystic Fibrosis
 Diagnosis of non-CF bronchiectasis
 Living in or around London or Liverpool
For sputum induction: with age matched healthy controls
For bronchoscopy: controls will be children under investigation for




The study is powered to detect a difference of 0.7 SD in 
macrophage black carbon levels and PGE2 metabolites level 








Study Duration 4 years 
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5. Introduction
Background: 
Cystic fibrosis (CF) is the commonest hereditary life-shortening respiratory condition, resulting in 
premature death secondary to recurrent airway infections and inflammation, leading to irreversible 
lung damage. The screening programme in infancy has improved life expectancy but the lifespan 
of CF patients is still reduced by 20 years at present 214. Thus interventions to reduce inflammation, 
infection and lung damage in CF are still needed 215.  
One potential intervention is to reduce exposure of CF children to air pollution. Particulate matter 
(PM) are microscopic soot particles from petrol and diesel engine emissions; PM is linked to 
adverse respiratory health effects in children. Children with cystic fibrosis are particularly vulnerable 
to PM but, to date, no exposure-reduction advice is available, and the mechanism underlying this 
vulnerability is unclear.  
Personal exposure of CF children to PM is due to: i) locally-generated sources (relative to the 
proximity to busy roads) and ii) background concentrations (i.e. PM blown across the whole city 
from other areas). Although a link between air pollution and reduced lung function growth in healthy 
children is well established 61, the link with CF lung disease has only recently emerged. A recent 
study found that long-term exposure of CF children to PM increases risk of airway infection with 
Pseudomonas 164. Another study also found that short-term background pollution is associated with 
increased need for antibiotics in children and adults with CF 163. The need to reduce patients’ 
personal exposure to PM has been recognised by Barts Health NHS Trust. Working with Global 
Action Plan, the Trust has developed tips on how to reduce adults’ personal exposure to air 
pollution. These tips include traveling outside rush hours, taking low pollution routes (maps 
provided), and signing up to the airText air pollution warning App. Since travel outside rush hours 
is not feasible for school children, child-friendly tips are urgently needed.  
Recent research in asthma patients suggests a putative mechanism of impaired removal of inhaled 
PM. In the healthy lung, inhaled PM is quickly removed (phagocytosed) by airway macrophages 
(AM). AM patrol the surface of epithelial cells lining the airways; after taking up PM, they move up 
and out of the lung. Thus AM with normal phagocytic function act to both reduce PM exposure of 
other airway cells – including epithelial cells, and to ensure that PM does not accumulate in the 
lung. The amount of carbon particles in AM was previously used to assess the effects of long-term 
effects of exposure of healthy children and adults 101,216. The amount of black carbon (BC) in AM 
reflects the intrinsic capacity of AM to remove PM (phagocytic capacity). AM carbon is significantly 
lower in conditions such as severe asthma 217, where AM phagocytic capacity is impaired. 
Furthermore, a role for prostaglandin E2 (PGE2) in mediating impaired phagocytic function in 
asthma has been identified. First, PGE2 suppresses AM phagocytosis of urban PM in vitro; and 
second, children with severe asthma had increased urinary PGE2 metabolites 102. Shift of inhaled 
PM away from AM to other cells has the potential to stimulate interleukin-8 (IL-8) release by 
epithelial cells – a phenomenon observed in mouse, where inhalation of non-inflammatory particles 
produces significant airway neutrophilia when AM phagocytic function is impaired 218.  
We hypothesise that impaired handling of inhaled PM by AM contributes to vulnerability of children 
with CF to air pollution. Specifically, increased vulnerability to inhaled PM in children with CF is due 
to PGE2-mediated impairment of AM phagocytosis. The corollary is that children with CF will have; 
i) reduced levels of AM carbon in vivo (reflecting reduced phagocytosis of inhaled PM in vivo), ii)
reduced capacity of AM to phagocytose carbon PM in vitro, iii) increased metabolites of PGE2 in
the airway and urine, and finally, iv) since PGE2 production is under the control of the enzyme
cyclooxygenase (COX, especially COX-2), CF airway cells have increased COX-2 expression, v)
COX inhibitors (e.g. Ibuprofen) should suppress PGE2 production, theoretically improving AM
function.
Non-cystic fibrosis bronchiectasis is a respiratory condition with multiple aetiology such as
congenital pathology, immunodeficiency, and primary ciliary dyskinesia. Patients with non-CF
bronchiectasis demonstrate similar clinical features to those with CF, patients with either conditions
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are managed with similar treatments, we therefore hypothesise that the above also apply to 
children with non-CF bronchiectasis. 
There has been evidence that some organisms are capable of reproducing and residing within 
airway macrophages without being destroyed by the traditional phagocytic pathway132. Often, 
unwell CF and non-CF bronchiectasis patients are admitted to the hospital for intensive antibiotic 
treatments but a proportion of their sputum samples yield no growth by routine hospital culture. We 
therefore propose to explore isolated airway macrophages and identify the organisms within – if 
any are present.  
Clinical Data: 
There is evidence to support this hypothesis; i) it was previously reported that phagocytosis of inert 
latex beads is impaired in AM from CF adults (71 + 15 % phagocytosis in controls vs. 23 + 9 % in 
CF) 123, ii), CF is associated with increased airway PGE2 144, and iii) in a pilot study, significantly 
(p<0.01) reduced AM carbon in 6 CF children compared with 6 healthy controls (mean 0 vs. 0.3 + 
.05, μm2 p<0.01) was found. 
Rationale: 
To date, the effect of impaired uptake of PM by AM on other airway cells has not been studied in 
vitro. We hypothesise that in co-cultures of human AM and airway epithelial cells exposed to urban 
PM, PGE2-mediated impairment of macrophage phagocytosis increases epithelial release of IL-8. 
Furthermore, since AM are a major source of airway PGE2 219, we speculate that there is increased 
COX-2 expression in AM from CF children. Thus suppression of AM phagocytic function in CF is 
an autocrine process; i.e. CF AM release more PGE2 - which in turn suppresses AM phagocytosis. 
In this study we will seek evidence for abnormal handling of PM by AM from CF children, and model 
this using cultures of human airway cells and macrophages.  
6. Study Objectives
Primary Objectives: 
i. To identify the mechanism for impaired removal of PM by AM in children with CF and non-
CF bronchiectasis in vivo and in vitro- using induced sputum (IS) or broncho-alveolar lavage
(BAL) fluid following diagnostic bronchoscopy, compared to healthy controls or those who
are undergoing bronchoscopy to investigate for non-inflammatory non-infective conditions
(e.g. those who do not have CF, non-CF bronchiectasis, or asthma).
ii. To test the hypothesis of PGE2 involvement in AM phagocytosis of PM - by comparing PGE2
metabolites in respiratory secretions and urine of children with CF and non-CF
bronchiectasis (both during periods of stable health status and exacerbations) to controls.
iii. To model whether decreased uptake of PM by macrophages in vitro increases release of
cytokines (e.g. IL-8) from airway epithelial cells in vitro.
Secondary Objectives: 
i. To identify the major sources of personal exposure of children with CF and non-CF
bronchiectasis to air pollution – this will be compared to healthy controls.
ii. To determine the amount of diesel soot in AM from children with CF and non-CF
bronchiectasis and healthy controls.
iii. To develop feasible, acceptable and evidence-based advice on short and long-term
exposure reduction.
iv. To explore and identify intracellular bacteria strains, if any, from within airway macrophages,
and compare with routine hospital culture results.
v. To explore whether COX inhibitors can reduce PGE2 production.
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Endpoint: 
i. Comparing personal exposure of children with CF and non-CF bronchiectasis to air pollution
to healthy controls.
ii. Quantifying the amount of black carbon in AM from children with CF and non-CF
bronchiectasis and healthy children.
iii. Quantifying and comparing PGE2 metabolites in respiratory secretions and urine of children
with CF and non-CF bronchiectasis and healthy children.
iv. Measuring cytokines (e.g. IL-8) from airway cells of children with CF and non-CF
bronchiectasis and healthy controls.
7. Methodology
Inclusion criteria: 
 Children with Cystic Fibrosis with age specified as above
 Children with non-CF bronchiectasis with age specified as above
 For children undergoing sputum induction: Age-matched healthy controls
 For children undergoing bronchoscopy: controls will be children without CF, non-CF
bronchiectasis or other inflammatory or infective respiratory conditions (e.g. those
undergoing bronchoscopy for investigation of airway anatomy but are otherwise well).
 All children should reside in urban areas.
Exclusion criteria: 
 Current active smoker
 Receiving immunosuppressive drug therapy
 For children with CF and non-CF bronchiectasis not on regular nebulised hypertonic saline:
drop in FEV1 of >15% post-bronchodilator (exclusion criterion for sputum induction) – this
only applies to those undergoing sputum induction.
 For healthy controls: Post-bronchodilator FEV1 <80% (standard exclusion criterion for
sputum induction in healthy individuals) – this only applies to those undergoing sputum
induction.
 For participants currently or recently involved in other research study, they will be excluded
if their current or recent research have any potential impact on our sampling or results.
Study Design: 
Cross sectional cohort study of children with CF and non-CF bronchiectasis recruited in London 
and Liverpool. CF and non-CF bronchiectasis children will be recruited at the participating hospital 
sites; controls (those without inflammatory respiratory conditions) will be recruited from children 
living in urban areas in London or Liverpool. In view of the CI’s particular interests and expertise in 
air pollution, and his contacts within the British media, charities, and health and education sectors, 
healthy children across London may also be invited to take part through these organisations. 
Potential participants will be identified and approached in the first instance by a member of their 
usual clinical care team. The research team will then review and ensure they meet the eligibility 
criteria. 
The study is planned for the duration of 4 years. Participants' will actively participate (monitoring 
and sampling) for an overall of 2 years, except for those undergoing bronchoscopy – their 
participation will end after bronchoscopy. 
Recruitment: 
 We aim to recruit approximately 100 children. 
Personal Exposure Study: 
We will monitor personal exposure of all recruited children including: 
o Approximately 40 children with CF and non-CF bronchiectasis (age 7-17)
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o Approximately 40 healthy controls (age 7-17)
o Approximately 10 children with CF and non-CF
bronchiectasis (age 1-6)
o Approximately 10 healthy controls (age 1-6)
Induced Sputum: 
Approximately 40 children with CF and non-CF bronchiectasis 
(age 7-17) and approximately 40 age-matched controls. 
Bronchoscopy (performed for diagnostic reasons not related to this project): 
Approximately 10 children with CF and approximately 10 controls without CF/  
non- CF bronchiectasis. 
Urine collection: 
All children as above – inability to produce a urine sample will not exclude participation. 
8. Study Procedures
Patient information sheets will be given out to potential participants. Informed consent and 
assent will be gained from participants and their parents/guardians during the recruitment 
phase of the study, after dissemination of information sheets. 
Data will be stored in paper and electronic formats. Participants’ data will be collected in 
Case Report Form which will be stored within the investigator’s site files, securely located in 
a locked cabinet within the Blizard Institute. Data stored on university computers will be de-
identified.  
Only participants' identification number will be recorded in the Case Report Form. The only 
document linking their personal details (name) to their participant ID is the consent form - 
one copy will be given to the patient, one copy to be stored in medical records and one copy 
to be kept within the investigator's site file. For Audit purposes, Sponsors/monitors will need 
to view information. 
Schedule of Assessment: 
Personal exposure 
With informed consent, we will record children with CF and non-CF bronchiectasis and 
controls’ demographics (postcodes, contact details), medical history, +/- usual travel 
routes, and sources of indoor and outdoor air pollution exposure (e.g. cigarette smoke, 
cooking) in the Case Report Form, for the purpose of pollution exposure monitoring, 
and potential house visit to carry out lung function and sputum induction.  
For children recruited in London, a black carbon PM monitor will be carried by each 
participant for 2 x 24 hour periods. A parent/child completed activity diary will identify 
routes and activities associated with high exposure. Nitrogen Dioxide (NO2) is a valid 
marker for fossil-fuel derived PM (outdoor) and natural gas e.g. cooking gas and heating 
(indoor). 2-week cumulative exposure will be assessed using NO2 badges. One NO2 
badge will be placed near the child (e.g. worn by child/carer, attached to buggy), an 
additional NO2 badge will be placed inside the participant’s home to detect indoor gas 
cooking emissions (a PM- independent source). Current health status of children with 
CF and non-CF bronchiectasis (e.g. lung function, medications, infection status) will be 
obtained from clinical records. The results will compare air pollution exposure of children 
with CF and non-CF bronchiectasis to healthy controls. 
Unless the children are 
undergoing bronchoscopy, they 
will only take part in the 
exposure monitoring and urine 
collection parts of the study.  
(Sputum induction is difficult 
under the age of 7) 
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Mechanism for impaired removal of PM 
We will compare in vivo AM carbon in children with CF and non-CF bronchiectasis and 
healthy age-matched controls by sputum induction or following diagnostic 
bronchoscopy. Sputum induction will only be done in children > 7years of age for 
practicality reasons. The induced sputum samples will then be used for AM black carbon 
analysis. For children who are undergoing bronchoscopy for diagnostic reasons (not 
related to this research project), any residual bronchoalveolar lavage (BAL) will also be 
used for research purpose. 
 Spirometry (Lung Function) – for those undergoing sputum induction only
Lung function will only be done in children over the age of 7 for practical
reasons. After baseline lung function, participants will be given 400g
salbutamol by metered dose inhaler and spacer. "Post-bronchodilator" lung
function will be obtained after 15 min. Forced expiratory volume in 1 sec (FEV1),
forced vital capacity (FVC), FEV1/FVC and mid-expiratory flow between 25%
and 75% of the forced vital capacity (FEF25-75) will be determined. A further lung
function will be repeated following sputum induction to ensure no side effect,
which may require treatment, has occurred.
 Sputum Induction
This will be done in all recruited children over the age of 7 for practical reasons,
the process will take approximately 30 minutes. Sputum (containing lower
airway cells including airway macrophages) will be induced using nebulised 3.5-
7% saline and an ultrasonic nebuliser. Participants will be given Salbutamol
prior to nebulised hypertonic saline to limit the effect of bronchospasms, and
lung function will be monitored (see above). Clinical samples are brought to the
Blizard Institute for analysis within 4 hours. Slides will be analysed using our
established methodology.
For children with CF and non-CF bronchiectasis who regularly use nebulised 
hypertonic saline, their routine practice will be replaced by our standardised 
protocol, including Salbutamol use and lung function monitoring. Sputum 
induction can be done in a place most convenient to the child/family (e.g. 
hospital, home, school).  The timing of sputum induction can be synchronised 
with children’s (those with CF and non-CF bronchiectasis) routine chest 
physiotherapy session to limit inconvenience. We may obtain multiple induced 
sputum samples (limiting to 1 sample/ day) – sputum induction is similar to these 
children’s daily chest physiotherapy, therefore obtaining multiple samples 
should be feasible, but this will be guided by children’s co-operation.  
For healthy controls, we will limit the number of samples to a maximum of 3. 
Sputum induction will be done at the Royal London Hospital, or at an 
appropriate and safe place which is convenient for the participants and their 
family – such as home or school, with close monitoring of lung function (see 
above). Our research team has vast experience on the procedure and have 
performed spirometry and sputum induction on over 400 children in their 
schools, with no major complications. Researchers who perform the procedures 
outside the hospital are trained paediatric doctors and are able to provide 
medical attention when needed, although this is not anticipated to be necessary. 
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Bronchoscopy 
For children undergoing diagnostic bronchoscopy, the BAL samples collected 
will be residual of that used for diagnostic purpose – to analyse AM function and 
AM black carbon analysis.  
The induced sputum samples will be processed in the Blizard Institute, and used for AM 
function analysis. The BAL samples will be processed in the local laboratory (London or 
Liverpool) and used to assess AM function. Following purification process of AM, they 
will also be used to model the effect of impaired AM phagocytosis of PM. Presence of 
Cyclooxygenase (COX)-2 will be quantified. Part of the sputum samples will be used for 
bacterial culture. Respiratory secretions supernatant and urine samples (minimum of 
1ml) will be anonymously labelled and transported to the analysis laboratory (in Poland) 
for prostanoid metabolites analysis. Participants undergoing sputum induction will be 
given the option to take a routine over-the-counter (no prescription needed) course and 
dose of COX- inhibitor (for example, a 3 day course of Ibuprofen – see below), followed 
by repeat measurements of PGE2 metabolites in their IS supernatant and urine samples. 
Feedback of findings to parents / children – London only 
For the participants in London, the above data, including individual black carbon PM 
findings, will be analysed and discussed with the children and their families. Options for 
reducing outdoor and indoor exposure will be discussed (e.g. alternative routes when 
travelling to school, improved ventilation during gas cooking). If appropriate, maps will 
be generated using an urban walking route planner and/or 
http://www.londonair.org.uk/london/asp/annualmaps.asp to show alternative routes to 
minimise exposure. The feasibility of adapting the adult-orientated Barts Health tips and 
exposure maps, and relevance of advice from airText will also be assessed.  
Should any incidental findings for healthy controls, relevant and significant to their health, 
be identified, the researchers will contact the participants as soon as possible and advise 
regarding management. 
Co-design of evidence-based guidance/tips for clinical use – London only 
After completion of data analysis, and in collaboration with the Trust, we will arrange 
further parent engagement meetings to co-design evidence-based Trust-wide exposure 
reduction guidance/tips for children with CF and non-CF bronchiectasis, with the 
participants in London. 
Assessment Recruitment 
phase 




Informed consent x 







Spirometry x x 
Sputum Induction x x 
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End of Study Definition 
End of study will be when data collection is complete. Participants' participation will 
complete before data analysis is finished - participation will involve air pollution monitoring 
(London), sampling (London / Liverpool) and engagement meeting (London) near the end 
of study. It is not anticipated there will be premature termination of the study.  Should any 
subject experience a serious adverse event associated with or attributable to any study 
procedure, the study status will then be reviewed. 
9. Statistical Considerations
We aim to recruit 40 school age children with CF or non-CF bronchiectasis and 40 age-matched 
controls. 40 children per group will provide power of 90% at 5% to detect a difference between 
groups of 0.7 SD. Cell culture data will be analysed by either one-way analysis of variance and 
Tukey’s post hoc test for > 2 groups, or unpaired t test for 2 groups. 
Additional observational personal exposure data and urine samples will be obtained from 10 
children with CF and non-CF bronchiectasis of 1-7 years, with 10 age-matched controls - the 
maximum feasible number in a 3-year time frame.  
10. Ethics
Ethical Review 
The protocol will be reviewed both within the Sponsor Institution and by an 
independent research ethics committee.  All the techniques are ethically acceptable 
in children. 
Rationale for research 
Ethical research must be informed by existing research, and investigate an 
important question. We have addressed this issue by thorough review of the existing 
literature, and by conducting appropriate background studies. 
Design of research 
Ethical research must employ the most appropriate design in order to answer the 
research question.  A cross-sectional cohort study design has been chosen to 
address the hypothesis. 
Minimisation of inconvenience, discomfort and risk for participants 
Ethical research must seek to minimize potential inconvenience, discomfort and risk 
that participants may experience during the course of a study. The principle 
inconveniences of the study to the participants are minimized through use of 
qualified and trained practitioners to collect sputum and urine samples. Any 
participants who are undergoing bronchoscopy are doing so for diagnostic reasons, 
no additional procedure will be required to take part in this study. Salbutamol and 
Hypertonic Saline will be applied according to British National Formulary 
recommendations. Inconvenience is further reduced by performing sampling in the 
most appropriate and convenient time and place for child/family. We have extensive 
expertise in modelling environmental interactions with airway cells in vitro, 
immunostaining of IS cells (in an on-going MRC-funded study of dendritic cells), and 
in personal monitoring. Regarding COX inhibitor (e.g. Ibuprofen), this is a commonly 
used medication for fever and pain, with most of the general population having been 
exposed to the use of this medication since infancy – a lot of the participants will 
have used this medication previously – medical staff on the research team will 
ensure there is no known allergy or contra-indications to this medication before 
offering this to participants.  
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Sputum induction with ultrasonic nebulisation of hypertonic saline is a procedure
that is used therapeutically in children with CF and non-CF bronchiectasis. The
procedure is well-tolerated, and we have extensive expertise in performing
induced sputum in healthy children (over 400 children studied to date).  The
small risk of bronchospasm is significantly reduced by pre-treatment with
inhaled salbutamol.  Inhalation of hypertonic saline can cause a sore throat,
however the effect is mild and short-lived.
ii. Lung Function
Lung function is a safe, non-invasive procedure and will be performed according
to standard European Respiratory Society Guidelines.
iii. Urinalysis
Urine samples will be obtained by the participant passing urine into a universal
container in privacy, accompanied by a responsible adult if required.
iv. Carbon monitoring
Carbon monitoring via use of a small, lightweight portable meter is convenient
and non-invasive. The NO2 badges will be placed near the child during the 2
weeks; for young children, this can be attached to their buggy/carer to avoid
accidental ingestion hazard; or it can be attached to older children’s clothes.
v. Bronchoscopy
Flexible Bronchoscopy is being done for existing clinical reasons. The
procedure will never be done solely for the purpose of this study. The study will
merely make use of any residual diagnostic samples for research.
vi. Investigator safety
Investigators will prevent personal exposure to airborne or blood-borne
infectious organisms by appropriate use of masks, goggles, lab coats and
gloves while obtaining and processing samples. Lone worker policies (NHS and
QMUL) will be in place for investigators to carry out home visits.
Benefits 
Participating children and families will benefit from increased knowledge and 
understanding of air pollution in their environment and ways to try decrease their 
exposure. We will produce feasible and evidence-based guidance to reduce pollution 
exposure – this has immediate applicability in our CF and Bronchiectasis clinics. By 
establishing biological plausibility for the interaction between air pollution and lung 
disease in children with CF and non-CF bronchiectasis, this study will strengthen the 
case for causality and thereby support exposure-reduction intervention policy. We will 
provide clinicians with the tools to answer parent’s questions about air pollution, in order 
to enhance patient experience. The acceptability of the guidance is improved by 
inclusion of patient/parent in its design.  
12. Data Handling and Record Keeping
Confidentiality 
Ethical research projects should ensure that participants' personal data remain 
confidential. Our procedures for handling, processing, storage and destruction of data 
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are compliant with the Data Protection Act 2018. Participants will be allocated a 
participant ID which will be used as a code to identify them on all study forms and 
samples. The only document that will link the participant’s personal details with the 
participant ID is the consent form, which will have 3 copies – one to be given to the 
patient, one to be kept in their medical records, one to be kept in the investigator’s site 
files which will be locked in a cabinet within the Blizard institute, only accessed by 
research team. Data will be stored in paper and electronic formats. Data stored on 
university computers will be de-identified. For Audit purposes, Sponsors/monitors will 
need to view information. 
Record Retention and Archiving 
In line with Good Clinical Practice guidelines, at the end of the study, your data will be 
securely archived for a minimum of 20 years. Arrangements for confidential destruction 
will then be made.  
13. Laboratories
A) Blizard Institute, London
Lab Procedures: 
i. AM Black Carbon Analysis
Cytospins stained by Diff-Quik are analysed for AM black carbon using
digital colour images of 50 randomly selected AM from each child, captured
at x100 magnification 101. The total area of carbon in each AM is calculated
by measuring the black content of each cell. Mean AM carbon per child is
then calculated from the 50 AM. To ensure exposure to fossil-fuel derived
air pollution is similar between the CF, non-CF bronchiectasis and controls,
we will compare their personal 2-week NO2 exposure. We will also record
the distance between home/ school and nearest main road, and mean
annual exposure to PM10 from the nearest monitoring station to the home.
ii. Relationship between impaired PM uptake and cytokines release
AM sampled by IS will be purified (25), incubated with ultrafine carbon black
in vitro for 2 hours at a concentration resulting in near maximal loading of
control AM. Uptake of ultrafine carbon between CF, non-CF bronchiectasis
and controls will be compared, after adjusting for in vivo basal loading. In
children (CF, non-CF bronchiectasis and controls) who produce large
numbers of AM, and/or are willing to undergo repeated IS, we will also
assess non-specific phagocytosis of latex beads by AM using our flow
cytometry assay 123. Cells will be cultured with urban PM10, with and without
exogenous PGE2 using our standard method 220,221. In this co-culture system,
normal macrophage phagocytic function results in all PM being taken up by
macrophages 222. IL-8 in co-cultures will be assessed by ELISA.
iii. Presence of Cyclooxygenase (COX)-2 in AM will be quantified.
iv. Purified AM from sputum samples will be cultured to identify, if any,
intracellular organisms – the results will then be compared to routine hospital
sputum culture.
Data Preparation and Collection: 
Samples will be labelled with the participant ID given to each participant – samples will 
be pseudo-anonymised. Date of collection and conditions at which the samples are 
sent and storied will be recorded to ensure integrity. Samples are collected from the 
Air Pollution and Children with Cystic Fibrosis
Version 1.11    19/02/2019     272 
Royal London Hospital or participant’s home, then sent to the Blizard institute for 
analysis within 4 hours. For procedures that do not have to be performed on the same 
day, the samples will be securely stored within the Blizard Institute.  
Following analysis, if any samples remain, 1ml aliquot of sputum and urine samples will 
be stored at -80C in a freezer located within the research institute – in case of any need 
for repeated experiments for the study. The remainder of the samples will be discarded 
according to our local disposal policy. 
B) Alder Hey Children’s Hospital, University of Liverpool
Lab Procedures: 
Residual from routine Bronchoalveolar Lavage (BAL) samples will be processed for 
assessment of AM function.  This will involve producing a cytospin microscopy slide from 
approximately 1ml of BAL fluid. The slide will be stained and transported to QMUL. While 
the cell pellet will be used for cytospin as above, the supernatant will be frozen (-80C) 
and transported to QMUL for functional analysis and prostanoid quantification. 
Urine (at least 1ml) from participants will be frozen (-80C) after collection prior to 
transport to QMUL. Inability to collect urine will not exclude participation. 
Data Preparation and Collection: 
 Samples will be labelled with the participant ID given to each participants, along with 
sampling date – samples will be pseudo-anonymised. Date of collection and conditions 
at which the samples are sent and storied will be recorded to ensure integrity. Samples 
are collected and processed at Alder Hey Children’s Hospital, then sent to the Blizard 
institute for further processing and analysis. 
  Following processing, if any samples remain, aliquots of BAL samples will be stored at -
80C in a freezer located within the research institute – in case of any need for repeated 
experiments for the study. The remainder of the samples will be discarded according to 
local disposal policy. 
C) Department of Medicine, Jagiellonian University Medical School, Krakow,
Poland
Lab Procedures: 
Total ISS protein concentration is measured (mg/mL). The concentration of PGE2 
metabolites in ISS is measured by high-performance liquid chromatography/tandem 
mass spectrometry using organic phase extraction 223. These metabolites of PGE2 will 
also be assessed in participants’ urine 102. Metabolites of PGE2 in respiratory secretions 
and urine samples from children with CF or non-CF bronchiectasis and controls will be 
compared.  
Data Preparation and Collection: 
Samples will be labelled with the participant ID given to each participant – samples will 
be pseudo-anonymised. Date of collection and conditions at which the samples are sent 
and storied will be recorded to ensure integrity. Samples are collected from the Royal 
London Hospital or participant’s home, then stored at the Blizard institute. IS 
supernatant (ISS) is then transported to the analysis laboratory. Samples will be 
discarded following analysis. Analysis results will be sent to the Blizard in an pseudo-
anonymised form, using only participant IDs. 
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14. Products, Devices, Techniques and Tools
Devices: 
Carbon Monitoring 
We will measure 24-hour personal external black carbon exposure in 
each child using a portable Aethalometer. Children carry the monitor in 
a small bag for 24 hours alongside a time/activity diary, which is filled 
in by child/parent. These monitors give a real time picture of exposure 
to pollution. A GPS device will identify their routes of traveling. We will 
measure 24-hour exposure on two separate occasions.  
Nitrogen Dioxide Monitoring 
A NO2 diffusion monitor (the size of a small badge) will be placed near 
child for 2 weeks to monitor their NO2 exposure. This can be placed on the 
buggy/ parent/ carer or on child’s clothes, depending on their age and level 
of cooperation. An additional NO2 badge will be placed inside the 
participant’s home to detect indoor natural gas exposure. The data will be 
analysed by the manufacturers of the NO2 diffusion monitor (IVL Swedish 
Environmental Research Institute Ltd, P.O. Box 53021, SE-400 14 
Gothenburg, Sweden) 
(http://www.diffusivesampling.ivl.se/oursamplers.4.75d7780712240e747ea80004619.html) 
 All devices are already owned by the research team at the Blizard Institute so no purchase 
is required.  
Techniques and Tools: 
Lung function 
This will be measured using MicroMedical MicroLab 3500 Spirometer Mk 8 with a data 
management system compliant with ATS/ERS 2005 guidelines. Flow volume loops are 
displayed for immediate quality control and stored for export to a relational database using 
customised software. Both unadjusted lung function and % predicted values adjusted for 
age, gender and height will be shown, together with variables describing adherence to 
standardised measures of technical quality such as start of test and end of test acceptability 
criteria and forced expiratory time.  
Medicinal products: 
Salbutamol – short-acting β2 agonist which comes in a pressurised inhaler. 
 Indication: Bronchodilator used for reversal of airway obstruction (e.g Asthma, wheeze). 
 Licensed to be used in participants’ age group in the UK. 
 Dose/ Route: 400 micrograms (4 puffs) via inhaler. 
 Storage: stored in room temperature. 
 Side effects: fine tremor, nervous tension, headache, muscle cramps, and palpitation. Other 
side-effects include tachycardia, arrhythmias, peripheral vasodilation, myocardial 
ischaemia, and disturbances of sleep and behaviour. Paradoxical bronchospasm 
(occasionally severe), urticaria, angioedema, hypotension, and collapse have also been 
reported 
Hypertonic Saline (3.5-7%)  
 Indication:  mobilise lower respiratory tract secretions in mucous consolidation (e.g. CF)
 Licensed to be used in participants’ age group in the UK. 
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 Storage: stored in room temperature. 
Side effects: Bronchospasm 
Cyclo-oxygenase inhibitor (Ibuprofen) 
Indication: Mild to moderate pain; pain and inflammation of soft tissue injuries; pyrexia 
with discomfort. 
Licensed to be used in participants’ age group in the UK. 
Dose/ Route: as per British National Formulary (BNF) 
 Child 7-9 years: 200mg 3 times a day, by mouth
 Child 10-11 years: 300mg 3 times a day, by mouth
 Child 12-17 years: 400mg 3 times a day, by mouth




Gastrointestinal discomfort; hypersensitivity; rash (discontinue); skin reactions 
Rare or very rare 
Angioedema; dyspnoea 





Rare or very rare 
acute kidney injury; agranulocytosis; anaemia; constipation; diarrhoea; fatigue; 
fever;  
gastrointestinal disorders; haemorrhage; hypotension; influenza like illness; 
leucopenia; liver disorder; meningitis aseptic (patients with connective-tissue 
disorders such as systemic lupus erythematosus may be especially 
susceptible); oedema; oral disorders; pancytopenia; renal papillary 
necrosis; respiratory disorders; severe cutaneous adverse reactions 
(SCARs); shock; tachycardia; throat pain; thrombocytopenia; vomiting 
Frequency not known 
Crohn's disease; fertility decreased female; fluid retention; heart 
failure; hypertension; increased risk of arterial thromboembolism; renal failure 
(more common in patients with pre-existing renal impairment); respiratory tract 
reaction. 
15. Safety Reporting
Adverse Events (AE) 
An AE is any untoward medical occurrence in a subject to whom a medicinal product has been 
administered, including occurrences which are not necessarily caused by or related to that product. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporarily associated with study activities. 
Notification and reporting Adverse Events or Reactions 
If the AE is not defined as SERIOUS, the AE is recorded in the study file and the participant is 
followed up by the research team. The AE is documented in the participants’ medical notes (where 
appropriate) and the CRF. 
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Serious Adverse Event (SAE) 
This is defined as an untoward occurrence that: 
(a) results in death; 
(b) is life-threatening; 
(c) requires hospitalisation or prolongation of existing hospitalisation; 
(d) results in persistent or significant disability or incapacity; 
(e) consists of a congenital anomaly or birth defect; or 
(f) is otherwise considered medically significant by the investigator. 
 
An SAE occurring to a research participant should be reported to the main REC where in the 
opinion of the Chief Investigator the event was: 
• Related – that is, it resulted from administration of any of the research procedures, and 
• Unexpected – that is, the type of event is not listed in the protocol as an expected occurrence.  
 
Notification and Reporting of Serious Adverse Events  
Serious Adverse Event (SAEs) that are considered to be ‘related’ and ‘unexpected’ are to be 
reported to the sponsor within 24 hours of learning of the event and to the Main REC within 15 days 
in line with the required timeframe. Refer to NRES website and JRMO SOPs for further guidance. 
 
Urgent Safety Measures 
The CI may take urgent safety measures to ensure the safety and protection of the subjects from 
any immediate hazard to their health and safety. The measures should be taken immediately. In 
this instance, the approval of the REC prior to implementing these safety measures is not required. 
However, it is the responsibility of the CI to inform the sponsor and Main Research Ethics 
Committee (via telephone) of this event immediately.  
The CI has an obligation to inform both the Main REC in writing within 3 days, in the form of a 
substantial amendment. The sponsor (Joint Research Management Office [JRMO]) must be sent 
a copy of the correspondence with regards to this matter. Refer to NRES website and JRMO SOPs 
for further guidance. 
 
Annual Safety Reporting  
The CI will send the Annual Progress Report to the main REC using the NRES template (the 
anniversary date is the date on the MREC “favourable opinion” letter from the MREC) and to the 
sponsor. Please see NRES website and JRMO SOP for further information 
 
Overview of the Safety Reporting responsibilities 
The CI/PI has the overall pharmacovigilance oversight responsibility. The CI/PI has a duty to 
ensure that safety monitoring and reporting is conducted in accordance with the sponsor’s 
requirements.  
 
16. Monitoring and Auditing 
 
A data monitoring committee will not be convened. Intermittent random audit of data quality will 
be performed by members of the investigating team under the supervision of the Chief 
investigator (CI). 
 
Research sponsor will ensure arrangements and systems are in place for the management and 
monitoring of research.   
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17. Trial Committees
This study is not a clinical trial – a trial committee is therefore not required. However there will
be a study committee consisting of the Chief Investigator and representatives from the
Research and Development Department – they will meet quarterly to ensure the study is
progressing satisfactorily.
18. Finance and Funding
This study is funded by Barts Charity (grant reference: MGU0312).
19. Indemnity
This study will be sponsored by Queen Mary University of London.  Contact details as
previously stated. Queen Mary University of London will arrange for suitable indemnity for
negligent harm arising as a result of participation in this study to be in place. The protocol will
be evaluated by the Governance Officer, Queen Mary University of London.
20. Dissemination of Research Findings:
Any manuscript reporting study findings will be prepared according to CONSORT guidelines
and submitted to peer-reviewed biomedical journals according to ICMJE Uniform
Requirements. Authorship will be based on individuals’ contribution to study design, conduct,
analysis, drafting/revision of manuscript and final approval of the version to be published.
Authorship will not necessarily be restricted to individuals named on this protocol; neither is
authorship guaranteed to any individual named on this protocol.  Contributors who do not meet
authorship criteria will be listed in ‘Acknowledgements’. The results of the study will be
disseminated to the participants and their family in a patient-engagement meeting towards the
end of the study.
21. Appendix
Appendix 1 – Black Carbon Monitoring: 
https://aethlabs.com/microaeth/ae51/overview 
Appendix 2 – Nitrogen Dioxide Monitoring: 
http://www.diffusivesampling.ivl.se/oursamplers.4.75d7780712240e747ea80004619.html 
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Appendix 5 – CF study: Examples of participant information sheets  
 
  
<CF AGE 16-17> PARTICIPANT INFORMATION SHEET    Version 1.7     30/10/2018 
REC reference: 17/EM/0023 
IRAS number: 215879 




You are being invited to take part in a research study.   Before you decide whether or not 
to take part, it is important for you to understand why the research is being done and what 
it will involve. Please take time to read the following information carefully, and discuss it 
with others if you wish.  
PART 1 tells you the purpose of this study and what will happen to you if you take part. 
PART 2 gives you more detailed information about the conduct of the study. 
Please ask us if there is anything that is not clear, or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
2. What is the purpose of the study? 
i. This study aims to see how the lung cells in children and young people with Cystic 
Fibrosis (CF) are affected by the soot from air pollution (e.g. traffic fumes, cooking 
fumes). We wish to identify children and young people’s sources of pollution 
exposure. 
ii. The findings will then be discussed with children/young people and parents. By 
engaging children/young people and parents, we intend to co-design tips/guidance 
on reduction of CF children/young people’s exposure to air pollution, thereby 
improving their quality of life. 
iii. We will look into whether concentration of certain substances called Prostaglandin 
(their presence can be detected in phlegm and urine) are associated with clearance 
of soot in the lungs.  
iv. We will find out if reducing the concentration of Prostaglandin (using the medication 
Ibuprofen) would improve clearance of soot. 
 
3. Why have I been chosen?  
You have been asked to take part because you have the condition Cystic Fibrosis, and live 
in or around London - London is known to have some of the most polluted air in Western 
Europe. 
 
4. Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you decide you would like to take 
part, then you will be given this information sheet to keep and be asked to sign a consent 
form, to confirm that you understand what is involved when taking part in this study. If you 
decide to take part you are free to leave the study at any time and without giving a reason. 
If you withdraw, unless you object, we will still keep records relating to your participation 
up to that point, as this is valuable to the study. A decision to withdraw at any time, or a 
decision not to take part, will not affect the quality of any care you may require from us in 
the future. 
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5. What will happen to me if I take part?
If you are interested in taking part, trained researchers will arrange a time to meet you at
the Royal London Hospital – this can coincide with your next hospital visit if you have one
pending. We will review your medical record for information such as CF status, baseline
lung function, medications.
We will then ask you to do the following – 
i. We will ask you several questions relating to your potential exposure to air pollutions
(e.g. mode of transport to/from school, presence of smokers at home, etc)
ii. Carrying a small pollution monitor for 24 hours, on 2 separate occasions, along
with a GPS device to map your travel route.
iii. Having 2 small pollution monitor badges for 2 weeks – one attached to your
clothes to detect outdoors pollution exposure, one being placed at home to detect
indoors pollution (e.g. cooking gases).
iv. Lung function – This is the same as you normally do in clinic. It involves blowing
into a machine to test how strong your breathing is. This should not take more than
20 minutes.
v. Induced sputum - Coughing up sputum (mucus and material from the lungs)
into a pot following nebulised hypertonic saline (inhaled salty vapour). This will
be similar to your routine chest physiotherapy. The sample will then be looked
at under a microscope.
vi. Giving a urine sample.
vii. Prostaglandin reduction – you will be offered a standard “over-the-counter” course
(usually 3 days) and dose of Iburprofen – a medication commonly used for fever or
pain; followed by repeat sputum and urine collection.
viii. Attend patients/parents engagement meetings.
We anticipate that you will actively be involved in the study for 2 years overall for sampling 
and monitoring, plus the patients/parents engagement meetings towards the end. 
6. What is the procedure that is being tested?
Carrying a pollution monitor is simple – we have small
pollution monitors that are about the size of juice carton.
They have a hose coming out of them that sucks in air and
measures how much soot there is in the air around you. We
ask you to carry them on your clothes for 24 hours, on 2
separate occasions, along with a GPS device to map your
travel routes, to get an accurate picture of when and where
you are exposed to air pollution.
We will also ask you to attach a small pollution monitoring 
badge to your bag or clothes to monitor the pollution over 2 
weeks. This badge is the size on a 10 pence piece and 
attaches using a small badge pin. There are no special 
instructions for looking after the badge but it should remain for 
2 weeks. If it gets lost, please inform the CF team or the 
research team. A second badge will be placed at home to 
detect any indoor pollution exposure (e.g. cigarette smoke, cooking fumes). 
Pollution Monitoring Badge 
Pollution 
Monitor 
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We will ask you to perform lung function (a test that measures how quickly you can expel 
air from your lungs).  We will then give you four puffs of Salbutamol (blue) inhaler and 
repeat the lung function test.  This reassures us that there is no airway narrowing reactions 
(called bronchospasm) to the next stage of the induction.    
Sputum induction is a way to get a sample of cells from inside the lungs. It is usually well 
tolerated and safe. This is similar to your routine chest physiotherapy. We will ask you to 
put the nozzle of a handheld nebuliser in your mouth and inhale the 
salty vapour it produces. It does not taste unpleasant - it’s a bit like 
standing on a beach near breaking waves – just a bit saltier. After 
some time this salty vapour will soften up the sputum in the lungs 
and you will then be asked to spit this out into a container for 
analysis.  You will be able to pause the inhalation to rinse your 
mouth or blow your nose (it can make your nose run a little) at any 
point.  Most children/ young people complete the procedure well 
within 30 minutes.  We will repeat lung function at appropriate 
intervals during the study.  We will stop the sputum induction at any 
point that you feel uncomfortable. This may be carried out at a time 
and place most convenient to you (e.g. to synchronise with your routine nebuliser/chest 
physiotherapy) – the researcher will discuss the details with you. Depending on the level 
of success, we may ask you to repeat sputum induction on separate occasions, limiting to 
1 sample/day (e.g. baseline state when well, during hospital admission, towards end of 
hospital admission). The research team will discuss with you regarding the number of times 
of sputum induction. 
Urine sampling involves passing a small amount of urine into a pot. This can be done 
privately. 
Ibuprofen is a medication commonly used for fever or pain and is generally well tolerated 
in the general population. If there is no allergies or contra-indications, the research doctor 
will offer you a short standard “over-the-counter” course of Ibuprofen, which will be 
provided by the research team. The dose and course used will be according to the current 
licence of the medication and not require any prescription. 
Participant/Parent engagement meetings will be held following pollution monitoring data 
collection and analysis. The findings will be presented to children/young people and 
parents. We then aim to co-design guidance/tips on air pollution exposure reduction with 
children/young people and parents. 
7. What do I have to do?
If you agree to take part, you can sign a consent form and give it back to any of the CF
doctors or nurses. We will then provide you with the pollution monitors and collect samples.
8. What are the alternatives for testing?
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It is difficult to otherwise get cells from the lungs – previously it would require an anaesthetic 
to obtain samples of cells from unwell children/young people in hospital (and obviously we 
do not want to do that in our air pollution study). 
 
9. What are the side effects of any treatment received when taking part? 
Part of testing lung function involves giving a medication that relaxes the muscles in the 
airways of the lungs – it is called Salbutamol (Ventolin) and comes in a blue inhaler. 
Children with asthma use salbutamol to help their airways/lungs relax when they get “tight-
chested” or “wheezy”. We use salbutamol to measure whether air pollution might be 
making children’s airways slightly narrowed, and to help with the sputum induction (see 
below). Salbutamol is a very safe drug used by thousands of children in the UK. It has mild 
side effects – it can make the heart beat a little faster for a few minutes after inhaling it. 
This effect wears off quickly (after 15-30 minutes) as the body uses up the medication. 
Details on the side effects Ibuprofen can be found in Appendix 1. 
 
10. What are other possible disadvantages and risks of taking part? 
Care should be taken when placing the monitoring badge, in order to avoid accidental 
swallowing hazard.  
Sputum induction will take around 30 minutes.  There is a very slight risk of wheeze 
developing when you inhale the salty solution (hypertonic saline), but this is minimised by 
giving the Salbutamol (blue) inhaler before induction; if wheeze does develop after 
hypertonic saline, we can treat it very quickly by giving more puffs of Salbutamol. We have 
done more than 400 sputum inductions in school children and have not had a problem with 
wheezing, but this is to make you aware that there is a small chance that it could occur. 
Ibuprofen has been used in children for years, it is a well-tolerated medication and most of 
the general population will have been exposed to its usage in infancy or childhood. You 
will only be offered this if there is no allergy or contra-indications, your doctor will go through 
this in details with you. 
Giving a urine sample is quick and easy to do – this can be done in private, or with the help 
of an adult. 
 
11. What are the possible benefits of taking part?  
We hope to show how air pollution affects the airways and lungs of children and young 
people with Cystic Fibrosis. We wish to co-design guidance/tips in reduction of air pollution 
exposure with CF children and parents. This study may influence how we try to reduce air 
pollution exposure and potentially limit its effect on CF children/young people’s lungs. 
 
12. What happens when the research study stops? 
Your samples will be disposed of and your anonymised data will be analysed and published 
in a medical journal. 
 
13. What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your question.  Our contact details can be 
found at the bottom of this sheet. If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure or contact Patient Advice and 
Liaison Service (PALS)  (details are at the end of this sheet). 
Queen Mary University of London has agreed that if you are harmed as a result of your 
participation in the study, you will be compensated, provided that, on the balance of 
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probabilities, an injury was caused as a direct result of the intervention or procedures you 
received during the course of the study. These special compensation arrangements apply 
where an injury is caused to you that would not have occurred if you were not in the study. 
These arrangements do not affect your right to pursue a claim through legal action. 
 
14. Will my taking part in this study be kept confidential? 
Yes.  All the information about your participation in this study will be kept confidential.  The 
details are included in Part 2. 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you would like to participate, please 






15.  What if new information becomes available? 
Sometimes during the course of a study, new information becomes available on the 
procedures that are being studied (such as new techniques for taking samples). If this 
happens, we will tell you about it and discuss with you whether you want to or should 
continue in the study. If you decide to withdraw, you will suffer no adverse effects as a 
result. If you decide to continue in the study you will be asked to sign an updated consent 
form. 
 
On receiving new information, we might consider it to be in your best interests to withdraw 
you from the study. If so, we will explain the reasons and arrange for your care to continue. 
If the study is stopped for any other reason, you will be told why. 
 
16. Will my part in this study be kept confidential? 
You will be allocated a participant ID, which will be used as a code to identify you on all 
study forms and samples. The participant ID, address and contact email/telephone 
numbers will be recorded for the purpose of pollution exposure monitoring, and if 
appropriate, potential house visit to carry out lung function and sputum induction. Data will 
be stored in paper and electronic formats - all de-identified and securely stored within the 
research institute.  
 
If you consent to take part in this study, the records obtained while you are in this study as 
well as related health records will remain strictly confidential at all times. The information 
will be held securely on paper and electronically at the research centre and the Royal 
London Hospital under the provisions of the 1998 Data Protection Act. Your name will not 
be passed to anyone else outside the research team or the sponsor, who is not involved 
in the study.  
 
Data generated will be analysed by the research team at the Blizard institute. Data will be 
securely locked and only accessed by the research team. You sample records will be 
available to people authorised to work on the study but may also need to be made available 
to people authorised by the Research Sponsor, which is the organisation responsible for 
ensuring that the study is carried out correctly.  
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The information collected about you may also be shown to authorised people from the UK 
Regulatory Authority; this is to ensure that the study is carried out to the highest possible 
scientific standards.  All will have a duty of confidentiality to you as a research participant. 
 
If you withdraw consent from further study involvement, we will seek your permission to 
include your sample results within the study.  We will not do so without your permission. 
Unless you object, your data and samples will remain on file and will be included in the 
final study analysis. 
 
In line with Good Clinical Practice guidelines, at the end of the study, your data will be 
securely archived for a minimum of 20 years. Arrangements for confidential destruction will 
then be made.  
 
Queen Mary University of London is the sponsor for this study based in the United 
Kingdom. We will be using information from you in order to undertake this study and will 
act as the data controller for this study. This means that we are responsible for looking 
after your information and using it properly. Queen Mary University of London will keep 
identifiable information about you for 20 years. 
 
Your rights to access change or move your information are limited, as we need to manage 
your information in specific ways in order for the research to be reliable and accurate. If 
you withdraw from the study, we will keep the information about you that we have already 
obtained. To safeguard your rights, we will use the minimum personally-identifiable 
information possible. 
 
You can find out more about how we use your information at http://www.jrmo.org.uk/  
Queen Mary University of London will keep identifiable information about you from this 
study for 20 years after the study has finished. 
 
17.  What will happen to any samples I give? 
Samples will be stored anonymously and processed as stated above, within the Blizard 
Institute. 
The pollution monitoring badges will be analysed in Sweden (IVL Swedish Environmental 
Research Institute Ltd, P.O. Box 53021, SE-400 14 Gothenburg, Sweden). No samples 
will be sent to this location. The devices will only have anonymised data prior to transport. 
 
Sputum and urine samples will be transported to a laboratory in Poland (Department of 
Medicine, Jagiellonian University Medical School, ul. św. Anny 12, 31-008 Kraków, 
Researchers from Queen Mary University of London will collect information from you for 
this research study in accordance with our instructions. 
Queen Mary University of London will keep your name and contact details confidential and 
will not pass this information to Barts Health NHS Trust. Queen Mary University of London 
will use this information as needed, to contact you about the research study, and make 
sure that relevant information about the study is recorded for your care, and to oversee the 
quality of the study. Certain individuals from Barts Health NHS Trust and regulatory 
organisations may look at your medical and research records to check the accuracy of the 
research study. Barts Health NHS Trust will only receive information without any identifying 
information. The people who analyse the information will not be able to identify you and 
will not be able to find out your name, or contact details. 
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Poland). Samples will be anonymised using the participant ID assigned to participants prior 
to transport. 
The samples are likely to be used up for the intended analysis, however, should there be 
remaining samples, 1ml aliquot of the sputum and urine may be stored anonymously in 
case of repeated experiments within the study period. All samples will be discarded at the 
end of the study (if not already discarded at the end of the intended analysis). 
18. What will happen to the results of this study?
The results of the study will be available after it finishes and will usually be published in a
medical journal or be presented at a scientific conference. The data will be anonymous
and none of the children/ young people involved will be identified in any report or
publication. Should you wish to see the results, or the publication, please ask your study
doctor.
19. Who is organising and funding this study?
The study is co-sponsored by Barts and the London School of Medicine, and it is funded
by Barts Charity (https://bartscharity.org.uk/).
20. Who has reviewed the study?
Before any research goes ahead it has to be checked by an independent Research Ethics
Committee. They make sure that the research is fair. This project has been checked by the
East Midlands Nottingham 1 Research Ethics Committee. (REC reference: 17/EM/0023)
21. Contact for further information
You are encouraged to ask any questions you wish, before, during or after your
participation. If you have any questions about the study, please speak to the research
team, who will be able to provide you with up to date information about the
drug(s)/procedure(s) involved. If you wish to read the research on which this study is
based, please ask your research team. If you require any further information or have any
concerns while taking part in the study please contact the research team (contact details
are at the end of this sheet).
If you decide you would like to take part then please read and sign the consent form, which 
will be the only document linking your name to the participant ID. You will be given a copy 
of this information sheet and the consent form to keep. One copy of the consent form will 
be given to you, one copy to be stored in medical records and one copy to be kept within 
the investigator's site file located at Blizard Institute (Queen Mary University of London). 
The investigator site file will be securely locked and only accessed by the research doctors. 
Thank you for taking the time to read this information sheet and to consider this study. 
Research Team: 
Chief Investigator: 
Professor Jonathan Grigg, 07787 550775, j.grigg@qmul.ac.uk 
Research Fellow: 
Dr Norrice Liu, 020 7882 2616, n.liu@qmul.ac.uk 
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For advice about taking part in research in the NHS: 
INVOLVE 
Wessex House 




Telephone: 023 8065 1088 
Textphone: 023 8062 6239 
Fax: 023 8065 2885 
Email: admin@invo.org.uk 
For advice about research and patient issues at The Royal London Hospital and Barts 
Health NHS Trust: 
Patient Advice and Liaison Service (PALS):  
Ground Floor, Front Block  
The Royal London Hospital  
Whitechapel Road  
London E1 1BB   
Tel: 020 7943 1335 
Fax: 020 7377 7361 
Minicom:  020 7943 1350  
E-mail:  PALS@bartshealth.nhs.uk
APPENDIX 1: 
Side effects of Ibuprofen: 
General side-effects 
Uncommon 
Gastrointestinal discomfort; hypersensitivity; rash (discontinue); skin 
reactions 
Rare or very rare 
Angioedema; dyspnoea 





Rare or very rare 
acute kidney 
injury; agranulocytosis; anaemia; constipation; diarrhoea; fatigue; fever; gas
trointestinal disorders; haemorrhage; hypotension; influenza like 
illness; leucopenia; liver disorder; meningitis aseptic (patients with 
connective-tissue disorders such as systemic lupus erythematosus may be 
especially susceptible); oedema; oral disorders; pancytopenia; renal 
papillary necrosis; respiratory disorders; severe cutaneous adverse 
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reactions (SCARs); shock; tachycardia; throat 
pain; thrombocytopenia; vomiting 
Frequency not known 
Crohn's disease; fertility decreased female; fluid retention; heart 
failure; hypertension; increased risk of arterial thromboembolism; renal 
failure (more common in patients with pre-existing renal 




Ai r P oll u ti o n a n d C hil d r e n wi t h C y s ti c Fi b r o si s
Air P oll uti o n a n d C hil dr e n wit h C y sti c Fi br o si s 
( C F 1 2- 1 5)  
C HI L D I N F O R M A TI O N S H E E T v 1. 5  3 0 / 1 0 / 2 0 1 8  
2 8 6  
< C F A G E 1 2- 1 5  > C HI L D I N F O R M A TI O N S H E E T    V er si o n 1. 5   3 0 / 1 0 / 2 0 1 8 
T O B E R E A D B Y P A R E N T S A N D C HI L D A L O N G WI T H P A R E N T I N F O R M A TI O N S H E E T V 1. 6 
R E C r ef er e n c e: 1 7 / E M / 0 0 2 3 
I R A S n u m b er: 2 1 5 8 7 9  
N a m e of r e s e ar c h er: D r N orri c e Li u  
Y o u a r e b ei n g i n vi t e d t o t a k e p a r t i n a r e s e a r c h s t u d y.   B e f o r e y o u d e ci d e w h e t h e r 
o r n o t t o t a k e p a r t, i t i s i m p o r t a n t f o r y o u t o u n d e r s t a n d w h y t h e r e s e a r c h i s b ei n g 
d o n e  a n d  w h a t  i t  will  i n v ol v e.  Pl e a s e  t a k e  ti m e  t o  r e a d  t h e  f oll o wi n g  i n f o r m a ti o n  
c a r e f ull y, a n d di s c u s s i t wi t h y o u r p a r e n t s a n d d o c t o r s .  
R e s e a r c h i s a w a y w e t r y t o fi n d t h e a n s w e r s. 
T hi s  r e s e a r c h  p r o j e c t  i s  l o o ki n g  a t  w h a t  i s  i n  t h e  ai r  w e  b r e a t h e . 
E n gi n e s i n c a r s a n d l o r ri e s b u r n f u el s t h a t c a u s e A I R P O L L U T I O N . 
Ai r p oll u ti o n c a n g e t i n t o t h e c ell s i n y o u r l u n g s.   
W e  a r e  d oi n g  a  R E S E A R C H  p r o j e c t  t o  m e a s u r e  A I R  
P O L L U T I O N i n t h e c ell s i n y o u r l u n g s.  
W e w a n t t o fi n d a n s w e r s f o r t h e s e q u e s ti o n s: 
1.  H o w m u c h ai r p oll u ti o n a r e y o u e x p o s e d t o ?
2.  H o w d o e s ai r p oll u ti o n a f f e c t t h e c ell s i n t h e l u n g s ?
3.  A r e t h e r e c e r t ai n t hi n g s t h a t will m a k e i t m o r e di f fi c ul t f o r y o u r b o d y t o g e t
ri d o f ai r p oll u ti o n ?
W e c h o s e y o u b e c a u s e y o u li v e i n a L o n d o n w hi c h i s a bi g ci t y wi t h l o t s o f c a r s 
a n d t r a f fi c a n d y o u h a v e a c o n di ti o n c all e d C y s ti c Fi b r o si s.   
A s k y o u a n d y o u r p a r e n t s s o m e q u e s ti o n s ? 
T e s t y o u r p e e ? 
A s k y o u t o b r e a t h e i n t o a t u b e t o t e s t y o u r b r e a t hi n g ? 
Gi v e y o u s o m e bl u e p u f f e r a n d....... 
A s k y o u t o b r e a t h e i n s al t y w a t e r v a p o u r, t h e n c o u g h a n d s pi t ? 
A s k y o u t o t a k e a n e w m e di ci n e f o r a f e w d a y s ? 
Ai r P oll u ti o n a n d C hil d r e n wi t h C y s ti c Fi b r o si s
Air P oll uti o n a n d C hil dr e n wit h C y sti c Fi br o si s 
( C F 1 2- 1 5)  
C HI L D I N F O R M A TI O N S H E E T v 1. 5  3 0 / 1 0 / 2 0 1 8  
2 8 7  
I t’ s t o t all y u p t o y o u a n d y o u r p a r e n t s!  
1.  W e will a s k y o u a f e w q u e s ti o n s a b o u t y o u r d ail y a c ti vi ti e s.
2.  W e will a s k y o u t o h el p u s m o ni t o r h o w m u c h Ai r P oll u ti o n y o u a r e
e x p o s e d t o - b y c a r r yi n g a s m all b a g wi t h a p oll u ti o n m o ni t o r i n f o r
2 d a y s a n d 2 ni g h t s, a n d w e a r a s m all b a d g e o n y o u r s c h o ol b a g f o r
2 w e e k s.
3. W e’ r e g oi n g t o a s k y o u t o bl o w i n t o a t u b e t o t e s t h o w s t r o n g y o u r
b r e a t hi n g i s.
4.  Y o u will t h e n b r e a t h e i n s o m e s al t y w a t e r v a p o u r, t h e n c o u g h a n d
s pi t i n t o a p o t, t hi s s h o ul d t a k e n o t m o r e t h a n 3 0 mi n u t e s.
5.  W e will al s o a s k y o u t o p e e i n t o a p o t.
6.  W e  will  a s k  y o u  t o  t a k e  a  n e w  m e di ci n e  f o r  a  f e w  d a y s,  a n d  t h e n
r e p e a t t h e s pi t ti n g a n d p e ei n g i n t o a p o t.
Will  i t  m a k e  m e  f e el  si c k ?  
N o –  t h a t’ s u n u s u al.  
S o m e ti m e s  i t  c a n  m a k e  y o u  w h e e z y  –  s o  w e  will  gi v e  y o u  s o m e  bl u e  
p u f f e r fi r s t. Bl u e p u f f e r c a n m a k e y o u r h e a r t b e a t f a s t e r b u t t h a t’ s 
o k . 
W e t h e n t a k e y o u r s p u t u m  ( s pi t)  a n d  u ri n e  ( p e e)  t o o u r L a b o r a t o r y 
f o r e x p e ri m e n t s …  
W e c a n n o t p r o mi s e t h e s t u d y will h el p y o u b u t t h e i n f o r m a ti o n w e g e t mi g h t h el p u s 
u n d e r s t a n d h o w A I R P O L L U T I O N a f f e c t s c hil d r e n i n t h e f u t u r e.  
I f a t a n y ti m e y o u d o n‘ t w a n t t o d o t h e r e s e a r c h a n y m o r e, j u s t t ell y o u r p a r e n t s, t h e 
d o c t o r o r a n u r s e. N o b o d y will mi n d o r b e u p s e t.  
P oll uti o n 
M o nit or  
P oll uti o n M o nit ori n g  B a d g e  
Ai r P oll u ti o n a n d C hil d r e n wi t h C y s ti c Fi b r o si s
Air P oll uti o n a n d C hil dr e n wit h C y sti c Fi br o si s 
( C F 1 2- 1 5)  
C HI L D I N F O R M A TI O N S H E E T v 1. 5  3 0 / 1 0 / 2 0 1 8  
2 8 8  
I f s o m e t hi n g g o e s w r o n g a n d y o u f e el si c k t ell a g r o w n u p s t r ai g h t a w a y. P e o pl e w h o 
k n o w w h a t t o d o will b e t h e r e t o h el p y o u. 
B e f o r e a n y r e s e a r c h i s all o w e d t o h a p p e n, i t h a s t o b e c h e c k e d b y a 
g r o u p  o f  p e o pl e  c all e d  a  R e s e a r c h  E t hi c s  C o m mi t t e e.  T h e y  m a k e  
s u r e t h a t t h e r e s e a r c h i s f ai r.  
O k!  I’ m  h a p p y  t o  t a k e  p a r t .  
M u m o r D a d o r a G r o w n - u p will s a y y e s o n t h e 
g r o w n  u p  f o r m …  a n d  w e  will  b e  i n  t o u c h  t o 
a r r a n g e t h e n e x t vi si t …  
N o  t h a n k  y o u!  
W e  will  s e e  y o u  n e x t  ti m e,  t h a n k s  f o r  
r e a di n g t hi s …  
C o n t a c t i n f o  
D r N o r ri c e Li u  
E m ail n.li u @ q m ul. a c. u k 
T el: 0 2 0 7 8 8 2 2 6 1 6  
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Appendix 6 – CF study: Examples of consent and assent forms 
Reducing the effects of air pollution on children with cystic fibrosis 
REC reference: 17/EM/0023 IRAS number: 215879 
Name of researcher: Dr Norrice Liu 
CF Participants (Age 16-17) 
Participant ID: __________________ 
CONSENT FORM  





I confirm that I have read and understood the information sheet dated 30 /10/2018 
version 1.7 for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
2 
I understand that my participation is voluntary and that I am free to withdraw at any 
time, wit hout giving a reason, and without my care or legal rights being affected.  
3 
I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by research doctors from Queen Mary University London, 
from regulato ry authorities or from the NHS Trust, where it is relevant for my taking 
part in this research. I give permission for these doctors to have access my records.  
4 I agree to answer questions regarding my exposure to air pollution.  
5 
I agree to use poll ution monitors, including a GPS device, to evaluate my personal 
exposure to air pollution. I understand the monitor badge will be analysed in a 
laboratory in Sweden but the device will only have anonymised data prior to 
transport. 
6 
I agree to have my sp utum and urine samples collected. I understand the urine 
samples and part of the sputum samples will be anonymised and sent to a laboratory 
in Poland for analysis, and all samples will be disposed of by the end of the study.  
7 
I agree to take a standard  over-the-counter course of Ibuprofen, followed by repeat 
sputum and urine collection.  
8 
I agree for my child to take part in this study, he/she will be identified by a participant 
ID within the study.  
Name of Participant Signature Date 
Name of Researcher Signature Date 
Air Pollution and Children with Cystic Fibrosis
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Reducing the effects of air pollution on children with cystic 
fibrosis 
REC reference: 17/EM/0023 
IRAS number: 215879 
Name of researcher: Dr Norrice Liu 
CF Participants (Age 12-15) 
Participant ID: __________________ 
ASSENT FORM 
Participant assent form Version 1.5     30/10/18 Please tick 
1 I have read the information sheet dated 30/10/18 version 1.5 
for the above study. 
2 Somebody else explained this project to me. 
3 I understand what this project is about. 
4 I have asked all the questions I want to. 
5 I understand the answers to my questions. 
6 I understand it is OK to stop taking part at any time. 
7 I am happy to take part. I am happy to give a sputum and a 
urine sample. 
8 I am happy to take the medicine (Ibuprofen) and give another 
sputum (phlegm) and urine (pee) samples. 
If you want to take part in the project, please write your name and today’s date.   
Name of Child   Signature Date 
Thank you so much for your help!!  
Name of Researcher Signature Date 
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Appendix 7 – Ethics approval and correspondence 





Please note:  This is the favourable opinion of the REC only and does not allow  you 
to start your study at NHS  sites in England until you  receive HRA Approval   
24 January 2017 
Professor Jonathan Grigg  
Blizard institute  
Queen Mary University of London 
4 Newark Street, London   
E1 2AT  
Dear Professor Grigg, 
Study title: Reducing the effects of air pollution on children with cystic 
fibrosis  
REC reference: 17/EM/0023 
IRAS project ID: 215879 
Thank you for your letter of 20th January 2017, responding to the Committee’s request for 
further information on the above research and submitting revised documentation.  
The further information has been considered on behalf of the Committee by the Chair. 
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three months 
from the date of this opinion letter.  Should you wish to provide a substitute contact point, 
require further information, or wish to make a request to postpone publication, please 
contact hra.studyregistration@nhs.net outlining the reasons for your request.  
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below.  
Conditions of the favourable opinion 
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The REC favourable opinion is subject to the following conditions being met prior to the 
start of the study.  
  
Management permission must be obtained from each host organisation prior to the start of 
the study at the site concerned.  
  
Management permission should be sought from all NHS organisations involved in the study 
in accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise).   
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.    
  
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be 
sought from the R&D office on the information it requires to give permission for this activity.  
  
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation.   
  
Sponsors are not required to notify the Committee of management permissions from host 
organisations  
  
Registration of Clinical Trials  
  
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees).    
  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as 
part of the annual progress reporting process.  
  
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory.  
  
If a sponsor wishes to request a deferral for study registration within the required 
timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all 
clinical trials will be registered, however, in exceptional circumstances non registration may 
be permissible with prior agreement from the HRA. Guidance on where to register is 
provided on the HRA website.    
  
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable).  
  
Ethical review of research sites  
  




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see "Conditions of the favourable opinion" below).  
  
Non-NHS sites  
  
The Committee has not yet completed any site-specific assessment (SSA) for the non-
NHS research site(s) taking part in this study.  The favourable opinion does not therefore 
apply to any non-NHS site at present. We will write to you again as soon as an SSA 
application(s) has been reviewed. In the meantime no study procedures should be initiated 
at non-NHS sites.  
  
Approved documents  
  
The final list of documents reviewed and approved by the Committee is as follows:  
Document    Version    Date    
Contract/Study Agreement [Sponsorship agreement]   1.0      
Covering letter on headed paper [REC cover letter]   1   19 January 2017   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Sponsor Indemnity]   
1.0      
IRAS Application Form [IRAS_Form_05122016]      05 December 2016  
IRAS Checklist XML [Checklist_20012017]      20 January 2017   
Letter from funder [Barts Charity letter]      14 March 2016   
Letter from sponsor [Sponsorship letter]   1.0   02 December 2016  
Other [Case Report Form]   1.0   19 September 2016  
Other [Chinedu Nwokoro CV]   1.0   19 January 2016   
Other [Air Pollution and CF Protocol]   1.5   19 January 2017   
Other [Cover letter to REC]   1   19 January 2017   
Other [Lone working guidance (NHS)]   1   19 January 2017   
Other [Lone working guidance (QMUL)]   1   19 January 2017   
Participant consent form [Control Consent Form Age 1-6]   1.3   30 November 2016  
Participant consent form [Control Consent Form Age 7-11]   1.3   30 November 2016  
Participant consent form [Control Consent Form Age 12-15]   1.3   30 November 2016  
Participant consent form [CF assent 1-6]   1.1   19 January 2017   
Participant consent form [CF assent 7-11]   1.5   19 January 2017   
Participant consent form [CF assent 12-15]   1.4   19 January 2017   
Participant consent form [Control assent 1-6]   1.2   19 January 2017   
Participant consent form [Control assent 7-11]   1.5   19 January 2017   
Participant consent form [Control assent 12-15]   1.4   19 January 2017   
Participant consent form [CF Consent 1-6]   1.4   19 January 2017   
Participant consent form [CF Consent 7-11]   1.4   19 January 2017   
Participant consent form [CF Consent 12-15]   1.4   19 January 2017   
Participant consent form [CF Consent 16-17]   1.5   19 January 2017   
Participant consent form [Control Consent 1-6]   1.4   19 January 2017   
Participant consent form [Control Consent 7-11]   1.4   19 January 2017   
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Participant consent form [Control Consent 12-15]   1.4   19 January 2017   
Participant consent form [Control Consent 16-17]   1.5   19 January 2017   
Participant information sheet (PIS) [Child PIS CF 7-11]   1.5   19 January 2017   
Participant information sheet (PIS) [Child PIS CF 12-15]   1.4   19 January 2017   
Participant information sheet (PIS) [Child PIS control 7-11]   1.5   19 January 2017   
Participant information sheet (PIS) [Child PIS control 12-15]   1.4   19 January 2017   
Participant information sheet (PIS) [PIS CF 1-6]   1.4   19 January 2017   
Participant information sheet (PIS) [PIS CF 7-11]   1.4   19 January 2017   
Participant information sheet (PIS) [PIS CF 12-15]   1.4   19 January 2017   
Participant information sheet (PIS) [PIS CF 16-17]   1.5   19 January 2017   
Participant information sheet (PIS) [PIS control 1-6]   1.4   19 January 2017   
Participant information sheet (PIS) [PIS control 7-11]   1.4   19 January 2017   
Participant information sheet (PIS) [PIS control 12-15]   1.4   19 January 2017   
Participant information sheet (PIS) [PIS control 16-17]   1.5   19 January 2017   
Sample diary card/patient card [Activity Diary]   1.0   27 September 2016  
Summary CV for Chief Investigator (CI) [Jonathan Grigg CV]         
Summary CV for student [Norrice Liu CV]         
  
Statement of compliance  
  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
  
After ethical review  
  
Reporting requirements  
  
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
  
Notifying substantial amendments  
Adding new sites and investigators  
Notification of serious breaches of the protocol  
Progress and safety reports  
Notifying the end of the study  
  
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.  
  
  
User Feedback  
  
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please use the 
feedback form available on the HRA website:  
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/     
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HRA Training 
We are pleased to welcome researchers and R&D staff at our training days – see details 
at http://www.hra.nhs.uk/hra-training/    
17/EM/0023   Please quote this number on all correspondence 
With the Committee’s best wishes for the success of this project. 
Yours sincerely,  
Mr John Aldridge 
Chair  
Email:   NRESCommittee.EastMidlands-
Nottingham1@nhs.net  
Enclosures: “After ethical review – guidance for 
researchers”  






Professor Jonathan Grigg   Blizard Institute  Email: hra.approval@nhs.net  
Queen Mary University of London  
4 Newark Street, London   
E1 2AT  
  
15 February 2017  
Amended and Reissued 22 February 2017  
  
Dear Professor Grigg,      
  
Letter of HRA Approval  
  
Study title:  Reducing the effects of air pollution on children with 
cystic fibrosis  
IRAS project ID:  215879   
REC reference:  17/EM/0023    
Sponsor  Queen Mary University of London  
  
I am pleased to confirm that HRA Approval has been given for the above referenced study, 
on the basis described in the application form, protocol, supporting documentation and any 
clarifications noted in this letter.   
  
Participation of NHS Organisations in England   
The sponsor should now provide a copy of this letter to all participating NHS organisations 
in England.   
  
Appendix B provides important information for sponsors and participating NHS 
organisations in England for arranging and confirming capacity and capability. Please read 
Appendix B carefully, in particular the following sections:  
Participating NHS organisations in England – this clarifies the types of participating 
organisations in the study and whether or not all organisations will be undertaking the same 
activities  
Confirmation of capacity and capability - this confirms whether or not each type of 
participating NHS organisation in England is expected to give formal confirmation of 
capacity and capability. Where formal confirmation is not expected, the section also 
provides details on the time limit given to participating organisations to opt out of the study, 
or request additional time, before their participation is assumed.  
Allocation of responsibilities and rights are agreed and documented (4.1 of HRA 
assessment criteria) - this provides detail on the form of agreement to be used in the study 
to confirm capacity and capability, where applicable.  
Further information on funding, HR processes, and compliance with HRA criteria and 
standards is also provided.  
  
Page 1 of 9  
It is critical that you involve both the research management function (e.g. R&D office) 
supporting each organisation and the local research team (where there is one) in setting 
up your study. Contact details and further information about working with the research 
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management function for each organisation can be accessed from www.hra.nhs.uk/hra-
approval.   
  
Appendices  
The HRA Approval letter contains the following appendices:  
A – List of documents reviewed during HRA assessment  
B – Summary of HRA assessment  
  
After HRA Approval  
The document “After Ethical Review – guidance for sponsors and investigators”, issued 
with your REC favourable opinion, gives detailed guidance on reporting expectations for 
studies, including:   
Registration of research  
Notifying amendments  
Notifying the end of the study  
The HRA website also provides guidance on these topics, and is updated in the light of 
changes in reporting expectations or procedures.  
  
In addition to the guidance in the above, please note the following:  
HRA Approval applies for the duration of your REC favourable opinion, unless otherwise 
notified in writing by the HRA.  
Substantial amendments should be submitted directly to the Research Ethics Committee, 
as detailed in the After Ethical Review document. Non-substantial amendments should be 
submitted for review by the HRA using the form provided on the HRA website, and emailed 
to hra.amendments@nhs.net.   
The HRA will categorise amendments (substantial and non-substantial) and issue 
confirmation of continued HRA Approval. Further details can be found on the HRA website.  
  
Scope   
HRA Approval provides an approval for research involving patients or staff in NHS 
organisations in England.   
  
If your study involves NHS organisations in other countries in the UK, please contact the 
relevant national coordinating functions for support and advice. Further information can be 
found at http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/.  
   
If there are participating non-NHS organisations, local agreement should be obtained in 
accordance with the procedures of the local participating non-NHS organisation.  
  
User Feedback  
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please email the 
HRA at hra.approval@nhs.net. Additionally, one of our staff would be happy to call and 
discuss your experience of HRA Approval.   
  
HRA Training  
We are pleased to welcome researchers and research management staff at our training 
days – see details at http://www.hra.nhs.uk/hra-training/   
  





HRA Assessor  
Email: hra.approval@nhs.net 
Copy to: Dr Sally Burtles, Barts Health NHS Trust, (Sponsor Contact) 
Ms Elizabeth Clough, Barts Health NHS Trust, (lead NHS R&D Contact) 
Appendix A - List of Documents  
The final document set assessed and approved by HRA Approval is listed below. 
Document Version Date 
Contract/Study Agreement [Sponsorship agreement]  1.0  12 October 2016  
Covering letter on headed paper [REC cover letter]  19 January 2017  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Sponsor Indemnity]   
15 July 2016  
IRAS Application Form [IRAS_Form_05122016] 05 December 2016  
Letter from funder [Barts Charity letter]  14 March 2016  
Letter from sponsor [Sponsorship letter]  2.0  02 December 2016  
Other [Case Report Form]  1.0  19 September 2016 
Other [Chinedu Nwokoro CV]  1.0  19 January 2016  
Other [Air Pollution and CF Protocol]  1.5  19 January 2017  
Other [Lone working guidance (NHS)]  2  01 January 2009  
Other [Lone working guidance (QMUL)]  01 September 2014 
Other [Confirmation from site re Statement of Activities and Schedule 
of Events]   
14 February 2017  
Other [Sponsor confirmation of non-substantial amendment]  15 February 2017  
Participant consent form [Assent Form CF 1 - 6 ]  1.1  30 November 2016  
Participant consent form [Assent Form CF 7 - 11]  1.5  19 January 2017  
Participant consent form [Assent Form CF 12 - 15]  1.4  19 January 2017  
Participant consent form [Assent Form Control 1 - 6]  1.2  19 January 2017  
Participant consent form [Assent Form Control 7 - 11]  1.5  19 January 2017  
Participant consent form [Assent Form Control 12 - 15]  1.4  19 January 2017  
Participant consent form [Consent Form CF 1 - 6]  1.5 14 February 2017  
Participant consent form [Consent Form CF 7 - 11]  1.5  14 February 2017  
Participant consent form [Consent Form CF 12 - 15]  1.5  14 February 2017  
Participant consent form [Consent Form CF 16 - 17]  1.6  14 February 2017  
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Participant consent form [Consent Form Control 1 - 6]   1.5   14 February 2017   
Participant consent form [Consent Form Control 7 - 11 ]   1.5   14 February 2017   
Participant consent form [Consent Form Control 12 - 15 ]   1.5   14 February 2017   
Participant consent form [Consent Form Control 16 - 17 ]   1.6   14 February 2017   
Participant information sheet (PIS) [Child PIS CF 1 - 6]   1.2   20 February 2017   
Participant information sheet (PIS) [Child PIS CF 7 - 11]   1.5   19 January 2017   
Participant information sheet (PIS) [Child PIS CF 12 - 15]   1.4   19 January 2017   
Participant information sheet (PIS) [Child PIS Control 1 - 6]   1.2   20 February 2017   
Participant information sheet (PIS) [Child PIS Control 7 - 11]   1.5   19 January 2017   
Participant information sheet (PIS) [Child PIS Control 12 - 15]   1.4   19 January 2017   
Participant information sheet (PIS) [Parents PIS CF 1 - 6]   1.5   14 February 2017   
Participant information sheet (PIS) [Parents PIS CF 7 - 11]   1.5   14 February 2017   
Participant information sheet (PIS) [Parents PIS CF 12 - 15]   1.5   14 February 2017   
Participant information sheet (PIS) [PIS CF 16 - 17]   1.6   14 February 2017   
Participant information sheet (PIS) [Parents PIS Control 1 - 6]   1.5   14 February 2017   
Participant information sheet (PIS) [Parents PIS Control 7 - 11]   1.5   14 February 2017   
Participant information sheet (PIS) [Parents PIS Control 12 - 15]   1.5   14 February 2017   
Participant information sheet (PIS) [PIS Control 16 - 17]   1.6   14 February 2017   
Sample diary card/patient card [Activity Diary]   1.0   27 September 2016  
Summary CV for Chief Investigator (CI) [Jonathan Grigg CV]      26 October 2016   
Summary CV for student [Norrice Liu CV]      26 October 2016   
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Appendix B - Summary of HRA Assessment  
  
This appendix provides assurance to you, the sponsor and the NHS in England that the 
study, as reviewed for HRA Approval, is compliant with relevant standards. It also provides 
information and clarification, where appropriate, to participating NHS organisations in 
England to assist in assessing and arranging capacity and capability.  
For information on how the sponsor should be working with participating NHS 
organisations in  
England, please refer to the, participating NHS organisations, capacity and 
capability and Allocation of responsibilities and rights are agreed and documented 
(4.1 of HRA assessment criteria) sections in this appendix.   
The following person is the sponsor contact for the purpose of addressing participating 
organisation questions relating to the study:  
  
Name: Dr Sally Burtles   
Email: sponsorsrep@bartshealth.nhs.uk   
  
HRA assessment criteria   




1.1  IRAS application completed 
correctly  
Yes  No comments   
        
2.1  Participant 
information/consent 
documents and consent 
process  
Yes  No comments  
        
3.1  Protocol assessment  Yes  No comments  
        
4.1  Allocation of responsibilities 
and rights are agreed and 
documented   
Yes  This is a non-commercial single site 
study taking place in the NHS where 
that single NHS organisation has 
confirmed that no study agreements 
are required. Therefore no Statement 
of Activities and Schedule of Events 
has been submitted.    
4.2  Insurance/indemnity 
arrangements assessed  
Yes  Where applicable, independent 
contractors (e.g. General 
Practitioners) should ensure that the 
professional indemnity provided by 
their medical defence organisation 
covers the activities expected of them 
for this  






   research study  
4.3  Financial arrangements 
assessed   
Yes  External study funding has been 
secured from Barts Charity.  
        
5.1  Compliance with the Data 
Protection Act and data 
security issues assessed  
Yes  No comments  
5.2  CTIMPS – Arrangements for 
compliance with the Clinical 
Trials Regulations assessed  
Not Applicable  No comments  
5.3  Compliance with any 
applicable laws or 
regulations  
Yes  No comments  
        
6.1  NHS Research Ethics  
Committee favourable 
opinion received for 
applicable studies  
Yes  
  
REC Favourable Opinion was issued 
by the Nottingham 1 Research Ethics 
Committee on the 24th January 2017   
Amended documents were submitted 
on by the researchers to comply with 
HRA Approval standards. These were 
classified by the sponsor as a 
nonsubstantial amendment.   
6.2  CTIMPS – Clinical Trials 
Authorisation (CTA) letter 
received  
Not Applicable  No comments  
6.3  Devices – MHRA notice of no 
objection received  
Not Applicable  No comments  
6.4  Other regulatory approvals 
and authorisations received  
Not Applicable  No comments  
  
Participating NHS Organisations in England  
This provides detail on the types of participating NHS organisations in the study and a statement as to whether 
the activities at all organisations are the same or different.   
This is a non-commercial single site study taking place in the NHS. Therefore there is only 
one site type involved in the research.   
  
If this study is subsequently extended to other NHS organisation(s) in England, an 
amendment should be submitted to the HRA, with a Statement of Activities and Schedule 
of Events for the newly participating NHS organisation(s) in England.   
  
The Chief Investigator or sponsor should share relevant study documents with participating 
NHS organisations in England in order to put arrangements in place to deliver the study. 
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The documents should be sent to both the local study team, where applicable, and the 
office providing the research management function at the participating organisation. For 
NIHR CRN Portfolio studies, the Local LCRN contact should also be copied into this 
correspondence.  For further guidance on working with participating NHS organisations 
please see the HRA website.  
If chief investigators, sponsors or principal investigators are asked to complete site level 
forms for participating NHS organisations in England which are not provided in IRAS or on 
the HRA website, the chief investigator, sponsor or principal investigator should notify the 
HRA immediately at hra.approval@nhs.net. The HRA will work with these organisations to 
achieve a consistent approach to information provision.   
Confirmation of Capacity and Capability 
This describes whether formal confirmation of capacity and capability is expected from participating NHS 
organisations in England. 
NHS organisations in England that are participating in the study will be expected to formally 
confirm their capacity and capability to host this research.    
Following issue of this letter, participating NHS organisations in England may now confirm to 
the sponsor their capacity and capability to host this research, when ready to do so. How 
capacity and capacity will be confirmed is detailed in the Allocation of responsibilities and rights 
are agreed and documented (4.1 of HRA assessment criteria) section of this appendix.   
The Assessing, Arranging, and Confirming document on the HRA website provides further 
information for the sponsor and NHS organisations on assessing, arranging and confirming 
capacity and capability.  
Principal Investigator Suitability 
This confirms whether the sponsor position on whether a PI, LC or neither should be in place is correct for each 
type of participating NHS organisation in England and the minimum expectations for education, training and 
experience that PIs should meet (where applicable). 
A Principal Investigator should be appointed at study sites  
GCP training is not a generic training expectation, in line with the HRA statement on training 
expectations.  
HR Good Practice Resource Pack Expectations 
This confirms the HR Good Practice Resource Pack expectations for the study and the pre-engagement checks 
that should and should not be undertaken 
If members of the external research team will be attending NHS sites to conduct the study 
activities  
detailed at IRAS A18 and A19 they should obtain an Honorary Research Contract for this 
purpose from one NHS organisation, followed by Letters of Access for subsequent 
organisations. This would be on the basis of a Research Passport or an NHS to NHS 
confirmation of pre-engagement checks letter (if NHS employed). Pre-engagement checks 
should confirm standard/enhanced DBS checks, appropriate barred list checks, and 
occupational health clearance.   
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For research team members only administering questionnaires or surveys, a Letter of 
Access based on enhanced DBS checks, appropriate barred list checks and occupational 
health clearance would be appropriate.   
  
Other Information to Aid Study Set-up   
This details any other information that may be helpful to sponsors and participating NHS organisations in England 
to aid study set-up.  










































East Midlands - Nottingham 1 Research Ethics Committee 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
Please note: This is the favourable opinion of the REC only and does not allow the 
amendment to be implemented    at NHS sites in England until  the outcome of the 
HRA  assessment has been  confirmed.   
19 October 2017 
Professor Jonathan Grigg  
Blizard institute  
Queen Mary University of London 
4 Newark street, London 
E1 2AT 
Dear Professor Grigg 
Study title: Reducing the effects of air pollution on children with 
cystic fibrosis  
REC reference: 17/EM/0023 
Amendment number: 1 
Amendment date: 28 September 2017 
IRAS project ID: 215879 
The above amendment was reviewed at the meeting of the Sub-Committee held in 
correspondence on 16 October 2017.   
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation.  
Approved documents  
The documents reviewed and approved at the meeting were: 
Covering letter on headed paper [REC cover letter - 
amendment.docx]   
  28 September 2017 
Notice of Substantial Amendment (non-CTIMP) [CF amendment 
IRAS form final.pdf]   
1  28 September 2017 
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Other [Conversation with applicant over re-consenting.pdf]  05 October 2017  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.6 clean.docx]   
1.6  26 October 2017  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.6 tracking.docx]   
1.6  26 October 2017  
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet.  
Working with NHS Care Organisations 
Sponsors should ensure that they notify the R&D office for the relevant NHS care 
organisation of this amendment in line with the terms detailed in the categorisation email 
issued by the lead nation for the study.  
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
We are pleased to welcome researchers and R & D staff at our Research Ethics Committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/   
17/EM/0023: Please quote this number on all correspondence 
Yours sincerely 
Professor Cris Constantinescu  Chair 
E-mail: NRESCommittee.EastMidlands-Nottingham1@nhs.net
Enclosures: List of names and professions of members who took part 
in the review  
Copy to:  Elizabeth Clough, Barts Health NHS Trust Dr Sally Burtles 
East Midlands - Nottingham 1 Research Ethics Committee  
Attendance at Sub-Committee of the REC meeting on 16 October 2017 
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Committee Members: 
Name Profession Present 
Professor Cris Constantinescu 
(Chair)   
Professor of Clinical 
Neurology   
Yes  
Ms Stephanie  Sampson  PhD Student  Yes  
Also in attendance: 
Name Position (or reason for attending) 
Mr George R. Martin  REC Assistant (Minutes)  
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East Midlands - Nottingham 1 Research Ethics Committee 
The Old Chapel 
Royal Standard Place 
Nottingham 




27 April 2018 
Dr Norrice Liu  
Clinical Research Fellow 
Blizard Institute  
4  Newark Street  
Whitechapel  
E1 2AT  
Dear Dr Liu 
Study title: Reducing the effects of air pollution on children with cystic 
fibrosis  
REC reference: 17/EM/0023 
Amendment number: 2 
Amendment date: 04 April 2018 
IRAS project ID: 215879 
The above amendment was reviewed on 24 April 2018 by the Sub-Committee in 
correspondence.   
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation.  
Decision: No ethical issues.   
Approved documents  
The documents reviewed and approved at the meeting were: 
Please note: This is the 
favourable opinion of the REC 
only and does not allow the 
 amendment to be implemented  
at NHS sites in England until 
the outcome of the HRA 
assessment has been 
confirmed.   
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Document Version Date 
Covering letter on headed paper [REC cover letter - amendment 2 
04132018.docx]   
N/a  04 April 2018  
Notice of Substantial Amendment (non-CTIMP)  
[AmendmentForm_ReadyForSubmission 20180416.pdf]  
2  04 April 2018  
Other [Bronchiectasis assent form (7-11).docx]  1.0  04 April 2018  
Other [Bronchiectasis assent form (12-15).docx]  1.0  04 April 2018  
Participant consent form [Bronchiectasis consent form (7-11).docx]   1.0  04 April 2018  
Participant consent form [Bronchiectasis consent form (12-15).docx] 1.0  04 April 2018  
Participant consent form [Bronchiectasis consent form (16-17).docx] 1.0  04 April 2018  
Participant information sheet (PIS) [Bronchiectasis child info sheet (7-
11) clean.docx]
1.0  04 April 2018  
Participant information sheet (PIS) [Bronchiectasis child infor sheet 
(12-15) clean.docx]   
1.0  04 April 2018  
Participant information sheet (PIS) [Bronchiectasis info sheet (1215) 
clean.docx]   
1.0  04 April 2018  
Participant information sheet (PIS) [Bronchiectasis infor sheet (1617) 
clean.docx]   
1.0  04 April 2018  
Participant information sheet (PIS) [Bronchiectasis info sheet (7-11) 
clean.docx]   
1.0  04 April 2018  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.7 clean.docx]   
1.7  04 April 2018  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.7 tracking.docx]   
1.7  04 April 2018  
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet.  
Working with NHS Care Organisations 
Sponsors should ensure that they notify the R&D office for the relevant NHS care 
organisation of this amendment in line with the terms detailed in the categorisation email 
issued by the lead nation for the study.  
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
We are pleased to welcome researchers and R & D staff at our Research Ethics Committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/   




Ellen Milazzo Chair 
E-mail: NRESCommittee.EastMidlands-Nottingham1@nhs.net
Enclosures:  List of names and professions of members who took part in the review 
Copy to:  Elizabeth Clough, Barts Health NHS Trust  
Dr Norrice Liu, Blizard Institute  
East Midlands - Nottingham 1 Research Ethics Committee 
Attendance at Sub-Committee of the REC meeting on 24 April 2018 
Committee Members: 
Name Profession Present 
Dr Sarah Forster  Respiratory Registrar  Yes  
Ms Ellen Milazzo (Chair) Development and Change 
Management Consultant   
Yes  
Also in attendance: 
Name Position (or reason for attending) 
 Ellena Stansbury REC Assistant  (Minutes) 
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East Midlands - Nottingham 1 Research Ethics Committee 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
Please note: This is the favourable opinion of the REC only and does not allow the 
amendment to be implemented    at NHS sites in England until  the outcome of the 
HRA  assessment has been  confirmed.   
17 September 2018 
Dr Norrice Liu  
Clinical Research Fellow 
Blizard Institute  
4  Newark Street  
Whitechapel  
E1 2AT  
Dear Dr Liu 
Study title: Reducing the effects of air pollution on children with cystic 
fibrosis  
REC reference: 17/EM/0023 
Amendment number: 3 
Amendment date: 23 August 2018 
IRAS project ID: 215879 
The above amendment was reviewed on 11 September 2018 by the Sub-Committee in 
correspondence.   
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation.  
Decision: No ethical issues. 
Approved documents  
Document Version Date 
Covering letter on headed paper [REC cover letter - amendment 3  23 August 2018  
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The documents reviewed and approved at the meeting were: 
3.docx]
Notice of Substantial Amendment (non-CTIMP) 
[AmendmentForm_snapshot20180823.pdf]  
3  23 August 2018  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.8 tracking.docx]   
1.8  25 June 2018  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.8 clean.docx]   
1.8  25 June 2018  
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet.  
Working with NHS Care Organisations 
Sponsors should ensure that they notify the R&D office for the relevant NHS care 
organisation of this amendment in line with the terms detailed in the categorisation email 
issued by the lead nation for the study.  
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
We are pleased to welcome researchers and R & D staff at our Research Ethics Committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/   
17/EM/0023: Please quote this number on all correspondence 
Yours sincerely 
Pp  
Mr Murthy Nyasavajjala Chair 
E-mail: NRESCommittee.EastMidlands-Nottingham1@nhs.net
Enclosures: List of names and professions of members who took part 
in the review  
Copy to:  Elizabeth Clough, Barts Health NHS Trust Dr Norrice Liu, 
Blizard Institute  
East Midlands - Nottingham 1 Research Ethics Committee 
Attendance at Sub-Committee of the REC meeting on 11 September 2018 
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Committee Members: 
Name Profession Present  Notes 
Dr Blerina Kellezi  Lecturer in Psychology  Yes  
Mr Murthy Nyasavajjala  Consultant Upper GI and 
General Surgery   
Yes  
Also in attendance: 
Name Position (or reason for attending) 
 Ellena Stansbury REC Assistant 
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East Midlands - Nottingham 1 Research Ethics Committee 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
Please note: This is the favourable opinion of the REC only and does not allow the 
amendment to be implemented    at NHS sites in England until  the outcome of the 
HRA  assessment has been  confirmed.   
08 January 2019 
Dr Norrice Liu  
Clinical Research Fellow 
Blizard Institute  
4 Newark Street  
Whitechapel  
E1 2AT  
Dear Dr Liu, 
Study title: Reducing the effects of air pollution on children with cystic 
fibrosis  
REC reference: 17/EM/0023 
Amendment number: 4 
Amendment date: 17 December 2018 
IRAS project ID: 215879 
The above amendment was reviewed on 03 January 2019 by the Sub-Committee in 
correspondence.   
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation.  
Decision: No ethical issues. 
Approved documents  
Document Version Date 
Covering letter on headed paper [REC cover letter - amendment 4 
.docx]   
4  15 November 2018  
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The documents reviewed and approved at the meeting were:  
  
 
Notice of Substantial Amendment (non-CTIMP)  
[AmendmentForm_ReadyForSubmission20181217.pdf]   
4   17 December 2018   
Participant consent form [Bronchiectasis assent form (12-15) v1.1 
clean.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis assent form (12-15) v1.1 
tracking.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis assent form (7-11) v1.1 
clean.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis assent form (7-11) v1.1 
tracking.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis consent form (12-15) v1.1 
tracking.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis consent form (16-17) v1.1 
clean.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis consent form (16-17) v1.1 
tracking.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis consent form (7-11) v1.1 
clean.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis consent form (7-11) v1.1 
tracking.docx]   
1.1   30 October 2018   
Participant consent form [Bronchiectasis consent form (12-15) v1.1 
clean.docx]   
1.1   30 October 2018   
Participant consent form [CF assent form (12-15) v1.5 clean 
REC.docx]   
1.5   30 October 2018   
Participant consent form [CF assent form (12-15) v1.5 tracking 
REC.docx]   
1.5   30 October 2018   
Participant consent form [CF assent form (7-11) v1.6 clean 
REC.docx]   
1.6   30 October 2018   
Participant consent form [CF assent form (7-11) v1.6 tracking 
REC.docx]   
1.6   30 October 2018   
Participant consent form [CF Consent Form (12-15) REC v1.6 
clean.docx]   
1.6   30 October 2018   
Participant consent form [CF Consent Form (12-15) REC v1.6 
tracking.docx]   
1.6   30 October 2018   
Participant consent form [CF Consent Form (16-17) REC v1.7 
clean.docx]   
1.7   30 October 2018   
Participant consent form [CF Consent Form (16-17) REC v1.7 
tracking.docx]   
1.7   30 October 2018   
Participant consent form [CF study info sheet (7-11) v1.6 
cleanHRA.docx]   
1.6   30 October 2018   
Participant consent form [CF study info sheet (7-11) v1.6 tracking 
HRA.docx]   
1.6   30 October 2018   
Participant consent form [CF Consent Form (7-11) REC v1.6 
clean.docx]   
1.6   30 October 2018   
Participant consent form [CF Consent Form (7-11) REC v1.6 
tracking.docx]   
1.6   30 October 2018   
Participant consent form [Control assent form (7-11) v1.6 
cleanREC.docx]   
1.6   30 October 2018   
Participant consent form [Control Consent Form (7-11) REC v1.6 
clean.docx]   
1.6   30 October 2018   
Participant consent form [Control Consent Form (7-11) REC v1.6 
tracking.docx]   
1.6   30 October 2018   
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Participant consent form [Control Consent Form (12-15) REC v1.6 
clean.docx]   
1.6   30 October 2018   
Participant consent form [Control assent form (7-11) v1.6 
trackingREC.docx]   
1.6   30 October 2018   
Participant consent form [Control assent form (12-15) v1.5 clean 
REC.docx]   
1.5   30 October 2018   
 
Participant consent form [Control assent form (12-15) v1.5 tracking 
REC.docx]   
1.5   30 October 2018   
Participant consent form [Control Consent Form (16-17) REC v1.7 
clean.docx]   
1.7   30 October 2018   
Participant consent form [Control Consent Form (16-17) REC v1.7 
tracking.docx]   
1.7   30 October 2018   
Participant consent form [Control Consent Form (12-15) REC v1.6 
tracking.docx]   
1.6   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis child info sheet (7-
11) v1.1 clean.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis child info sheet (7-
11) v1.1 tracking.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis child infor sheet 
(12-15) v1.1 clean.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis info sheet (7-11) 
v1.1 clean.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis info sheet (7-11) 
v1.1 tracking.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis info sheet (1215) 
v1.1 clean.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis child infor sheet 
(12-15) v1.1 tracking.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [CF child info sheet (7-11) REC 
v1.1 tracking.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [CF child info sheet (7-11) REC 
v1.1 tracking.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [CF child info sheet (12-15) REC 
v1.1 clean.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis info sheet (1215) 
v1.1 tracking.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis infor sheet (1617) 
v1.1 clean.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [Bronchiectasis infor sheet (1617) 
v1.1 tracking.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [CF study info sheet (12-15) v1.6 
clean HRA.docx]   
1.6   30 October 2018   
Participant information sheet (PIS) [CF child info sheet (12-15) REC 
v1.1 tracking.docx]   
1.1   30 October 2018   
Participant information sheet (PIS) [CF study info sheet (control 711) 
v1.6 trackingHRA.docx]   
1.6   30 October 2018   
Participant information sheet (PIS) [CF study info sheet (control 1215) 
v1.6 clean HRA.docx]   
1.6   30 October 2018   
Participant information sheet (PIS) [CF study info sheet (control 1215) 
v1.6 tracking HRA.docx]   
1.6   30 October 2018   
Participant information sheet (PIS) [CF study info sheet (control 1617) 
v1.7 cleanHRA.docx]   
1.7   30 October 2018   
Participant information sheet (PIS) [CF study info sheet (control 1617) 
v1.7 trackingHRA.docx]   
1.7   30 October 2018   
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Participant information sheet (PIS) [CF study info sheet (12-15) v1.6 
tracking HRA.docx]   
1.6  30 October 2018  
Participant information sheet (PIS) [CF study info sheet (16-17) v1.7 
clean HRA.docx]   
1.7  30 October 2018  
Participant information sheet (PIS) [CF study info sheet (16-17) v1.7 
tracking HRA.docx]   
1.7  30 October 2018  
Participant information sheet (PIS) [CF study info sheet (control 711) 
v1.6 cleanHRA.docx]   
1.6  30 October 2018  
Participant information sheet (PIS) [Control child infor sheet (12-15) 
REC v1.1 clean.docx]   
1.1  30 October 2018  
Participant information sheet (PIS) [Control child infor sheet (12-15) 
REC v1.1 tracking.docx]   
1.1  30 October 2018  
Participant information sheet (PIS) [Control child infor sheet (7-11) 
REC v1.1 clean.docx]   
1.1  30 October 2018  
Participant information sheet (PIS) [Control child infor sheet (7-11) 
REC v1.1 tracking.docx]   
1.1  30 October 2018  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.9 clean.docx]   
1.9  30 October 2018  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.9 tracking .docx]   
1.9  30 October 2018  
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet.  
Working with NHS Care Organisations 
Sponsors should ensure that they notify the R&D office for the relevant NHS care 
organisation of this amendment in line with the terms detailed in the categorisation email 
issued by the lead nation for the study.  
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
We are pleased to welcome researchers and R & D staff at our Research Ethics Committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/   
17/EM/0023: Please quote this number on all correspondence 
Yours sincerely 
Pp  
Professor Cris Constantinescu Chair 
E-mail: NRESCommittee.EastMidlands-Nottingham1@nhs.net
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Enclosures: List of names and professions of members who took part 
in the review  
Copy to:  Elizabeth Clough, Barts Health NHS Trust Dr Norrice Liu, 
Blizard Institute  
East Midlands - Nottingham 1 Research Ethics Committee 
Attendance at Sub-Committee of the REC meeting on 03 January 2019 
Committee Members: 
Name Profession Present 
Professor Cris Constantinescu (Chair) Professor of Clinical Neurology Yes  
Mr Murthy Nyasavajjala  Consultant Upper GI and General 
Surgery   
Yes  
Also in attendance: 
Name Position (or reason for attending) 




East Midlands - Nottingham 1 Research Ethics Committee  
The Old Chapel  
Royal Standard Place  
Nottingham  
NG1 6FS  
  
Please note: This is the favourable opinion of the REC only and does not allow the  
amendment to be implemented at NHS sites in England until  the outcome of the 
HRA  assessment has been  confirmed.   
   
  
  
28 February 2019  
  
Dr Norrice Liu  
Clinical Research Fellow  
Blizard Institute  
4  Newark Street  
Whitechapel  
E1 2AT  
  
  
Dear Dr Liu  
  
Study title:  Reducing the effects of air pollution on children with cystic 
fibrosis  
REC reference:  17/EM/0023  
Amendment number:  5  
Amendment date:  04 February 2019  
IRAS project ID:  215879  
  
The above amendment was reviewed on 26 February 2019 by the Sub-Committee in 
correspondence.   
  
Ethical opinion  
  
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation.  
  
The Sub-Committee agreed that the substantial amendment did not raise any material 
ethical issues. However, did ask for some clarity to be provided via email to the below 
queries.   
  
Will the researcher actively reach out to this healthy cohort via the various organisations 
mentioned and if so, how will this be achieved?  
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Equally, does the team hope to recruit via self-referral method or a mixture of the two? 
Approved documents  
The documents reviewed and approved at the meeting were: 
Document Version Date 
Covering letter on headed paper [REC cover letter - amendment 5 
.docx]   
5  04 February 2019  
Notice of Substantial Amendment (non-CTIMP)  
[AmendmentForm_ReadyForSubmission20190208.pdf]  
5  04 February 2019  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.10 tracking.docx]   
1.10 04 February 2019  
Research protocol or project proposal [Air Pollution and CF Protocol 
1.10 clean.docx]   
1.10 04 February 2019  
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet.  
Working with NHS Care Organisations 
Sponsors should ensure that they notify the R&D office for the relevant NHS care 
organisation of this amendment in line with the terms detailed in the categorisation email 
issued by the lead nation for the study.  
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
We are pleased to welcome researchers and R & D staff at our Research Ethics Committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/   
17/EM/0023: Please quote this number on all correspondence 
Yours sincerely 
Pp  
Professor Cris Constantinescu Chair 
E-mail: NRESCommittee.EastMidlands-Nottingham1@nhs.net
Enclosures: List of names and professions of members who took part 
in the review  
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Copy to:   Elizabeth Clough, Barts Health NHS Trust Dr Norrice Liu, 
Blizard Institute 
East Midlands - Nottingham 1 Research Ethics Committee  
Attendance at Sub-Committee of the REC meeting on 26 February 2019 
Committee Members: 
Name Profession Present 
Professor Cris Constantinescu (Chair) Professor of Clinical Neurology Yes  
Mrs Norma Thompson  Clinical Research Nurse  Yes  
Also in attendance: 
Name Position (or reason for attending) 
 Ellena Stansbury REC Assistant  (Minutes) 
Air Pollution Particles in Placenta (APPIP) 
Version 1.5  24/04/2019           Air Pollution Particles in Placenta (APPIP) 321 
Appendix 8 – Protocol: Air pollution particles in placenta (APPIP) 
1. GENERAL INFORMATION
Full Title Presence of Air Pollution Particles in Placental Macrophages 
Short Title/Acronym Air Pollution Particles in Placenta (APPIP) 
Sponsor: Queen Mary, University of London 
Dr Mays Jawad, R&D operations manager 
Joint Research Management Office 
Queen Mary Innovation Centre 
5 Walden Street 
London, E1 2EF 
Tel: 020 7882 7275 
Email: sponsorsrep@bartshealth.nhs.uk 
REC reference: 17/NW/0092 
IRAS project ID: 219053 
Chief Investigator: Professor Jonathan Grigg 
Centre for Paediatrics, Blizard Institute 
4 Newark Street, London E1 2AT, UK 
Tel: 02078822206 
Fax: 02078825555  
Email: j.grigg@qmul.ac.uk 
Principal Investigator: Dr Norrice Liu 
Centre for Paediatrics, Blizard Institute 
4 Newark Street, London E1 2AT, UK 
Tel: 02078822616 
Fax: 02078825555  
Email: n.liu@qmul.ac.uk 
Co-Investigator: Professor Shakila Thangaratinam 
Women's Health Research Unit 
Multidisciplinary Evidence Synthesis Hub (MESH) 
The Blizard Institute  
4 Newark Street, London E1 2AT, UK 
Mobile: 07887775891 
Email: s.thangaratinam@qmul.ac.uk 
Sites/ Organisations: Barts and The London School of Medicine and Dentistry 
Centre for Paediatrics  
Blizard Institute 
4 Newark Street 
London E1 2AT, United Kingdom 
Barts Health NHS Trust, Royal London Hospital 
Whitechapel Road 
London E1 1BB, United Kingdom 
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Laboratory: Blizard Institute 
4 Newark Street 
London E1 2AT 
United Kingdom 
Tel:  020 7882 2483 
Funder: Barts Charity 
Ground Floor 
12 Cock Lane 
London, EC1A 9BU 
Tel: 02076181717  
Fax: 02072489395 
Emails: blcharity@bartshealth.nhs.uk 
Grant Reference: MGU0312 
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2. GLOSSARY  of Terms and Abbreviations 
 
 
AE   Adverse Event 
AM   Airway macrophage   
AR   Adverse Reaction 
ASR   Annual Safety Report 
BC   Black Carbon 
CA   Competent Authority 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
GAfREC Governance Arrangements for NHS Research Ethics Committees 
ICF   Informed Consent Form 
IUGR   Intra-uterine growth restriction 
JRMO   Joint Research Management Office 
NHS REC  National Health Service Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
Participant  An individual who takes part in a clinical trial 
PI   Principal Investigator 
PIS   Participant Information Sheet  
PM   Particulate Matter 
QA   Quality Assurance 
QC   Quality Control 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAE   Serious Adverse Event 
SDV   Source Document Verification 
SOP   Standard Operating Procedure  
SSA   Site Specific Assessment 
TMG   Trial Management Group 
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3. SIGNATURE PAGE
Chief Investigator Agreement 
The clinical study as detailed within this research protocol (Version 1.5, dated 24/04/2019), or any 
subsequent amendments will be conducted in accordance with the Research Governance 
Framework for Health & Social Care (2005), the World Medical Association Declaration of Helsinki 
(1996) and the current applicable regulatory requirements and any subsequent amendments of the 
appropriate regulations. 
Chief Investigator Name: Professor Jonathan Grigg 
Chief Investigator Site: Blizard Institute, Queen Mary University of London 
Signature and Date:     24/04/2019 
Principal Investigator Agreement (if different from Chief investigator) 
The clinical study as detailed within this research protocol (Version 1.5, dated 24/04/2019), or any 
subsequent amendments will be conducted in accordance with the Research Governance 
Framework for Health & Social Care (2005), the World Medical Association Declaration of Helsinki 
(1996) and the current applicable regulatory requirements and any subsequent amendments of the 
appropriate regulations. 
Principal Investigator Name: Dr Norrice Liu 
Principal Investigator Site: Blizard Institute, Queen Mary University of London 
Signature and Date:     24/04/2019 
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4. SUMMARY/SYNOPSIS
Short Title Air Pollution Particles in Placenta (APPIP) 
Methodology Pilot cross sectional study 
Research Sites  Barts Health NHS Trust
 Blizard Institute, Queen Mary University of London
Objectives/Aims To establish whether maternal exposure to black carbon 
will result in its presence in placental cells 
Number of 
Participants/Patients 
20 expectant mothers will be recruited for placental 
retrieval at delivery 
Main Inclusion Criteria 1. Uncomplicated term pregnancy (>37 week
gestation)




Analysis (if applicable) 
This is a pilot study. 20 participants will be a feasible 
number regarding time and cost. 
Proposed Start Date 21/11/2016 
Proposed End Date 20/11/2020 
Study Duration 4 years 
Air Pollution Particles in Placenta (APPIP)  
 






Microscopic particles of soot (particulate matter, PM) from petrol and diesel engine 
emissions are linked to a wide range of adverse health effects.  
 
Antenatal health of the baby is closely related to maternal health. Exposure to air pollution 
during pregnancy can affect foetal and postnatal development. Foetal cells are fast 
replicating and are therefore sensitive to external factors. Airway development begins at 4 
weeks of gestation with alveolar development starting at around 36 weeks to early 
adulthood. Exposure to air pollution can disturb alveolarisation, leading to impaired lung 
development and function (1,2). Previous studies have reported a link between maternal 
pollution exposure and adverse birth outcomes such as increased infant mortality, lower 
birth weight, impaired lung function and later respiratory problems (3,4). Possible 
mechanisms include particle translocation across tissue barriers or particle penetration 
across cellular membranes (3). Potential trans-placental transfer of nanomaterials up to 
240nm was shown to be possible (5).  
 
Removal of PM involves phagocytosis by macrophages, this usually takes place in the 
airway following PM inhalation. One established way of assessing air pollution exposure is 
quantifying the amount of black carbon (BC) in airway macrophages (AM).  
 
Similar idea can be applied to the defense mechanism within the placenta. Many 
macrophages are present in the placenta, they can be detected early in the first trimester. 
Placental macrophages assist in host defense as well as placental development and 
maintenance of pregnancy (6). Any presence of black carbon should theoretically be 
phagocytosed by placental macrophages. 
 
Rationale 
To date, presence of PM in the placenta has not been studied. This pilot study will look into 
whether maternal exposure to PM, particularly black carbon, will result in trans-placental 
transfer, thereby having possible direct casual effect on birth outcomes.  
 




Primary Objective  
 
I. To establish whether maternal exposure to black carbon will result in its presence 
in placental cells. 
II. To establish whether there is a link between concentrations of maternal exposure 
to air pollution to the amount of black carbon in placental cells. 
 
Primary Endpoint  
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5. METHODOLOGY
Inclusion Criteria 
1. Term pregnancy (≥37 week gestation)






c. Intra-uterine growth restriction (IUGR)
2. Abnormal placental perfusion – reduced, absent or reversed end diastolic flow on Doppler
study
3. Maternal request to take placenta home
Study Design / Plan 
Participants (20 in total) will be expectant mothers, with an uncomplicated pregnancy, who proceed 
to term delivery by elective Caesarean section. They will be recruited from the maternity unit at the 
Royal London Hospital. Potential participants will be identified and approached in the first instance 
by a member of their usual clinical care team. A research physician will then review and ensure 
each participant meets the eligibility criteria before entering into the study. With informed consent, 
provided the placenta is not needed for other medical purposes, the placenta will be retrieved from 
the operating theatre immediately after delivery. The participant will be asked to wear a nitrogen 
dioxide diffusion monitor on their clothes for 2 weeks. 
Duration of participation will start from recruitment antenatally to the delivery of the placenta 
(maximum 9 months). 
Study Scheme Diagram 
Review of medical notes by Obstetrics 
team to ensure still meeting criteria of 
study before delivery 
Participant Written 
Informed Consent 
Participant Enrolment  
Nitrogen Dioxide monitoring 
Placenta retrieval from operating theatre 
Elective Caesarean section on 
the same day 
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6. STUDY PROCEDURES
Participants (10 in total) will be expectant mothers, with an uncomplicated pregnancy, who 
proceed to term delivery (at least 37 weeks of pregnancy) by planned Caesarean section. 
Pregnant women will be recruited from the maternity unit at the Royal London Hospital.  
Enrolment 
Potential participants will be identified and approached by a member of their usual clinical care 
team. A study physician will then review and ensure each participant meets the eligibility criteria 
before enrolling into the study. 
Informed Consent Procedures 
Once participants are identified as eligible, patient information sheets will be given to them on the 
day of their elective Caesarean section. Informed consent will be gained from participants on the 
same day. At the Royal London Hospital, patients are often asked to attend the hospital at 7am 
on the morning of surgery and will therefore have a few hours on the ward before heading to the 
operating theatre. Their partners will often accompany them - this presents an opportunity to 
explain to both the patient and their partner about the study, allowing them to consider and ask 
questions before consenting. 
Procedure for Collecting Data 
As part of the consent form, participants will be informed that their medical records will be 
reviewed by their direct care team and the research doctors, in order to ensure they fit the study 
criteria - this will only take place after obtaining informed consent. All participants will be allocated 
a participant ID which will be used to label samples within the study. The only document linking 
their personal information and participant ID is the consent form – one copy will be given to the 
participant, one copy will be kept in their medical records and one copy will be kept in the 
investigator’s site file, securely stored within the Blizard Institute, accessed only by the research 
team. No other information from the participants will be used.  
Subject withdrawal 
Should participants withdraw consent from further study involvement, we will seek their 
permission to include their sample results within the study.  Unless they object, the data from their 
samples will remain on file and will be included in the final study analysis. 
In line with Good Clinical Practice guidelines, at the end of the study, the results data will be 
securely archived for a minimum of 20 years. Arrangements for confidential destruction will then 
be made.  
Schedule of intervention 
Participants will be asked to wear a Nitrogen Dioxide Diffusion Monitor badge on their clothes for 
2 weeks after informed consent. Medical notes will be reviewed by the research doctor prior to 
delivery to ensure all inclusion/ exclusion criteria still apply. Following delivery of the placenta, it 
will be washed and transferred in a specimen jar at 40C to the Blizard Institute for processing.  
Following analysis, the findings of the study will be shared with the participants and their direct 
care team. 
Assessment Recruitment phase Placenta retrieval (Delivery) 
Dissemination of information 
leaflets 
x 
Informed consent x 
Nitrogen Dioxide Monitoring x 
Placenta collection x 
End of Study Definition 
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End of study will be when data collection is complete. Participants' participation will 
complete before this - their participation will end when placenta is retrieved and nitrogen 
dioxide monitoring has completed. 
It is not anticipated that there will be cause for premature termination of the study.  Should any 
subject experience a serious adverse event (AE) associated with or attributable to any study 
procedure, the study status will then be reviewed. 
The project will be part of the Principle Investigator (Dr Norrice Liu)'s PhD degree, under the 
supervision of Chief Investigator (Professor Jonathan Grigg). Principle Investigator (Dr Norrice 
Liu) and Co-Investigator (Professor Shakila Thangaratinam) will undertake the roles of providing 
information regarding study (information sheets) and obtaining informed consent. Principle 
Investigator (Dr Norrice Liu) will sample and process the placentas, and analyse data. 
STATISTICAL CONSIDERATIONS 
The main objective of this pilot study is to detect the presence of black carbon in placental 
macrophages. This study aims to generate data for hypothesis testing, therefore a formal sample 
size calculation has not been done.  The aim is to generate data to inform a subsequent larger 
study, if black carbon is detected in placental macrophages.   
In the time period of the study, recruitment of 20 pregnant women is feasible. Since this is a pilot 
study, the study population will not be representative of the general population. The 20 participants 
will be the first 20 pregnant women who are eligible for the study, who provide informed consent, 
during the recruitment phase. 
ETHICS 
No significant ethical, legal or management issues expected for this project. The procedures 
proposed in the project are ethically acceptable. 
Ethical Review 
The protocol will be reviewed both within the Sponsor Institution and by an independent research 
ethics committee.  All the techniques are ethically acceptable. 
Rationale for research 
Ethical research must be informed by existing research, and investigate an important 
question. We have addressed this issue by thorough review of the existing literature, and 
by conducting appropriate background studies. 
Design of research 
Ethical research must employ the most appropriate design in order to answer the 
research question.  A cross-sectional study design has been chosen for this study. 
Minimisation of inconvenience, discomfort and risk for participants 
Ethical research must seek to minimize potential inconvenience, discomfort and risk that 
participants may experience during the course of a study. The principle inconveniences of the 
study to the participants are minimised through use of qualified and trained practitioners to collect 
placenta specimens. Inconvenience is further reduced by recruiting participants during their 
routine hospital visits, and by performing sampling immediately after delivery.  
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SAFETY CONSIDERATIONS: 
No additional risks or harm are anticipated on the participants. 
Investigator safety 
Investigators will prevent personal exposure to airborne or blood-borne infectious organisms by 
appropriate use of masks, goggles, lab coats and gloves while obtaining and processing samples. 
DATA HANDLING AND RECORD KEEPING: 
Confidentiality 
Ethical research projects should ensure that participants' personal data remain confidential. Our 
procedures for handling, processing, storage and destruction of data are compliant with the Data 
Protection Act 1998. Participants will be allocated a participant ID which will be used as a code to 
identify them on all study samples. The only document that will link the participant’s personal details 
with the participant ID is the consent form, which will have 3 copies – one to be given to the patient, 
one to be kept in their medical records, one to be kept in the investigator’s site files which will be 
locked in a cabinet within the Blizard institute, only accessed by research team. Data will be stored 
in paper and electronic formats. Data stored on university computers will be de-identified. For Audit 
purposes, Sponsors/monitors will need to view information. 
Record Retention and Archiving 
Data stored in university computers will be anonymised. In line with Good Clinical Practice 
guidelines, at the end of the study, data will be securely archived for a minimum of 20 
years. Arrangements for confidential destruction will then be made.  
LABORATORIES  
Blizard Institute, London 
Lab Procedures 
Following elective Caesarean section, the placenta and umbilical cord are usually examined for 
size, shape, colour, smell and structure. If no abnormalities or clinical indications identified, the 
placenta is usually discarded. 
Participant’s placenta will be examined as routine. If no other medical use/ need is identified, the 
placenta will be rinsed and transferred to a sterile container at 40C to the Blizard Institute. The 
specimen will be processed on the same day. Specimen will be placed in enzyme solution for 
digestion before further washing. Cell suspensions will then be enriched for macrophages using 
discontinuous density gradients. Cells will be harvested and washed before resuspending (7,8). 
Cytospins stained by Diff-Quik are analysed for macrophage black carbon using digital colour 
images of 50 randomly selected macrophages from each placenta, captured at x100 magnification 
101. The total area of carbon in each macrophage is calculated by measuring the black content of
each cell. Mean AM carbon per placenta is then calculated from the 50 macrophages.
Data Preparation and Collection 
Samples will be labelled with the participant ID given to each participant. Date of collection 
and conditions at which the samples are sent and storied will be recorded to ensure 
integrity. Samples are collected from the Royal London Hospital, then stored and 
processed at the Blizard institute. All specimens will be discarded following analysis.  
7. PRODUCTS, DEVICES, TECHNIQUES AND TOOLS
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Devices 
Nitrogen Dioxide Monitoring 
A NO2 diffusion monitor (the size of a small badge) will be placed near 
child for 2 weeks to monitor their NO2 exposure. This can be placed on the 
buggy/ parent/ carer or on child’s clothes, depending on their age and level 
of cooperation. An additional NO2 badge will be placed inside the 
participant’s home to detect indoor natural gas exposure. The data will be 
analysed by the manufacturers of the NO2 diffusion monitor (IVL Swedish 
Environmental Research Institute Ltd, P.O. Box 53021, SE-400 14 
Gothenburg, Sweden) 
(http://www.diffusivesampling.ivl.se/oursamplers.4.75d7780712240e747ea80004619.html) 
 All devices are already owned by the research team at the Blizard Institute so no purchase 
is required.  
Tools 
No tool is needed for the study. 
Medicinal product  
No medicinal product will be used for the study. 
SAFETY REPORTING 
Adverse Events (AE) 
An AE is any untoward medical occurrence in a subject to whom a medicinal product has 
been administered, including occurrences which are not necessarily caused by or related to 
that product.  An AE can therefore be any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom or disease temporarily associated with study activities. 
Notification and reporting Adverse Events or Reactions 
If the AE is not defined as SERIOUS, the AE is recorded in the study file and the participant 
is followed up by the research team. The AE is documented in the participants’ medical notes 
(where appropriate). 
Serious Adverse Event (SAE) 
In other research other than CTIMPs, a serious adverse event (SAE) is defined as an 
untoward occurrence that: 
(a) results in death;
(b) is life-threatening;
(c) requires hospitalisation or prolongation of existing hospitalisation;
(d) results in persistent or significant disability or incapacity;
(e) consists of a congenital anomaly or birth defect; or
(f) is otherwise considered medically significant by the investigator.
An SAE occurring to a research participant should be reported to the main REC where in 
the opinion of the Chief Investigator the event was: 
• Related – that is, it resulted from administration of any of the research procedures, and
• Unexpected – that is, the type of event is not listed in the protocol as an expected
occurrence.
Notification and Reporting of Serious Adverse Events 
Pollution Monitoring 
Badge
Air Pollution Particles in Placenta (APPIP) 
Version 1.5     24/04/2019               Air Pollution Particles in Placenta (APPIP) 333 
Serious Adverse Event (SAEs) that are considered to be ‘related’ and ‘unexpected’ are to be 
reported to the sponsor within 24 hours of learning of the event and to the Main REC within 15 
days in line with the required timeframe. For further guidance on this matter, please refer to 
NRES website and JRMO SOPs 
Urgent Safety Measures 
The CI may take urgent safety measures to ensure the safety and protection of the clinical 
trial subjects from any immediate hazard to their health and safety,. The measures should be 
taken immediately. In this instance, the approval of the REC prior to implementing these 
safety measures is not required. However, it is the responsibility of the CI to inform the 
sponsor and Main Research Ethics Committee (via telephone) of this event immediately.  
The CI has an obligation to inform both the Main REC in writing within 3 days, in the form of 
a substantial amendment. The sponsor (Joint Research Management Office [JRMO]) must 
be sent a copy of the correspondence with regards to this matter. For further guidance on this 
matter, please refer to NRES website and JRMO SOPs. 
Annual Safety Reporting 
The CI will send the Annual Progress Report to the main REC using the NRES template (the 
anniversary date is the date on the MREC “favourable opinion” letter from the MREC) and to 
the sponsor. Please see NRES website and JRMO SOP for further information. 
Overview of the Safety Reporting responsibilities 
The CI/PI has the overall pharmacovigilance oversight responsibility. The CI/PI has a duty to 
ensure that safety monitoring and reporting is conducted in accordance with the sponsor’s 
requirements.  
MONITORING &AUDITING 
A data monitoring committee will not be convened. Intermittent random audit of data quality will be 
performed by members of the investigating team under the supervision of the Chief investigator 
(CI). 
Research sponsor will ensure arrangements and systems are in place for the management and 
monitoring of research.   
The arrangements will be in accordance to the Research Governance Framework. 
TRIAL COMMITTEES 
This study is not a clinical trial – a trial committee is therefore not required. However there will be 
a study committee consisting of the Chief Investigator and representatives from the Research and 
Development Department – they will meet quarterly to ensure the study is progressing 
satisfactorily.  
FINANCE AND FUNDING 
This study is funded by Barts Charity (grant reference: MGU0312). 
INDEMNITY 
This study will be sponsored by Queen Mary University of London.  Contact details as 
previously stated. Queen Mary University of London will arrange for suitable indemnity 
for negligent harm arising as a result of participation in this study to be in place.  
DISSEMINATION OF RESEARCH FINDINGS: 
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The results will be reported and disseminated to the clinical and scientific community 
through ways such as peer reviewed scientific journals, internal reports or conference 
presentations. 
Any manuscript reporting study findings will be prepared according to CONSORT 
guidelines and submitted to peer-reviewed biomedical journals according to ICMJE 
Uniform Requirements. Authorship will be based on individuals’ contribution to study 
design, conduct, analysis, drafting/revision of manuscript and final approval of the version 
to be published. Authorship will not necessarily be restricted to individuals named on this 
protocol; neither is authorship guaranteed to any individual named on this protocol.  
Contributors who do not meet authorship criteria will be listed in ‘Acknowledgements’. 
The results will also be available to participants. They will be given contact information of 
the research teams. 
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Appendix 9 – APPIP study: Participant information sheet  
 
PATIENT INFORMATION SHEET    Version 1.3    28/07/2017 
REC reference: 17/NW/0092         
IRAS number: 219053 





You are being invited to take part in a pilot research study.   Before you decide whether or 
not to take part, it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully, and discuss 
it with others if you wish.  
 
PART 1 tells you the purpose of this study and what will happen if you take part. 
 
PART 2 gives you more detailed information about the conduct of the study. 
 
Please ask us if there is anything that is not clear, or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
2. What is the purpose of the study? 
Air pollution, such as emissions from petrol and diesel car engines, is linked to a wide range 
of adverse health effects. Exposure to air pollution during pregnancy can affect the unborn 
baby. The baby’s breathing system starts to develop from about 4 weeks of pregnancy, this 
continues until their early adulthood, and can be affected by air pollution. There is a link 
between mothers who are exposed to high level of air pollution during pregnancy and 
outcomes such as small babies (lower birth weight) and breathing problems later in the 
baby’s life. It is uncertain whether the pollution particles can be passed directly across the 
placenta from the mother to the baby.  
 
3. Why have I been chosen? 
You have been chosen because you have a relatively uncomplicated pregnancy, and you 
live in or around London - London is known to be a well polluted area.  
 
4. Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you decide that you would like to 
take part, then you will be given this information sheet to keep and be asked to sign a 
consent form to confirm that you understand what is involved when taking part in this study. 
If you decide to take part you are free to leave the study at any time and without giving a 
reason. If you withdraw, unless you object, we will still keep records relating to your 
participation up to that point, as this is valuable to the study. A decision to withdraw at any 
time, or a decision not to take part, will not affect the quality of any care you may require 
from us in the future. 
 
5. What will happen to me if I take part? 
If you are interested in taking part, trained researchers will arrange a time to meet you at the 
Royal London Hospital – this can coincide with your next hospital visit if you have one 
pending.  With your consent, the research doctor will review your antenatal record to ensure 
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you fit the enrolment criteria of the study. You will receive your routine antenatal care as 
planned. This study will not add extra procedures/ appointments. 
You will be asked to wear a small pollution monitor badge for 2 
weeks – this can be attached to your clothes to detect your 
pollution exposure level. The badge will be collected by the 
researcher at the end of the 2 weeks. 
Usually following delivery of the baby, the placenta will be 
delivered. The placenta is usually looked at by the midwife before it is discarded. If the 
placenta looks normal and no further medical intervention is needed, the research team will 
take the placenta to the research institute (Blizard Institute) for processing and analysis. The 
study report will be fed back to you after the results are analysed. 
6. What do I have to do?
If you agree to take part, you can sign a consent form and give it back to the Obstetrics team
or the research doctor. We will then collect the placenta after your delivery. There is nothing
extra you will need to do. Your participation will be from recruitment til the collection of the
placenta and completion of the 2 week pollution monitoring (maximum 9 months).
7. What are the alternatives for testing?
Extracting cells directly from the placenta is the only way to detect the presence of air
pollution particles.
8. What are other possible disadvantages and risks of taking part?
There is no extra treatment or procedure other than your routine antenatal care, so no
additional disadvantages or side effects are anticipated.
9. What are the possible benefits of taking part?
This study will help us understand whether air pollution particles that mothers are exposed
to on a daily basis, are passed directly to the baby, as it will provide no information of clinical
significance for you and your baby. The pollution monitor badge will provide you with
information regarding your personal exposure to pollution over the course of 2 weeks.
Barts Health NHS Trust (The Royal London Hospital) has been working with Global Action
Plan to reduce patients’ personal exposure to air pollution. We think this study will influence
in trying to reduce air pollution exposure and limit its effect on expectant mothers and their
babies.
10. What happens when the research study stops?
The placenta will be disposed of following analysis – the study report will be published in a
medical journal.
11. What if there is a problem?
If you have concern about any aspect of this study, you should ask to speak with the
researchers who will do their best to answer your question.  Our contact details can be found
at the bottom of this sheet. If you remain unhappy and wish to complain formally, you can
do this through either the NHS Complaints Procedure (details are at the end of this sheet).
Queen Mary University of London has agreed that if you are harmed as a result of your
participation in the study, you will be compensated, provided that, on the balance of
probabilities, an injury was caused as a direct result of the intervention or procedures you
Pollution Monitoring Badge 
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received during the course of the study. These special compensation arrangements apply 
where an injury is caused to you that would not have occurred if you were not in the study. 
These arrangements do not affect your right to pursue a claim through legal action. 
12. Will my taking part in this study be kept confidential?
Yes.  All the information about your participation in this study will be kept confidential.  (See
Part 2)
This completes Part 1 of the Information Sheet. If the information has interested you and you 
would like to participate, please continue to read the additional information in Part 2 before 
making any decision. 
PART 2 
13. What if new information becomes available?
Sometimes during the course of a study, new information becomes available on the
procedures that are being studied. If this happens, we will tell you about it and discuss with
you whether you want to or should continue in the study. If you decide to withdraw, you will
suffer no adverse effects as a result. If you decide to continue in the study you may be asked
to sign an updated consent form.
On receiving new information, we might consider it to be in your best interests to withdraw
you from the study. If so, we will explain the reasons and arrange for your care to continue.
If the study is stopped for any other reason, you will be told why.
14. Will my part in this study be kept confidential?
You will be allocated a participant ID, which will be used to label the placenta. Data will be
stored in paper and electronic formats, data generated will be analysed by the research
team - all de-identified and securely stored within the Blizard Institute, only accessed by the
research team. All information will be held securely at the research centre and the Royal
London Hospital under the provisions of the 1998 Data Protection Act.
Your data records will be available to people authorised to work on the study but may also
need to be made available to people authorised by the Research Sponsor, which is the
organisation responsible for ensuring that the study is carried out correctly. The information
collected about you may also be shown to authorised people from the UK Regulatory
Authority and Independent Ethics Committee; this is to ensure that the study is carried out
to the highest possible scientific standards.  All will have a duty of confidentiality to you as a
research participant.
By signing the consent form you agree to this access for the current study and any further
research that may be conducted in relation to it, even if you withdraw from the current study.
If you withdraw consent from further study involvement, we will seek your permission to
include your sample results within the study.  We will not do so without your permission.
Unless you object, your data and samples will remain on file and will be included in the final
study analysis.
In line with Good Clinical Practice guidelines, at the end of the study, your data will be
securely archived for a minimum of 20 years. Arrangements for confidential destruction will
then be made.
 




15. What will happen to the sample I give? 
The placenta will be labelled with the participant ID, and transported to the Blizard Institute 
for processing and analysis. We will extract cells called macrophages, which are usually 
involve in removing unwanted particles or substances, from the placenta and look for the 
presence of air pollution particles. 
 
The pollution monitoring badges will be analysed in Sweden (IVL Swedish Environmental 
Research Institute Ltd, P.O. Box 53021, SE-400 14 Gothenburg, Sweden). No samples will 
be sent to this location. The devices will only have anonymised data prior to transport. 
 
16. What will happen to the results of this study? 
The results of the study will be available after it finishes and will usually be published in a 
medical journal or be presented at a scientific conference. The data will be anonymous, you 
will not be identified in any report or publication. Should you wish to see the results, please 
ask your study doctor. 
 
17. Who is organising and funding this study? 
The study is sponsored by Queen Mary University of London, and it is funded by Barts 
Charity (https://bartscharity.org.uk/). 
 
18. Who has reviewed the study? 
Before any research goes ahead it has to be checked by an independent Research Ethics 
Committee. They make sure that the research is fair. Your project has been checked by the 
London - Bloomsbury Research Ethics Committee. (REC reference:  17/NW/0092) 
 
19. Contact for further information 
You are encouraged to ask any questions you wish, before, during or after your participation. 
If you have any questions about the study, please speak to the research team, who will be 
able to provide you with up to date information about the study. If you wish to read the 
research on which this study is based, please ask your research team. If you require any 
further information or have any concerns while taking part in the study please contact the 
research team (contact details are at the end of this sheet). 
 
If you decide you would like to take part then please read and sign the consent form, which 
will be the only document linking your name to the participant ID. You will be given a copy 
of this information sheet and the consent form to keep. One copy of the consent form will be 
given to you, one copy to be stored in medical records and one copy to be kept within the 
investigator's site file.  
 








Professor Jonathan Grigg, 07787 550775, j.grigg@qmul.ac.uk 
Clinical Research Fellow: 
Dr Norrice Liu, 020 7882 2616, n.liu@qmul.ac.uk 
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For advice about taking part in research in the NHS: 
INVOLVE 
Wessex House 
Upper Market Street 
Eastleigh, Hampshire 
SO50 9FD 
Telephone: 023 8065 1088 
Textphone: 023 8062 6239 
Fax: 023 8065 2885 
Email: admin@invo.org.uk 
For advice about research and patient issues at The Royal London Hospital and Barts 
Health NHS Trust: 
Patient Advice and Liaison Service (PALS):  
Ground Floor, Front Block  
The Royal London Hospital  
Whitechapel Road, London E1 1BB   
Tel: 020 7943 1335 
Fax: 020 7377 7361 
Minicom:  020 7943 1350  
E-mail:  PALS@bartshealth.nhs.uk
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1 copy for participant; 1 copy for researcher site file; 1 (original) copy to be kept in medical notes. 
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Appendix 10 – APPIP: Consent form 
Air Pollution Particles in Placenta 
REC reference: 17/NW/0092  IRAS number:  219053 
Name of researcher: Dr Norrice Liu  
Participant ID: __________________  
CONSENT FORM  
Participant consent form Version 1.3  28/07/2017  
Please initial 
all boxes  
1 
I confirm that I have read and understood the information sheet dated 
28/07/2017 version 1.3  for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
2 
I understan d that my participation is voluntary and that I am free to 
withdraw at any time, without giving a reason, and without my care or legal 
rights being affected.  
3 
I agree to carry a pollution monitor to evaluate my personal exposure to 
air pollution. I und erstand the monitor badge will be analysed in a 
laboratory in Sweden but the device will only have anonymised data prior 
to transport.  
4 
I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by resea rch doctors from Queen Mary 
University London, from regulatory authorities or from the NHS Tru st, 
where it is relevant for my  taking part in this research. I give permission for 
these doctors to have access to my records.  
5 
I agree for the placenta of m y current pregnancy to be collected following 
delivery. I understand the placenta will be disposed of after analysis.  
6 
I agree to take part in this study. I understand I will be assigned a 
participant ID which will be used to identify me within the stu dy, and I will 
not be identified in any report or publication of the study results.  
Name of Participant Signature Date 
Name of Researcher Signature Date 
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Appendix 11 – Ethics approval and correspondence 
North West - Greater Manchester West 
Research Ethics Committee  
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
Please note:  This is the  favourable opinion of the  REC only and does not allow 
you to start your study at NHS  sites in England until you  receive HRA Approval   
09 February 2017 
Professor Jonathan Grigg  
Blizard Institute, Queen Mary University of London 
4 Newark St  
London  
E1 2AT  
Dear Professor Grigg  
Study title:  Presence of Air Pollution Particles in 
Placental  
Macrophages  
REC reference:  17/NW/0092  
IRAS project ID: 219053  
The Proportionate Review Sub-committee of the North West - Greater Manchester West 
Research Ethics Committee reviewed the above application on 03 February 2017.  
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three months 
from the date of this favourable opinion letter.  The expectation is that this information will 
be published for all studies that receive an ethical opinion but should you wish to provide 
a substitute contact point, wish to make a request to defer, or require further information, 
please contact hra.studyregistration@nhs.net outlining the reasons for your request. Under 
very limited circumstances (e.g. for student research which has received an unfavourable 
opinion), it may be possible to grant an exemption to the publication of the study.   
Ethical opinion 
On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the 
above research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below.  
Conditions of the favourable opinion 
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The REC favourable opinion is subject to the following conditions being met prior to the 
start of the study.  
The sub-committee would like the second sentence in point 3 of the PIS, ‘- London is known 
to have some of the most polluted air in Western Europe.’, to be changed to  
‘London is known to be a well polluted area’.  
The sub-committee would like the last sentence on paragraph 6 of the PIS to be removed, 
‘This study aims to look into whether mother’s exposure to air pollution will result in the 
presence of pollution particles within the placenta, thereby having possible direct effect on 
birth outcomes’.   
The sub-committee would like point 9 of the PIS to include the following after the first 
sentence, ‘As it will provide no information of clinical significance for you and your baby’.  
The sub-committee would like the word ‘findings’ in point 5 and point 10 of the PIS to  
be replaced with ‘study report’.  
You should notify the REC once all conditions have been met (except for site 
approvals from host organisations) and provide copies of any revised 
documentation with updated version numbers. Revised documents should be 
submitted to the REC electronically from IRAS. The REC will acknowledge receipt 
and provide a final list of the approved documentation for the study, which you can 
make available to host organisations to facilitate their permission for the study. 
Failure to provide the final versions to the REC may cause delay in obtaining 
permissions.  
Management permission must be obtained from each host organisation prior to the start of 
the study at the site concerned.  
Management permission should be sought from all NHS organisations involved in the study 
in accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise).  
Guidance on applying for HRA Approval (England)/ NHS permission for research is 
available in the Integrated Research Application System, www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk.   
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be 
sought from the R&D office on the information it requires to give permission for this activity. 
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation.  
Sponsors are not required to notify the Committee of management permissions from host 
organisations.  
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Registration of Clinical Trials 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database. This should be before the first participant 
is recruited but no later than 6 weeks after recruitment of the first participant.  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as 
part of the annual progress reporting process.  
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory.  
If a sponsor wishes to request a deferral for study registration within the required 
timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all 
clinical trials will be registered, however, in exceptional circumstances non registration may 
be permissible with prior agreement from the HRA. Guidance on where to register is 
provided on the HRA website.   
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable).  
Ethical review of research sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see  
“Conditions of the favourable opinion”).  
Summary of discussion at the meeting   
Ethical issues raised, noted and resolved in discussion: 
Informed consent process and the adequacy and completeness of participant 
information  
The sub-committee were of the opinion the PIS well written and raised no ethical issues. 
The sub-committee had noted a few minor changes they would like to be made. Please 
see these changes mentioned below in the decision.   
Approved documents  
The documents reviewed and approved were: 
Document Version Date 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Verification of Insurance]   
15 July 2016  
IRAS Application Form [IRAS_Form_19012017] 19 January 2017  
IRAS Application Form XML file [IRAS_Form_19012017]  19 January 2017  
IRAS Checklist XML [Checklist_19012017] 19 January 2017  
Letter from funder [Barts Charity letter]  20 December 2016 
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Letter from sponsor [Sponsorship agreement]  19 January 2017  
Other [Case Report Form]  1.0  12 December 2016 
Participant consent form [Consent]  1.1  12 January 2017  
Participant information sheet (PIS) [PIS] 1.1  12 January 2017  
Research protocol or project proposal [Air Pollution Particles in 
Placenta Protocol]   
1.2  13 January 2017  
Summary CV for Chief Investigator (CI) [CV J.Grigg] 1.0  08 November 2016 
Summary CV for student [CV N.Liu]  1.0  08 November 2016 
Summary CV for supervisor (student research) [CV J.Grigg]  1.0  08 November 2016 
Membership of the Proportionate Review Sub-Committee 
The members of the Sub-Committee who took part in the review are listed on the attached 
sheet.  
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
After ethical review  
Reporting requirements 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
Notifying substantial amendments  
Adding new sites and investigators  
Notification of serious breaches of the protocol 
Progress and safety reports  
Notifying the end of the study  
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.  
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please use the 
feedback form available on the HRA website:  
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/     
HRA Training 
We are pleased to welcome researchers and R&D staff at our training days – see details 
at http://www.hra.nhs.uk/hra-training/    
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With the Committee’s best wishes for the success of this project. 
17/NW/0092 Please quote this number on all 
correspondence 
Yours sincerely 
Dr Lorraine Lighton (Chair) Chair  
Email: nrescommittee.northwest-gmwest@nhs.net 
Enclosures: List of names and professions of members who took part in the 
review   
“After ethical review – guidance for researchers” [SL-AR2]  
Copy to: Dr Sally Burtles, Elizabeth Clough, Barts Health NHS Trust 
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North West - Greater Manchester West Research Ethics Committee  
Attendance at PRS Sub-Committee of the REC meeting on 03 February 2017 
Committee Members: 
Name Profession Present  Notes 
Mrs Seonaid  Beddows  Research Governance 
and Administration 
Manager   
Yes  
Dr Lorraine Lighton (Chair)  Retired Consultant in  
Communicable Disease 
Control    
Yes  
Dr Gideon Smith Consultant in Public 
Health Medicine  
Yes  
Also in attendance: 
Name Position (or reason for attending) 
Miss Anna Bannister  REC Manager  





North West - Greater Manchester West 
Research Ethics Committee  
Barlow House  
3rd Floor  
4 Minshull Street  
Manchester  
M1 3DZ  
  
 Please note:  This is an  acknowledgement letter from  the REC only and does not  
allow you to start your study  at NHS sites in England until  
 you receive HRA Approval   
   
  
  
15 February 2017  
  
Professor Jonathan Grigg  
Blizard Institute, Queen Mary University of London  
4 Newark St  
London  
E1 2AT  
  
  
Dear Professor Grigg  
  
Study title:  Presence of Air Pollution Particles in Placental  
Macrophages  
REC reference:  17/NW/0092  
IRAS project ID:  219053  
  
Thank you for your letter of 10/02/2017.  I can confirm the REC has received the documents listed 
below and that these comply with the approval conditions detailed in our letter dated 09 February 
2017  
  
Documents received  
  
The documents received were as follows:  
  
Document    Version    Date    
Covering letter on headed paper [Cover letter]   1.0   10 February 2017   
IRAS Checklist XML [Checklist_10022017]      10 February 2017   
Participant consent form [Consent]   1.2   10 February 2017   




Approved documents  
  
The final list of approved documentation for the study is therefore as follows:  
  
Document    Version    Date    
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Covering letter on headed paper [Cover letter]  1.0  10 February 2017  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Verification of Insurance]   
15 July 2016  
IRAS Application Form [IRAS_Form_19012017] 19 January 2017  
IRAS Checklist XML [Checklist_19012017] 19 January 2017  
IRAS Checklist XML [Checklist_10022017] 10 February 2017  
Letter from funder [Barts Charity letter]  20 December 2016 
Letter from sponsor [Sponsorship agreement]  19 January 2017  
Other [Case Report Form]  1.0  12 December 2016 
Participant consent form [Consent]  1.2  10 February 2017  
Participant information sheet (PIS) [PIS] 1.2  10 February 2017  
Research protocol or project proposal [Air Pollution Particles in 
Placenta Protocol]   
1.2  13 January 2017  
Summary CV for Chief Investigator (CI) [CV J.Grigg] 1.0  08 November 2016 
Summary CV for student [CV N.Liu]  1.0  08 November 2016 
Summary CV for supervisor (student research) [CV J.Grigg]  1.0  08 November 2016 
You should ensure that the sponsor has a copy of the final documentation for the study.  It is the 
sponsor's responsibility to ensure that the documentation is made available to R&D offices at all 
participating sites.  
17/NW/0092 Please quote this number on all correspondence 
Yours sincerely 
Nafeesa Khanam REC Assistant 
E-mail: nrescommittee.northwest-gmwest@nhs.net
Copy to:  Dr Sally Burtles 
 Elizabeth Clough, Barts Health NHS Trust 
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Professor Jonathan Grigg  
Blizard Institute, Queen Mary University of London 
4  Newark St  
London  
E1 2AT  
Email: hra.approval@nhs.net 
20 March 2017  
Amended and Reissued 23 March 2017 
Dear Professor Grigg, 
Letter of HRA Approval 
Study title:  Presence of Air Pollution Particles in Placental Macrophages 
IRAS project ID: 219053   
REC reference:  17/NW/0092    
Sponsor  Queen Mary University of London  
I am pleased to confirm that HRA Approval has been given for the above referenced study, 
on the basis described in the application form, protocol, supporting documentation and any 
clarifications noted in this letter.   
Participation of NHS Organisations in England   
The sponsor should now provide a copy of this letter to all participating NHS organisations 
in England.   
Appendix B provides important information for sponsors and participating NHS 
organisations in England for arranging and confirming capacity and capability. Please read 
Appendix B carefully, in particular the following sections:  
Participating NHS organisations in England – this clarifies the types of participating 
organisations in the study and whether or not all organisations will be undertaking the same 
activities  
Confirmation of capacity and capability - this confirms whether or not each type of 
participating NHS organisation in England is expected to give formal confirmation of 
capacity and capability. Where formal confirmation is not expected, the section also 
provides details on the time limit given to participating organisations to opt out of the study, 
or request additional time, before their participation is assumed.  
Allocation of responsibilities and rights are agreed and documented (4.1 of HRA 
assessment criteria) - this provides detail on the form of agreement to be used in the study 
to confirm capacity and capability, where applicable.  
Further information on funding, HR processes, and compliance with HRA criteria and 
standards is also provided.  
It is critical that you involve both the research management function (e.g. R&D office) 
supporting each organisation and the local research team (where there is one) in setting 
up your study. Contact details  
Page 1 of 8 
and further information about working with the research management function for each 
organisation can be accessed from www.hra.nhs.uk/hra-approval.   
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Appendices  
The HRA Approval letter contains the following appendices: 
A – List of documents reviewed during HRA assessment  
B – Summary of HRA assessment  
After HRA Approval  
The document “After Ethical Review – guidance for sponsors and investigators”, issued 
with your REC favourable opinion, gives detailed guidance on reporting expectations for 
studies, including:   
Registration of research  
Notifying amendments  
Notifying the end of the study  
The HRA website also provides guidance on these topics, and is updated in the light of 
changes in reporting expectations or procedures.  
In addition to the guidance in the above, please note the following:  
HRA Approval applies for the duration of your REC favourable opinion, unless otherwise 
notified in writing by the HRA.  
Substantial amendments should be submitted directly to the Research Ethics Committee, 
as detailed in the After Ethical Review document. Non-substantial amendments should be 
submitted for review by the HRA using the form provided on the HRA website, and emailed 
to hra.amendments@nhs.net.   
The HRA will categorise amendments (substantial and non-substantial) and issue 
confirmation of continued HRA Approval. Further details can be found on the HRA website. 
Scope   
HRA Approval provides an approval for research involving patients or staff in NHS 
organisations in England.   
If your study involves NHS organisations in other countries in the UK, please contact the 
relevant national coordinating functions for support and advice. Further information can be 
found at http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/.  
If there are participating non-NHS organisations, local agreement should be obtained in 
accordance with the procedures of the local participating non-NHS organisation.  
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please use the 
feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-
hra/governance/quality-assurance/.  
HRA Training  
We are pleased to welcome researchers and research management staff at our training 
days – see details at http://www.hra.nhs.uk/hra-training/   
Your IRAS project ID is 219053. Please quote this on all correspondence. 
Yours sincerely  
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Thomas Fairman 
HRA Assessor  
Email: hra.approval@nhs.net 
Copy to:  Dr Sally Burtles, Queen Mary University of London, (Sponsor Contact)  
Ms Elizabeth   Clough, R&D Governance Operations Manager, Barts Health, (Lead NHS 
R&D Contact)  
Appendix A - List of Documents  
The final document set assessed and approved by HRA Approval is listed below. 
 Document Version Date 
Covering letter on headed paper [Cover letter]  10 February 2017  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Verification of Insurance]   
15 July 2016  
IRAS Application Form [IRAS_Form_19012017] 19 January 2017  
Letter from funder [Barts Charity letter]  20 December 2016  
Letter from sponsor [Sponsorship agreement]  19 January 2017  
Other [Case Report Form]  1.0  12 December 2016  
Other [Response to HRA request for clarifications]  20 March 2017  
Other [Sponsor confirmation of non-substantial amendment]  20 March 2017  
Participant consent form [Consent]  1.2  10 February 2017  
Participant information sheet (PIS) [PIS] 1.2  10 February 2017  
Research protocol or project proposal [Air Pollution Particles in 
Placenta Protocol]   
1.2 13 January 2017  
Summary CV for Chief Investigator (CI) [CV J.Grigg] 08 November 2016  
Summary CV for student [CV N.Liu]  08 November 2016  
Summary CV for supervisor (student research) [CV J.Grigg]  08 November 2016  
Appendix B - Summary of HRA Assessment 
This appendix provides assurance to you, the sponsor and the NHS in England that the 
study, as reviewed for HRA Approval, is compliant with relevant standards. It also provides 
information and clarification, where appropriate, to participating NHS organisations in 
England to assist in assessing and arranging capacity and capability.  
For information on how the sponsor should be working with participating NHS 
organisations in  
England, please refer to the, participating NHS organisations, capacity and 
capability and Allocation of responsibilities and rights are agreed and documented 
(4.1 of HRA assessment criteria) sections in this appendix.   
The following person is the sponsor contact for the purpose of addressing participating 
organisation questions relating to the study:  
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Name: Dr Sally Burtles  
Email: sponsorsrep@bartshealth.nhs.uk  
HRA assessment criteria 




1.1 IRAS application completed 
correctly  
Yes No comments 
2.1 Participant 
information/consent 
documents and consent 
process  
Yes No comments 
3.1 Protocol assessment Yes No comments 
4.1 Allocation of responsibilities 
and rights are agreed and 
documented   
Yes This is a non-commercial single site 
study taking place in the NHS where 
that single NHS organisation’s 
partner University is the study 
sponsor. Therefore no study 
agreements are expected.   
4.2 Insurance/indemnity 
arrangements assessed 
Yes Where applicable, independent 
contractors (e.g. General 
Practitioners) should ensure that the 
professional indemnity provided by 
their medical defence organisation 
covers the activities expected of them 
for this research study 




4.3 Financial arrangements 
assessed  
Yes External study funding has been 
secured from Barts Charity.  
5.1 Compliance with the Data 
Protection Act and data 
security issues assessed  
Yes No comments 
5.2 CTIMPS – Arrangements for 
compliance with the Clinical 
Trials Regulations assessed  
Not Applicable No comments 
5.3 Compliance with any 
applicable laws or 
regulations  
Yes No comments 
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6.1 NHS Research Ethics 
Committee favourable 
opinion received for 
applicable studies 
Yes REC Favourable Opinion was issued 
by the Greater Manchester West 
Research Ethics Committee on the 
15th February 2017.   
Clarifications were provided by the 
researchers to comply with HRA 
Approval standards. These were 
classified by the sponsor as a 
nonsubstantial amendment.   
6.2 CTIMPS – Clinical Trials 
Authorisation (CTA) letter 
received  
Not Applicable No comments 
6.3 Devices – MHRA notice of no 
objection received  
Not Applicable No comments 
6.4 Other regulatory approvals 
and authorisations received  
Not Applicable No comments 
Participating NHS Organisations in England 
This provides detail on the types of participating NHS organisations in the study and a statement as to whether 
the activities at all organisations are the same or different. 
This is a non-commercial single site study taking place in the NHS where that single NHS 
organisation’s partner University is the study sponsor. Therefore there is only one site type 
involved in the research.   
If this study is subsequently extended to other NHS organisation(s) in England, an 
amendment should be submitted to the HRA, with a Statement of Activities and Schedule 
of Events for the newly participating NHS organisation(s) in England.   
The Chief Investigator or sponsor should share relevant study documents with participating 
NHS organisations in England in order to put arrangements in place to deliver the study. 
The documents should be sent to both the local study team, where applicable, and the 
office providing the research management function at the participating organisation. For 
NIHR CRN Portfolio studies, the Local LCRN contact should also be copied into this 
correspondence.  For further guidance on working with participating NHS organisations 
please see the HRA website.  
If chief investigators, sponsors or principal investigators are asked to complete site level 
forms for participating NHS organisations in England which are not provided in IRAS or on 
the HRA website, the chief investigator, sponsor or principal investigator should notify the 
HRA immediately at hra.approval@nhs.net. The HRA will work with these organisations to 
achieve a consistent approach to information provision.   
Confirmation of Capacity and Capability  
This describes whether formal confirmation of capacity and capability is expected from participating NHS 




This is a non-commercial single site study taking place in the NHS where that single NHS 
organisation’s partner University is the study sponsor. The participating NHS organisation will 
therefore be expected to formally confirm their capacity and capability to host this 
research according to local requirements.   
Following issue of this letter, participating NHS organisations in England may now confirm to 
the sponsor their capacity and capability to host this research, when ready to do so. How 
capacity and capacity will be confirmed is detailed in the Allocation of responsibilities and rights 
are agreed and documented (4.1 of HRA assessment criteria) section of this appendix.   
The Assessing, Arranging, and Confirming document on the HRA website provides further 
information for sponsors and NHS organisations on assessing, arranging and confirming 
capacity and capability.  
  
Principal Investigator Suitability  
This confirms whether the sponsor position on whether a PI, LC or neither should be in place is correct for each 
type of participating NHS organisation in England and the minimum expectations for education, training and 
experience that PIs should meet (where applicable).  
A Principal Investigator should be appointed at study sites.   
  
GCP training is not a generic training expectation, in line with the HRA statement on training 
expectations.  
  
HR Good Practice Resource Pack Expectations  
This confirms the HR Good Practice Resource Pack expectations for the study and the pre-engagement checks 
that should and should not be undertaken  
As a non-commercial single site study taking place in the NHS where that single NHS 
organisation’s partner University is the study sponsor, it is unlikely that letters of access or 
honorary research contracts will be applicable, except where local network staff employed by 
another Trust (or University) are involved (and then it is likely that arrangements are already in 
place).    
  
If members of an external research team will be attending NHS sites to conduct the study 
activities detailed at IRAS A18 and A19 they should obtain a Letter of Access. This would be 
on the basis of a Research Passport or an NHS to NHS confirmation of pre-engagement 
checks letter (if NHS employed). Pre-engagement checks should confirm standard DBS 
checks, appropriate barred list checks, and occupational health clearance.  
  
Other Information to Aid Study Set-up   
This details any other information that may be helpful to sponsors and participating NHS organisations in England 
to aid study set-up.  









North West - Greater Manchester West Research Ethics Committee 
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
Tel: 0207 104 8021 
22 August 2017
Dr Sally Burtles  
Joint Research Management Office 
Queen Mary Innovation Centre  
5, Walden Street  
E1 2EF  
Dear Dr Burtles 
Study title: Presence of Air Pollution Particles in 
Placental  
Macrophages  
REC reference:  17/NW/0092  
Amendment number: 1  
Amendment date:  28 July 2017  
IRAS project ID:  219053  
The above amendment was reviewed the Sub-Committee in correspondence. 
Ethical opinion 
The Sub-Committee reviewed the amendment and requested further information below: 
How many monitors will there be, where will they be placed, and will they be used before 
or after the birth.  
Have any mothers been recruited yet? If so, will they be re-consented to use the monitor(s). 
Researcher Dr Norrice Liu explained there would be one monitor per mother, the monitor 
is the size of a 10p coin and can be clipped onto clothing- we would advise mothers to clip 
the monitor onto their outer-wear wherever they go, for the duration of two weeks. The 
monitors would be used around delivery time- ideally from recruitment antenatally, until the 
two week period has completed. Mothers are often recruited from antenatal clinic 1-2 
weeks before planned  
Caesarian sections so the monitor can either be collected at delivery or after delivery, 
depending on when the 2 week period completes. So the monitoring period would span 
across before/after birth but would vary with different participants. We would arrange for 
monitor collection in order to limit inconvenience.    
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He further explained that 7 participants have been recruited already and we would not 
reconsent them for monitor use. We would only start adding monitor usage for all new 
participants after new ethics approval has been granted.  
The Sub-Committee were satisfied with the clarification but requested the protocol was 
updated to include the above wording.  
Researcher Dr Norrice Liu submitted an amended protocol which the Sub-Committee 
reviewed and were happy they had addressed their concerns. The Sub-Committee had no 
further issues.  
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation.  
Approved documents  
The documents reviewed and approved at the meeting were: 
Document Version Date 
Covering letter on headed paper  28 July 2017  
Notice of Substantial Amendment (non-CTIMP)  1 28 July 2017 
Participant consent form [APPIP Clean] 1.3  28 July 2017  
Participant consent form [APPIP Tracking]  1.3  28 July 2017  
Participant information sheet (PIS) [APPIP Clean]  1.3  28 July 2017  
Participant information sheet (PIS) [APPIP Tracked]  1.3  28 July 2017  
Referee's report or other scientific critique report [Case Report Form 
Clean]   
1.1  28 July 2017  
Referee's report or other scientific critique report [Case Report Form 
Tracked]   
1.1  28 July 2017  
Research protocol or project proposal [Clean] 1.4  21 August 2017  
Research protocol or project proposal [Tracked]  1.4  21 August 2017  
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet.  
Working with NHS Care Organisations 
Sponsors should ensure that they notify the R&D office for the relevant NHS care 
organisation of this amendment in line with the terms detailed in the categorisation email 
issued by the lead nation for the study.  
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
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We are pleased to welcome researchers and R & D staff at our Research Ethics Committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/   
17/NW/0092: Please quote this number on all correspondence 
Yours sincerely 
Dr Lorraine Lighton (Chair) Chair 
E-mail: nrescommittee.northwest-gmwest@nhs.net
Enclosures: List of names and professions of members who took part 
in the review  
Copy to:   Elizabeth Clough, R&D Governance Operations 
Manager Professor Jonathan Grigg 
North West - Greater Manchester West Research Ethics Committee  
Attendance at Sub-Committee of the REC meeting on 14 August 2017 
Committee Members: 
Name Profession Present  Notes 
Dr Lorraine Lighton (Chair)  Retired Consultant in  
Communicable Disease 
Control    
Yes  
Dr Peter Owen Retired Mathematics 
Lecturer  
Yes  
Also in attendance: 
Name Position (or reason for attending) 
Miss Anna Bannister  REC Manager  
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North West - Greater Manchester West Research Ethics Committee 
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
Tel: 0207 104 8021 
01 June 2018
Dr Norrice Liu  
Clinical Research Fellow 
Blizard Institute  
4  Newark St  
London  
E1 2AT  
Dear Dr Liu 
Study title: Presence of Air Pollution Particles in 
Placental Macrophages  
REC reference:  17/NW/0092  
Amendment number: 2  
Amendment date:  27 April 2018  
IRAS project ID:  219053  
- This amendment consists of changes to the consent procedure, as well as updates
to the protocol and sponsor details.
The above amendment was reviewed by the Sub-Committee in correspondence. 
Ethical opinion  
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation.  
Approved documents  
The documents reviewed and approved at the meeting were: 
Document Version Date 
Covering letter on headed paper  04 May 2018  
Notice of Substantial Amendment (non-CTIMP)  2  27 April 2018  
Research protocol or project proposal [Clean] 1.4  20 April 2018  
Research protocol or project proposal [Tracked]  1.4  20 April 2018  
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Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet.  
Working with NHS Care Organisations 
Sponsors should ensure that they notify the R&D office for the relevant NHS care 
organisation of this amendment in line with the terms detailed in the categorisation email 
issued by the lead nation for the study.  
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
We are pleased to welcome researchers and R & D staff at our Research Ethics Committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/   
17/NW/0092: Please quote this number on all correspondence 
Yours sincerely 
Dr Lorraine Lighton Chair 
E-mail: nrescommittee.northwest-gmwest@nhs.net
Enclosures: List of names and professions of members who took part 
in the review  
Copy to:   Elizabeth   Clough, R&D Governance Operations Manager 
Dr Norrice Liu, Blizard Institute  
North West - Greater Manchester West Research Ethics Committee 
Attendance at Sub-Committee of the REC  
Committee Members:   
Name Profession Present  Notes 
Dr Lorraine Lighton (Chair)  Retired Consultant in Communicable Disease 
Control    
Yes  
Dr Gideon Smith Consultant in Public Health Medicine  Yes  
Also in attendance: 
Name Position (or reason for attending) 
Mr Ewan Waters  REC Assistant 
Air Pollution and Children with Cystic Fibrosis  
Version 1.0  27/09/2016 
REC reference: 17/EM/0023 
IRAS number: 219053 






Appendix 12 – Aethalometer activity diary 
Participant’s Activity Diary 
To be filled in by participant / parent during carbon monitoring 
Date Time Activity 




(e.g. home, school, 
playground) 
Mode of transport 
(e.g. walking, bus, 
tube, car) 
